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ABBREVIATIONS
The following abbreviations have been used in this thesis - 
CAO Chronic airflow obstruction
Ca^+ calcium ion
VOC voltage operated calcium channel
FEV^ forced expiratory volume in 1 second
Raw airways resistance
TGV Thoracic gas volume
sGaw specific airways conductance ( = Raw*"^  x TGV” )^
TLC total lung capacity
Vx(p) partial expiratory flow rate at x% of TLC
Vx(c) complete expiratory flow rate at x% of TLC
PC Provocation concentration
NSBR Non specific bronchial responsiveness
PG Prostaglandin
LT leukotriene
ECX measure of in vitro sensitivity being the concentration of
agonist producing x% of maximum response obtained for that tissue
NANC Non-Adrenergic, non cholinergic nervous system
SRS-A Slow reacting substance of anaphylaxis
mg milligrams
ml millilitres
G grammes
L litres
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SUMMARY
This project tested the hypothesis that variation in non specific 
bronchial responsiveness between individuals could be explained by 
differences in the sensitivity of the smooth muscle present in the 
airway. Non-specific bronchial responsiveness (NSBR) is closely 
associated with asthma and chronic airflow obstruction. The
approach used was to measure the NSBR of patients due to undergo 
thoracic surgery, and compare this with the in vitro sensitivity 
of bronchial strips obtained from thoracotomy specimens.
In vivo measurements
The first part of the project was devoted to developing 
methods and protocols to measure changes in airway calibre so that 
responsiveness could be measured. FEV^ is a reliable measure of 
airway calibre, but reflects overall airway function. As the in 
vitro measurements were made on larger airways, changes in specific 
airways conductance (sGAW) were used because they reflect changes 
in the larger airways. The measurement of sGaw by hand was 
time consuming and the measurement had large co-efficient of 
variation. To overcome these problems an automated system for the 
measurement of sGaw was developed.
In vivo versus in vitro
The first agonist used to ;compare jm vivo responsiveness and 
in vitro smooth muscle sensitivity was the cholinergic agonist 
methacholine. Patients were assessed for evidence of baseline 
airflow obstruction, chronic bronchitis and atopy. One patient's 
results were highly suggestive of asthma, but this diagnosis had 
not been confirmed before his presentation for thoracotomy. Both 
in vivo responsiveness and in vitro sensitivity varied widely, but 
there was no correlation between the results. The probable 
asthmatic patient was most responsive in vivo but did not have 
increased sensitivity in vitro.
Methacholine acts by inhibiting the cholinergic system, rather
than/
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than as a direct receptor agonist. A direct smooth muscle
stimulator histamine was next tested. A group of 'non-smoking'
normal subjects, and a group of asthmatic patients both in the 
same age range as the thoracic surgical patients were assessed by 
the in vivo protocol with histamine.
There was complete separation of the two groups as assessed by 
PC2qFEV^ and only slight overlap when assessed by PC3 5 sGaw and
pc30^ 30^ *
Using histamine as agonist to compare in vivo responsiveness 
and jri vitro sensitivity did not demonstrate a relationship. As 
histamine may act both directly on a specific smooth muscle 
receptor and indirectly (via vagal reflexes) another group of 
patients were pretreated with atropine to reduce the effect of in 
vivo vagal reflexes, which would not be present in the denervated 
in vitro preparations. Atropine modified In vivo 
responsiveness, but did not improve the relationship between in 
vivo responsiveness and in vitro sensitivity. An asthmatic 
patient in this group was the most sensitive by in. vivo criteria 
but his smooth muscle was not more sensitive in vitro.
As an adjunct to the main thrust of the project the 
ultrastructure of airway smooth muscle was examined. Electron 
micrographs of bronchial samples which demonstrate the major 
structural features of human bronchial smooth muscle are included.
The leukotrienes (formerly known as slow reacting substance 
of anaphylaxis) are released in acute bronchoconstriction, cause a 
slow onset, prolonged smooth muscle contraction, similar to that 
occurring in acute asthma, and alter in vitro smooth muscle 
sensitivity in animals models of asthma. A series of experiments 
was embarked upon to investigate the importance of leukotriene 
in airway responsiveness.
The first investigation looked at LTD^ induced 
bronchoconstriction in normal volunteers and the effect of the 
calcium blocker verapamil on this leukotriene produced 
bronchoconstriction/
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bronchoconstriction at doses of <50 ug/ml. Bronchconstriction was 
inhibited by verapamil, indicating that LTD^ was acting, in part, 
via voltage dependent calcium channels. . The lack of effect of 
verapamil in the in vitro system suggests that LTD^ must be acting 
both by a direct action on smooth muscle receptors, and by an 
indirect verapamil sensitive pathway in vivo.
The second study looked at LTD^ induced bronchconstriction in 
asthmatic patients, and the effect of verapamil and sodium 
cromoglycate on this. The asthmatic subjects were more 
responsive to LTD^ by a factor of 1 0 , but in contrast with the 
normal subjects verapamil did not inhibit LTD^ induced 
bronchoconstriction. Possible reasons for this difference are 
discussed.
LTD^ was used as the agonist in the in vivo responsiveness 
and in vitro sensitivity protocol. There was no relationship 
between in vivo responsiveness and in vitro sensitivity. In this 
study the amount of smooth muscle present in the bronchial strips 
was measured. The quantity of smooth muscle present correlated 
significantly with the maximum tension produced in vitro but 
neither muscle quantity nor tension generated per unit mass of 
muscle was related to in vivo responsiveness. This result 
suggests that smooth muscle hypertrophy may contribute to NSBR.
Using 3 bronchconstrictor agents no relation was found 
between in vivo NSBR and in vitro smooth muscle. Two asthmatic 
patients were responsive by in vivo criteria, but smooth muscle 
obtained from them did not have increased sensitivity.
The final chapter of the thesis examines whether passive 
sensitisation of muscle, to render it atopic as in allergic 
asthma, alters in vitro sensitivity to histamine. Neither 
sensitisation per se, nor sensitisation followed by specific 
allergen challenge altered in vitro sensitivity of human airway 
smooth muscle.
In conclusion, airway smooth muscle sensitivity is not the
sole/
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sole determinant of NSBR. Smooth muscle hypertrophy did not 
relate to .in vivo responsiveness, although this result was 
obtained in patients with C.A.O. who may have different mechanisms 
for NSBR. Increased NSBR is due to a complex interaction between 
smooth muscle, neural and humoral factors.
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C H A P T E R  I
I N T R O D U C T I O N
1. INTRODUCTION
1.1.1. Mechanisms of airflow obstruction
Airflow obstruction is a common respiratory condition and is 
a major cause ofv morbidity and mortality in the community (Black 
and Pole 1975) (WHO - 1977). The condition can be divided into 
two sub groups - asthma and chronic airflow obstruction. Asthma 
is a disease characterised by wide variations over a short period 
of time in resistance to flow in intra-pulmonary airways 
(Scadding 1982). Chronic airflow obstruction (CAO) (also 
referred to as chronic obstructive airways disease or chronic 
obstructive pulmonary disease) is characterised by increased 
resistance to flow in the intra pulmonary airways which is 
relatively fixed, i.e. does not vary by >15% (Thurlbeck 1977).
Asthma divides into two subgroups. The first is closely 
associated with atopy. It tends to occur in children and often 
resolves before adulthood. Asthma occurring de novo in adults 
is less clearly characterised. It is not related to atopy and 
tends to be less responsive to treatment (Turner-Warwick 1971).
Chronic airflow obstruction shares some of the 
characteristics of adult onset asthma, but differs in that there 
is little or no reversibility in the degree of airflow 
obstruction. It is often co-incident with chronic bronchitis and 
usually occurs in cigarette smokers (Higgins 1957, Fletcher et al 
1976).
To reduce the prevalence and improve the treatment of asthma 
and CAO, it is important to understand the pathophysiology of 
airflow obstruction. There are three major determinants of 
airflow obstruction.
1.1.2 Mucous Secretion
Mucous secretion is increased in asthma ( Florey 1962) and 
CAO when associated with chronic bronchitis. In patients dying 
of an acute asthmatic attack the characteristic findings at post 
mortem/
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mortem are increased mucous gland and goblet cell numbers with 
plugging of the peripheral bronchi by mucous (Spenser 1971). 
The increase in intra-luminal mucous may be related in part to a 
failure of clearance mechanisms (Warner et al 1975).
1.1.3 Mucosal Inflammation
The superficial layers of the epithelium may be shed in 
severe cases of asthma (Reid 1954, Dunill 1960) and is 
incomplete, even in mild asthma (Laitinen et al 1985). 
Inflammatory cells invade the whole thickness of the bronchial 
wall. The majority of these cells are eosinophils (Lowell 1967) 
although plasma cells, polymorphs and lymphocytes are also 
present. Epithelial cells are joined by tight junctions at 
points of membrane to membrane contact. Electron microscope 
studies suggest that these are normally impermeable to large 
molecules (Hogg et al 1979) but antigen challenge in asthma, or 
cigarette smoke in CAO (Boucher et al 1980) may cause leakiness 
of these junctions allowing penetration of the mucosa by 
inflammatory mediators which can then act on airway smooth 
muscle.
1.1.4 Airway smooth muscle
Hypertrophy/hyperplasia of airway smooth muscle is an 
important feature of asthma (Spenser 1977) and CAO (Hossain and 
Heard 1970). Whether this is a prime cause of airways narrowing 
in asthma or CAO, or is a secondary response to another 
determining stimulus, has not been established.
However smooth muscle contraction is a major factor in the 
acute asthmatic response. The reversal of acute bronchospasm 
by adrenoceptor agonists occurs too rapidly for clearance of 
secretions or oedema to have occurred.
The reasons for increased responses of muscle in airflow 
obstruction/
Page 22
obstruction are unknown. They may be due to muscle hypertrophy, 
to altered physiological and/or pharmacological responses of 
muscle, or to differences in the neurohumeral regulation of the 
smooth muscle. Alternatively, other factors, not directly 
related to smooth muscle could be important, e.g. differences in 
the distribution or penetration of bronchoconstrictor agonists to 
their site of action (see 1.1.2 )
1.2 AIRWAY SMOOTH MUSCLE
1.2.1 Anatomy
The arrangement of muscles in airway is relevant to an 
understanding of airflow obstruction. Within the walls of the 
trachea and main bronchi smooth muscle is arranged as circular 
bands in bundles attached to the two limbs of C shaped cartilege. 
The muscle lies posteriorly. There are also smaller longitudinal 
bands of muscle. Contraction of muscle in this region draws the 
plates of cartilege together but does not obliterate the airway 
lumen.
Where the main bronchi enter the lung, the cartilege plates 
become smaller and are distributed around the entire 
circumference of the airway. Muscle bundles are arranged around 
the circumference of the airway. Muscle does not form a compact 
coat but branches and connects to form a geodesic network so that 
the arrangement of muscle is more spiral than circular (Miller 
1947). Within the lung, the contraction of muscle has a 
sphincteric action which may completely occlude the airway lumen.
Bronchomotor tone is present in normal subjects (Vincent 
1970) and may have the effect of improving airway stability and 
preventing collapse during dynamic expiratory effort. Excess 
bronchomotor tone produces airway narrowing 
(bronchoconstriction).
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1.2.2 Ultrastructure
Under the light microscope airway smooth muscle comprises 
fusiform cells approximately 1 mm. in length with a diameter of 
3 urn. The nucleus is cigar shaped and lies centrally 
within the cell. The long axes of cells within a muscle are 
parallel. Mast cells are found in close proximity to bundles of 
smooth muscle. Thick, intermediate and thin filaments are 
abundant, and microtubules are present (Stephens et al 1980). 
Nerve axons run parallel to smooth muscle bundles. Nerve bundles 
are present at all levels (trachea to 7th order bronchi), but 
are more frequent in the smaller bronchi (Daniel et al 1986).
Frequent connections exist between cells, often of the gap 
junction type. This form of connection implies electrical 
coupling of the cells, such as has been demonstrated in cardiac 
muscle (Richardson and Ferguson 1979). The presence of 
significant numbers of gap junctions will cause a spread of a 
contractile stimulus from cell to cell producing an increased 
response to that stimulus. This form of neuro-muscular 
arrangement is known as myogenic (Bumstock 1970).
In more exacting examination of human smooth muscle Daniel 
et al (1986) found moderate numbers of gap junctions 2.7/100 
cells, in larger order airway (_> 2nd order bronchi) but found 
fewer gap junctions in 4th - 7th order bronchi. However 
numerous small cell to cell contacts were present, but the 
authors were unable to confirm that these were functional as 
cell-to cell electrical connections.
1.2.3 Smooth Muscle Contraction
Smooth muscle contraction is initiated at the cellular level 
by cell membrane depolarisation. In its resting state the cell
9 4-
membrane is largely impermeable to calcium ions (Ca ) (Van
Breenan et al 1975). When the membrane depolarises, a large
• • 24-increase in the permeability of the membrane to Ca and hence an
influx/
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influx of Ca occurs (Bolton 1979). An alternative source of
2+intracellular calcium is the release of Ca from intracellular 
stores (Evans et al 1958, Bolton 1979). The relative importance 
of these two sources has not been defined for human airway smooth 
muscle.
Extracellular calcium enters the cell through at least two 
distinct channels - a receptor operated channel (ROC) and a 
voltage dependant channel (VOC), VOC can be anatagonised by 
various "calcium blocking drugs".
2+Once inside the cell the Ca complexes with calmodulin 
2+which has 4 Ca binding sites. Once two or more of these sites 
are occupied, the calmodulin changes conformation and may then 
activate myosin light chain kinase. Myosin is phosphorylated 
and may then interdigitate with actin and then, by the action of 
act in-myosin ATPase, produces muscle fibre shortening and hence 
smooth muscle contraction.
1.3 FACTORS INCREASING SMOOTH MUSCLE RESPONSES
Increase in the contractility of smooth muscle could be due 
to three separate mechanisms. The muscle cell could produce a 
greater shortening for a given stimulus, there could be more 
muscle which would therefore produce a stronger contraction, or 
more muscle cells could be recruited by a single stimulus. These 
mechanisms are discussed below,
i. Increased response. Changes in the calcium channel permeability
could affect smooth muscle responses. Either a 'leaky' channel 
or a channel allowing a greater number of calcium ions through 
would have the effect of producing an increase in smooth muscle 
contraction. If this mechanism involved the VOC then specific 
blockers of this channel might alter smooth muscle responses.
Differences in calcium handling could also explain increases 
in smooth muscle responses. If the smooth muscle was in a state 
of/
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of partial depolarisation so that it were reactive to low 
concentrations of various agonists the airway would appear 
hyper-responsive (Middleton 1983). In support of this theory in 
vitro smooth muscle which is partially depolarised is hyper­
reactive to various agonists (Fleming 1980). However there is no 
evidence that smooth muscle in asthmatic airway is partially 
depolarised. Indeed Souhadra et 31(1981) have demonstrated
increased depolarisation in the airway of sensitised guinea-pig.
2+Other factors increasing availability of Ca to intracellular
mechanisms such as increased release or reduced sequestration
2+from intracellular stores or decreased efflux of Ca from the 
cell could increase cellular responses to stimuli (Rodger 1985).
ii. An increase in the absolute amount of smooth muscle would 
generate more tension, thereby increasing the apparent response 
of the airway to a stimulus. Hypertrophy and hyperplasia of 
smooth muscle occurs in asthma (Huber and Koesler 1983, Dunill 
1960, Takizawa et al 1971) and chronic bronchitis (Hossain and 
Heard 1970). Increased thickness of vascular wall has been 
shown to increase vascular reactivity in rats (Foklow 1978). The 
dose response curve to norepinephrine had a steeper slope and a 
greater maximum response in hypertensive than normotensive 
animals. However, an increased quantity of smooth muscle could 
not explain the transient increase in airway responsiveness that 
occurs in normal human subjects during viral infections (Empey et 
al 1976) or after exposure to irritant chemicals (Goldie et al 
1978, Orehek et al 1976). Thus it is possible that the smooth 
muscle hypertrophy observed in asthma may be an effect of 
increased responsiveness, rather than a primary cause of same.
iii. Increased contractility of smooth muscle could be an intrinsic 
property of the muscle cell, or could be related to modifying 
factors acting on the airway (discussed later).
Properties of the muscle which could alter contractility conclude 
an increase in the cell-to-cell connections (gap junctions) 
between/
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between smooth muscle cells. These would allow action 
potentials to spread between cells thereby increasing the 
response to a depolarisation of a single muscle cell. (Perechia 
1974).
Smooth muscle may be divided into two sub types 
distinguished by different control mechanisms. These have been 
designated myogenic or neurogenic (Bumstock 1972).
Myogenic muscle has numerous cell-to-cell connections and 
few efferent nerves. Muscle bundles therefore respond as a unit. 
Single stimuli will produce a larger response and spontaneous 
activity is more likely. An example of this type of muscle is 
that found in the intestine.
Neurogenic or 'multi-unit' systems have few inter-cellular 
connections and a rich nerve supply. This allows finer control 
of response. Neurogenic mechanisms are present in larger blood 
vessels and the pupillary muscles of the eye.
There are few studies of the ultrastructure of human airway 
smooth muscle. Daniel et al (1980) showed cell-to-cell 
connections (gap junctions) were present in human bronchial and 
tracheal airway.
More recent studies have shown more gap junctions in the 
proximal, and less in the distal airway (Daniel et al 1986).
Increased responsiveness of airway could be explained by 
increased cell-to-cell coupling due to increased numbers of gap 
junctions. An example of this mechanism occurs in rat 
myometrium at the time of parturition (Garfield et al 1978). 
Gap junction numbers increase dramatically around the time of 
parturition, thereby facilitating the synchronised muscle 
contractions of labour. Numbers decrease to normal levels within 
48 hours of parturition. A mechanism such as this could explain 
the rapid changes in responsiveness seen in airway smooth muscle.
1.4/
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1.4 MEASUREMENT OF AIRWAY CALIBRE
The resistance of the airways depends on the driving 
pressure, i.e. the difference between alveolar pressure and mouth 
pressure, and the flow rate analagous to Ohms law of electricity, 
where Resistance = Voltage/current.
1.4.1. In routine clinical use, the commonest index of airway 
resistance is the volume of air able to be exhaled in 1 second 
the forced expiratory volume in one second (FEV^). The FEV^ 
typically involves 70% or more of the expiratory flow volume 
curve and so is an index of the integrated value of a large part 
of the curve. The test is simple for both subject and operator. 
FEVj reflects a flow-limiting segment of the airway. Changes 
distal to this rate limiting area do not affect readings and are 
therefore not detected by this measurement. In normal subjects 
most of the airway resistance is in central airways so FEV^ will 
not detect changes distal to these airways. Furthermore FEV^ is, 
to an extent, effort dependent.
1.4.2. Airways resistance (Raw)
Airway resistance may be assessed using the body 
plethysmograph which measures mouth pressure and flow directly, 
and alveolar pressure by an indirect method using volume changes 
and Boyles Law.
Airways resistance is a sensitive measure of bronchial 
calibre as the resistance of a tube is inversely proportional to 
the fourth power of its radius. Because the surface area of the 
airways increases towards the periphery, most of the resistance 
of human airway is located in the central intrathoracic airways 
and the extrathoracic airways. By measuring Raw during a panting 
manoeuvre which causes abduction of the vocal cords, a sensitive 
index of large airway changes is obtained. As airway calibre is 
to a degree dependent on lung volume, it is usual to correct 
values/
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values obtained for the thoracic gas volume (TGV)
1 producing the airways specific conductance sGaw =
XRaw x TGV).
1.4.3 Partial expiratory flow rates
Partial expiratory flow rates were measured as a sensitive 
index of changes in airway calibre. They were obtained by 
measuring the flow rates towards the end of expiration. As full 
inspiration may produce a transient bronchodilation (Nadel and 
Tierney 1961) assessment of the expiratory flow rate is best 
made without the subject inhaling to TLC. The total manoeuvre 
is a complete exhalation from tidal volume, followed by 
inhalation to TLC and then a full exhalation. If these 
manoeuvres are recorded as a flow against volume tracing TLC and 
a flow rate at a chosen percentage of TLC (eg 30%) can be 
measured.
1.4.4 Concentration-response curves
Non-specific bronchial responsiveness is usually assessed 
using methacholine or histamine as the bronchoconstrictor 
agonist. Increasing doses (usually doubling) of the agonist are 
inhaled through a nebuliser for a specified period. The output 
characteristics of the. nebuliser must be measured and, ideally 
the same nebuliser used for a series of measurements where 
comparisons of responses are measured. The change in airway 
calibre is measured and a log concentration-response curve is 
constructed. From this an end point fall in airway calibre is 
selected and the concentration of agonist producing this fall is 
recorded. For FEVp the provocation concentrations producing a 
2 0 % fall (the PC2 qFEV^) is used as an index of airways 
responsiveness. A wide experience with this measurement for both 
methacholine and histamine has accummulated in the literature and 
generally accepted normal ranges are available. A PC2 qFEV^ 
methacholine/
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methacholine or histamine of < 8 mg/ml indicates increased airway 
responsiveness and a PC2 QFEV2 >1 6 mg/ml is considered normal 
(Hargreave et al 1985). Provocation concentrations producing 
falls in sGaw and partial expiratory flow rates V^ q(p) are also 
used as an index of airway responsiveness. A greater percentage 
fall is taken as the end point with sGaw and V^ q(p) (usually 35 
or 40%) as these are more sensitive and hence more variable 
measurements. Experience with these latter measures is less so 
that normal ranges cannot be confidently stated.
1.5 NON SPECIFIC BRONCHIAL RESPONSIVENESS FIGURE 1.1
1.5.1. Introduction
Increased nonspecific bronchial responsiveness (NSBR) is 
characteristic of asthma (Curry 1946, Cockcroft et al 1977) and 
also occurs in chronic airflow obstruction (Klein and Salvaggio 
1966, Laitinen 1974). Patients with NSBR have an increased 
sensitivity to a wide range of unrelated physical and chemical 
stimuli.
Historical perspective
In 1929 Weiss et al demonstrated that intravenous histamine 
precipitated bronchospasm in patients 'prone to bronchial or 
cardiac asthma', and subsequently demonstrated that this change 
did not occur in normal subjects (Weiss et al 1932). Since this 
initial observation differences in responses between normal 
subjects and asthmatic patients have been described to 
methacholine (Curry 1947) prostaglandin (Mathe et al 1973)
leukotriene (Barnes et al 1986) and also to physical stimuli 
such as exercise (McNeill et al 1966), hyperventilation 
(Simonsson et al 1967) and cold air inhalation (Wells et al 
1960).
This increased responsiveness occurs to such a wide range of 
unrelated/
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unrelated stimuli. It suggests that airway smooth muscle is 
producing a greater contraction in asthmatic patients, i.e. that 
the airway is hyper-responsive and that the cause of the 
increased responsiveness must be due to post receptor differences 
in the airway smooth muscle. The first possibility is that the 
muscle itself is more sensitive for reasons discussed in section 
1.3. Other possible differences are altered nerve supply, or 
the presence of chemical factors which modify airway function.
Increased bronchial responsiveness is closely associated 
with asthma and some authorities suggest it is a prerequisite 
(Hargreave et al 1981). Some authors who have induced hyper­
responsiveness by allergen challenge have suggested that it is 
the cause of asthma (Cockcroft et al 1979, Permutt et al 1977, 
Stephens et al 1980) although this has been disputed (Stanescu 
and Frans 1982). It seems likely that clinical asthma is an 
interaction between increased bronchial responsiveness and a 
broncho-constrietor stimulus.
Although less well defined, increased bronchial 
responsiveness has also been found in patients with chronic 
airflow obstruction (Orie et al 1961, Barter and Campbell 1976) 
and also in patients who smoke cigarettes (Mullen et al 1984). 
It is not clear whether the aetiology of bronchial responsiveness 
in chronic airflow obstruction is different (Du Toit et al 
1986), e.g. it has been suggested that starting airway calibre is 
important (Orehek and Gayrard 1976) although it does not fully 
explain changes in airway responses (Mullen et al 1984).
1.5.2 Neural mechanisms
The role of neural influences on the airway has been 
extensively studied (reviewed by Boushey et al 1980, Barnes 
1986). The presence of nerve supply to the human lung has been 
known for 3 centuries. The presence of nerves in the airway was 
first described by Willis who also suggested a connection with 
asthma/
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FIGURE 1.1
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asthma (Willis 1679). Animal models in which vagal stimulation 
produced airway spasm similar to that in human asthma have been 
produced (Dixon and Brodie 1903). Airway innervation has been 
extensively studied using numerous animal models: cat (Silva and 
Ross 1974) domestic chicken (McLelland 1973), mouse (Honjin 
1956) and rat (Zussman 1966), rabbit (Mann 1971), guinea pig 
(Coburn and Tomita 1973) and non human primates (El-Bermann and 
Grant 1975).
The message which arises from this research is that nerve 
supply is present in all species investigated but that there are 
large inter-species differences (Richardson 1979) so that 
extrapolation to human airway is of dubious merit. The 
following review therefore refers only to studies of human 
airway unless stated.
Parasympathetic supply
The parasympathetic nerve supply to human airway is carried 
via the vagus nerve. Parasympathetic agonists produce 
bronchoconstriction (Alexander and Paddock 1921) and antagonists 
produce bronchodilation and are used as inhaled therapy for 
asthma (Ward et al 1981). It has been hypothesised that 
parasympathetic reflex activity could be exaggerated in asthma 
(Simonsson et al 1967). However, although some studies have 
reported significant reductions in bronchial responsiveness to 
histamine after atropine (Holtzman et al 1980), prostaglandins 
(Alanko and Poppius 1974) and exercise (Sheppherd et al 1982) 
others have not (Itkin and Anand 1970, Casterline et al 1976). 
Furthermore, there is no evidence for increased vagal tone in 
asthma (Barnes 1986).
Thus, although vagal reflexes may have a minor role in the 
control of airway responsiveness it is unlikely that they are a 
major determining factor.
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Sympathetic nervous system
The sympathetic nerve supply to the airway arises from upper 
thoracic preganglionic fibres that end in the extra pulmonary 
stellate ganglion. Sympathetic nerve supply to human airway is 
sparse and greatly outnumbered by cholinergic (Laitinen et al 
1985). Electric field stimulation is unaffected by pretreatment 
with propranolol suggesting that there is no direct sympathetic 
innervation of airway smooth muscle (Doidge and Satchell 1982, 
Davis et al 1982).
However, human airway smooth muscle relaxes when exposed to 
B-agonists in vitro (Davis et al 1982, Goldie et al 1982) so 
circulating catecholamines may have an influence on airway 
responses to bronchoconstrictors. Catecholamine levels in 
asthma are within the normal range, but infusions of adrenaline, 
but not noradrenaline, which produce physiological blood levels 
cause bronchodilat ion in asthmatic (Berkin et al 1984) and normal 
subjects (Berkin et al 1983) suggesting normal B receptor 
sensitivities and lack of functional^ receptors on human airway 
smooth muscle.
(Barnes et al 1980) found that the clinical variation in 
airway function parallels circulating adrenaline concentrations 
suggesting that adrenaline may be influencing airway calibre, 
although a direct effect on smooth muscle was unlikely at the low 
levels of adrenaline measured. This relationship could be 
caused by effects on mast cells stabilisation. Furthermore, 
studies have demonstrated a blunted increase in plasma adrenaline 
in asthmatic patients after exercise (Barnes et al 1981, Warren 
et al 1982) but not in acute severe asthma warranting hospital 
admission (Ind et al 1985). However, although the B adrenergic 
system may have a role in control of airway function it does not 
appear to have any relationship with bronchial hyper­
responsiveness .
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Other neural mechanisms
A third autonomic nervous system is present in the airway. 
It is neither cholinergic nor adrenergic, and when stimulated 
produces relaxation (Bulbring and Tomita 1967). It has been 
demonstrated in vitro in man. (Doidge and Satchell 1982, Davis 
et al 1982, Richardson and Beland 1976). Unfortunately, the 
transmitter used in this system is unknown. This limits in vivo 
investigation in man but animal work has demonstrated an in vivo 
bronchochodilator effect in cats after cholinergic and adrenergic 
blockade by electrical stimulation of the vagus nerve (Irvin et 
al 1980). If this system, designated the non adrenergic, non- 
cholinergic (NANC) system were having a significant regulatory 
role in normal airway, impaired function of the NANC pathway 
could explain increased bronchial reactivity in asthma. However, 
until the pathway is better characterised, its transmitter 
substances clarified, and specific antagonists developed, the 
role of NANC in the determination of the level of bronchial 
responsiveness will remain speculative.
1.5.3 Mediators
Bronchoconstriction is due to a combination of smooth muscle 
contraction, oedema of the bronchial mucosa and mucous 
hypersecretion (Hogg et al 1977). Asthma in young subjects (< 20 
years) is usually associated with atopy to a variety of allergies 
(Brown et al 1979). Exposure of susceptible subjects to allergen 
produces an immediate bronchoconstriction reaching maximum 1 0 - 
15 minutes after challenge. This is often followed by a 'late 
reaction' 3 - 2 4  hours later. This late response is associated 
with a rise in non-specific bronchial responsiveness (Cartier et 
al 1982).
The early reaction is thought to be due to IgE - antibody 
complexes forming on the mast cell surface inducing secretion of 
mediators in the airways (Pepys 1967). Various mediators are 
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released. The first discovered and most studied is histamine 
(Atkins et al 1980, Holgate 1985). Histamine is present in high 
concentrations in the membrane bound granules of mast cells and 
is released from the mast cell following antigen challenge or 
exercise. It produces immediate bronchoconstriction but is not 
associated with the late response or increased bronchial hyper­
responsiveness. The older anti-histamines do not block the 
immediate response after allergen (Eiser et al 1978) or exercise 
(Thomson 1980) challenge in susceptible patients, although 
recent work with non sedative H^ antagonists has demonstrated a 
significant inhibitory effect on acute bronchoconstriction 
(Rafferty et al 1987).
Prostanoids
Mast cell degranulation releases biologically significant 
levels of prostaglandin ^  (Lewis et al 1981) and thromboxane A£ 
(Lewis et al 1981). These are generated from cell membrane 
arachidonic acid via the cyclooxygenase enzyme. Mast cells 
produce mainly PGD£ (Holgate et al 1984). There is an eighty 
fold increase in PGD2 after in vitro anaphylaxis of human lung 
fragments (Schulmann et al 1981). PGD£ concentrations in 
bronchial lavage fluid increased 150 fold following specific 
allergen challenge in asthmatic subjects (Murray et al 1986). 
PGD2 causes bronchconstriction in normal and asthmatic subjects 
with asthmatic subjects being more sensitive (Hardy et al 1984). 
If prostaglandins were a major mediator in the active asthmatic 
response, non steroidal anti-inflammatory drugs such as aspirin 
or indomethacin should modify the acute bronchoconstriction 
observed. Although this has been shown to be the case in some 
patients (Kordanzky et al 1978) in the majority they have little 
effect (Smith and Dunlop 1975, Fish et al 1981). Using the 
thromboxane synthetase inhibitor 0Ky-046 Fujimara et al (1986) 
found a reduced bronchial responsiveness to acetylcholine in 
asthmatic/
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asthmatic subjects. In a small sub group of asthmatic patients 
NSAIDS may stimulate bronchoconstriction (Szczeklik et al 1975). 
This has been suggested to be due to diversion of arachidonic 
acid metabolism to the lipoxygenase pathway to produce 
leukotrienes (Walker 1972), although an alternative explanation 
would be that the inhibition affects preferentially the 
bronchodilater prostaglandins (Szczeklic et al 1975).
More important than an immediate bronchoconstrictive 
response is the ability to modify airway responses to other 
bronchoconstrictors thereby producing hyper-responsiveness. 
Recent work with PGD2 has shown a small but statistically 
significant increase in non-specific responsiveness of asthmatic 
patient following PGD2 inhalation (Fuller et al 1986). The 
duration of this effect was not assessed. However, Hardy et al 
(1986) were unable to demonstrate a pharmacological interaction 
between PGD2 and histamine in asthmatic subjects. Thus it seems 
unlikely that PGD2 is having a clinically significant effect on 
bronchial responsiveness in asthma.
Ecosanoids
Slow reacting substance of anaphylaxis (SRS-A) has been 
recognised as a mast cell product which produces 
bronchoconstriction since the 1940's (Kellaway and Trethewie 
1940). Because of its slow onset and prolonged effect it was 
called slow reacting substance of anaphylaxis. During the 1950's 
evidence for the role of SRS-A in hypersensitivity reactions 5 
accumulated (Brocklehurst 1962). It was not until the late 70's 
that it was discovered that SRS-A was a product of lypoxygenase 
metabolism of arachidonic acid (Samuelsson et al 1979).
SRS-A is a mixture of several lipoxygenase metabolisms 
designated leukotriene B^ , D^ and E^ . Leukotriene (LTC^ ) and 
leukotriene D^ (LTD^ ) account for the major biological activity 
from human lung (Lewis et al 1981).
Since/
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Since its discovery and synthesis LTD^ has been shown to be 
a potent bronchoconstrictor in human airway, both normal (Kern et 
al 1985, Barnes et al 1986, Smith et al 1985) and asthmatic 
(Smith et al 1985, Dahlen 1983). Not only are the leukotrienes 
the most potent bronchoconstrictors discovered, but the 
bronchoconstriction produced is of slow onset and lasts 1 - 2  
hours which is more akin to the bronchconstriction occurring in 
acute asthma than that produced by other mediators.
In vitro studies have shown that LTD^ can increase guinea- 
pig smooth muscle sensitivity to histamine and acetylcholine 
(Creese and Bach 1983). LTD^ is released by in vitro antigen 
challenge of lung tissue obtained from asthmatic patients (Dahlen 
et al 1983). All these results are consistent with an important 
role for leukotrienes in asthma. However, the importance of 
leukotrienes in asthma is not yet defined.
Studies examining the effect of leukotriene antagonists are 
necessary to define the role of leukotrienes in clinical 
bronchoconstriction. Piriprost, a lipoxygenase inhibitor had no 
effect on allergen nor exercise induced bronchoconstriction when 
given by the inhaled route (Mann et al 1987). An LTD^ 
antagonist, L649,923, did not alter allergen induced 
bronchoconstriction when taken orally (Britton et_ al 1987). 
However, these studies did not assess the potency of the 
inhibitor under the experimental conditions used, and in both 
cases, side effects were a problem. L649,923 has been shown to 
produce a 4 fold shift of the LTD^ dose-response curve to the 
right (Barnes et_ al. 1987). More potent antagonists are needed to 
fully assess the role of leukotrienes in determining bronchial 
responsiveness.
1.5.4 Other Factors in increased responsiveness
The mucosal layer in normal airway is complete (Laitinen et
al/
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al 1985). In patients who die during an acute attack, the 
mucosa is extensively damaged (Filley et al 1985) and even in 
mildly asthmatic patients the mucosa has areas of damage 
(Laitinen et al 1985). Chronic cigarette smoking increases the 
permeability of airway mucosa (Kennedy et al 1984). These facts 
have led to the hypothesis that bronchconstricting stimuli have 
better access to airway muscle when the mucosa is damaged, and 
that the lack of mucosal barrier may play a part in determining 
increased airway responsiveness. Further work is required to 
test this hypothesis.
1.6 AIRWAY SMOOTH MUSCLE PHARMACOLOGY
Smooth muscle pharmacology has been extensively investigated. 
Gut wall has been a useful source of smooth muscle preparations. 
Airway has been less studied because of marked variation in the 
characteristics of airway smooth muscle responses between species and 
between different ages of animal. No model demonstrating 
characteristics similar to human airway has been developed. The use of 
in vitro preparations has been the only method of studying human airway 
smooth muscle. In vitro preparations have the advantage of simplicity. 
Neural influences and reflexes are absent, and conditions such as 
temperature, pH, pC^ , pCC^ , drug concentrations and exposure time can be 
closely controlled and/or monitored.
Furthermore, passive forces on the muscle are also a source of 
variation, and these many also be determined by the experimenter. Drug 
access to smooth muscle receptors is also much less of a problem 
compared with the in vivo approach.
The importance of temperature in airway responses has been 
suggested by McFadden and Ingram (1982) who have proposed that airway 
cooling is a major cause of bronchconstriction in exercise induced 
asthma. In vitro human airway preparations produce a lower maximum 
contraction and have a reduced sensitivity to histamine when tested at 
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20°C as compared to 37°C (Black et al 1984). In experimental animals,
in vivo increases in inhaled pCC^ produce bronchoconstriction
(Loofbourrow et al 1957) but this has not been consistently found in
human subjects (Butler et al 1960) and, using rat trachea, Twort and
Cameron (1986) demonstrated that responses to changes in pC0 2 in vitro
occurred and that these appeared to be due to pH dependent changes in 
7+Ca uptake by smooth muscle. Thus it is important to control pCC^ and 
temperature when using in vitro preparations.
The reproducibility of response is also an important feature if 
useful in vitro studies are to be performed. Experiments with human 
airway, obtained at post mortem, have demonstrated that reproducible 
responses to a variety of stimuli, including acetylcholine and 
histamine, were obtainable for up to 30 hours after death. (Thulesius 
and Boe 1978).
It would appear that, if care is taken of the ,in vitro 
environment of human airway preparations, that investigation of smooth 
muscle responses, removed from the influence of neural and humoral 
factors, is practical.
In vitro smooth muscle may be kept in a closely controlled 
environment at a fixed temperature. Differences in the sensitivity of 
tissues are assessed by a shift in the dose response curve 
conventionally quantified as the concentration of agonist producing a 
concentration 50% of the maximum obtained although, in practice, any 
percentage of maximum could be chosen. The maximum contraction can 
also be measured. This depends on the contractility and the quantity of 
smooth muscle present.
1.7 IN VITRO STUDIES OF HUMAN AIRWAY
The response of airway smooth muscle in vivo is a complicated 
interaction of myogenic, neurogenic, chemical and perhaps other 
undiscovered factors. Investigation of bronchial strips of tissue 
containing smooth muscle simplifies this system and allows analysis of 
the/
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the role of the airway smooth muscle in determining airway 
responsiveness. Major differences exist in the control mechanisms in 
the airways of different species (Richardson 1979). Thus, applying 
results of experiments on in vitro animal airways must be interpreted 
with caution when trying to understand human airway. Fortunately, it 
is possible to study human airway obtained when removed at thoracotomy 
(usually from patients with underlying bronchial carcinoma, or from post 
mortem specimens). Reliable supplies of human airway have been 
difficult to obtain and so there is a relative paucity of studies of in 
vitro human airway smooth muscle.
Shultz and Dale (1910) first demonstrated that passively 
sensitised guinea-pig airway smooth muscle contracted when exposed to 
specific antigen in vitro. Lung tissue obtained from human asthmatic 
patients will contract when exposed to antigen (Schild et al 1951, 
Dahlen et al 1983). Passive sensitisation using human sera from atopic 
patients has also been achieved (Sheard et al 1967). More recently, 
release of bronchoconstrictor mediators from passively sensitised human 
lung have been demonstrated in vitro in human tissue (Adkinson et al 
1980 Davis et al 1983).
It therefore appears possible to produce a good in vitro model of 
airway sensitisation. However, the effect of sensitisation on the 
sensitivity of in vitro airway has not, to date, been assessed.
In vitro tissue will produce a contractile response to all the in 
vivo chemical bronchconstrictors including methacholine, histamine, 
prostaglandin D£ and the leukotrienes. Thus, in vitro human airway 
provides a useful model for studying the role of smooth muscle in 
determining differences in airway responsiveness and factors which might 
modify this. Leukotrienes have been shown, in vitro, to produce hyper­
reactivity of guinea-pig airway to acetylcholine and histamine, but only 
if the concentration of extra-cellular calcium was low (Creese and Bach 
1983).
There are few studies of in vitro human asthmatic tissue and 
conflicting results exist for this. (Dahlen et al 1980) examined 
bronchial/
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bronchial strips from two birch pollen sensitive asthmatics obtained at 
thoracotomy from patients with bronchial carcinoma, and found that 
bronchial strips were no more sensitive to histamine or leukotriene than 
strips from non-asthmatics. Post mortem tissue from 2 asthmatic 
patients who died during an acute asthmatic attack did not exhibit 
increased sensitivity, using histamine and carbachol as agonists 
(Paterson et al 1982) but tissue from an asthmatic subject who also had 
a carcinoid tumour had increased responsiveness to histamine, but not 
methacholine or leukotriene (Schnellenberg and Foster 1984). 
Dejongste et. at_ (1987) found increased responses in bronchial strips 
obtained from an asthmatic subject. The results show in increased 
maximum response rather than increased smooth muscle sensitivity. 
Cerrina et. al (1986) found no evidence of increased responses to 
histamine in vitro in tissue from 5 asthmatic subjects but did 
demonstrate reduced sensitivity to isoprotenerol of asthmatic tissue. 
However, the asthmatic patients were poorly characterised. This is an 
interesting result which requires further study. It does not fit in 
with the observation that B blockade does not alter bronchial 
responsiveness (Zaid and Beal 1966). Because it is very unusual for 
asthmatic patients to require thoracotomy, these case reports represent 
all the information available on asthmatic airway responses in vitro.
1.8 AIMS OF STUDY
Increased non-specific airway responsiveness is an important 
feature of obstructive airways disease. Understanding the mechanisms 
underlying differences in airway responsiveness is an important step in 
the understanding of the causes of airflow obstruction and may lead to 
improvement in the treatment of this condition.
One possible cause of increased airway responsiveness is 
increases in the sensitivity of airway smooth muscle. In this thesis I 
will use in vitro preparations of human bronchi which removes the smooth 
muscle from neural and humeral effects encountered in vivo. Using this 
model/
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model I will establish whether differences in airway responsiveness 
measured in vivo can be correlated with differences in smooth muscle 
sensitivity measured in vitro.
Initially, I will establish a reliable means of measuring airway 
responsiveness using several different measures of airway calibre.
I will then measure bronchial responsiveness in patients due to 
undergo thoracotomy, and compare this to the sensitivity of bronchial 
preparations obtained from these patients. Thus differences in vivo 
responsiveness will be compared to smooth muscle sensitivity. I will 
use several bronchoconstrictor agonists including methacholine, 
histamine and leukotriene D .^ The last of these will be of great 
interest as leukotrienes may be important in the development of airway 
hyperresponsiveness (Robinson and Holgate 1985).
I will also examine the ultras true tural appearances of bronchi 
obtained from the thoracotomy patients to assess whether there are 
obvious structural differences in preparations which exhibit different 
airway responsiveness in vivo, e.g.whether gap junction numbers differ.
In the second part of the study I will examine the mode of action 
of leukotriene in vivo and in vitro to assess the role of calcium ion 
influx in its production of bronchoconstriction. I will use the calcium 
antagonist, verapamil, to assess whether the voltage dependent calcium 
channel is important in leukotriene induced bronchconstrietion.
The in vitro model will also allow assessment of factors which 
modify smooth muscle sensitivity. I will passively sensitise smooth 
muscle and assess whether sensitisation itself or subsequent specific 
antigen exposure alters the sensitivity of the isolated airway 
preparations to pharmacological agonists.
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M A T E
C H A P T E
R I A L S  A N D
2
M E T H O D S
MATERIALS AND METHODS
2.1 HUMAN VOLUNTEERS
This section summarizes the groups of human volunteers who 
participated in these experiments. More detailed description of each 
group of patients is tabulated in the appropriate chapter of the thesis.
2.1.1 Normal Subjects
(a) Surgical Controls
Seven male and three female patients undergoing routine 
general surgery were studied. They were aged 46-67 (mean +. 
SD = 53+8). None were smokers. Three were atopic as 
judged by positive skin tests but none had raised levels of 
RAST IgE.
(b) Normal Volunteers
Six normal subjects were recruited. They were aged 20-36 
(mean+ SD = 28 +3.6). All were non smokers and had no 
history of respiratory disease. None were atopic.
2.1.2 Surgical patients
Forty two patients due to undergo thoracotomy, usually for 
removal of a bronchial carcinoma, were recruited. Their ages 
ranged from 43-72 (Mean +SD - 60 +.7). Thirty were male and twelve 
female. Thirteen were atopic as judged by skin testing and six had 
elevated levels of RAST IgE. One patient had a history of asthma 
since childhood and had reversible airflow obstruction. Another 
had a history of wheezy dyspnoea and hay fever, although a 
diagnosis of asthma had not been established in the past.
2.1.3 Asthmatic Patients
(a) Volunteers
Seven asthmatic patients were studied. They were aged 22- 
36 years (mean +SD = 31 +10). All were atopic and were 
non-smokers. All were taking inhaler B2 adrenoceptor 
agonists/
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agonists by pressurised aerosols, two were taking regular 
inhaler steroids and two were taking sodium cromoglycate.
2.1.4 (b) Surgical controls
Ten asthmatic patients were studied to establish the range 
of values expected for asthmatic subjects for the 
measurements used in this thesis. They were chosen to be 
in the same age range as the surgical patients. Age range 
44-75 (mean +SD = 60 +9). One smoked cigarettes and one a 
pipe. Four had positive skin prick tests and three had 
raised levels of specific IgE. All were taking regular 
inhaler B2 adrenoceptor agonists, seven were taking regular 
inhaler beclomethasone and one patient was taking sodium 
cromoglycate.
The nature of each study was explained to both patients and normal 
subjects. All investigations were approved by the Ethical 
Committee of the Western Infirmary and all patients and normal 
subjects gave informed consent.
2.2 EXPERIMENTAL EQUIPMENT
2.2.1 Body Plethysmograph
The constant--volume plethysmograph (Dubois et_ al, 1956) used in 
this study was manufactured by Fenyves & Gut (Basle, Switzerland). 
The chamber was fitted with a large window in the front wall, and a 
Perspex door with an electro-magnetic catch (Figure 2.1). A 
calibration pump for the chamber was incorporated. The volume of 
the plethysmograph was 690 litres. A heated air selector allowed 
the subject to be connected either to the outside air, the chamber 
or the BTPS breathing bag. Pressure changes in the plethysmograph 
were monitored by a capacitive differential pressure transducer 
(Fenyves & Gut, Basle) (sensitivity 0.001 - 0.2 kPa: frequency 
response flat to 50 Hz) backed off against a rigid metal container 
(volume 50 litres) to stabilize against thermal drift. Pressure 
changes/
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FIGURE 2.1
Mouth pressure
shutter 
Pneumotachograph
Diagramatic representation of the constant volume body plethysmograph.
When the subject pants, the glottis is fully open and P.mouth = P alveoli
resistance = A Pressure hence airways resistance may be calculated 
flow
changes at the mouth produced by the inspiratory effort against the 
closed shutter were measured by a differential pressure transducer 
(Fenyves & Gut, Basle) sensitivity 0.5 - 5 kPa : frequency response 
flat to 50 Hz backed off against the interior of the box. Airflow 
was measured with a heated Fleisch pneumotachograph and 
differential pressure transducer (Fenyves & Gut, Basle) with a 
linear response to 14 1/sec (frequency response flat to 50 Hz). 
Box and mouth pressure plus airflow were plotted on an X-Y recorder 
(Hewlett Packard, 7041A) with a writing speed of more than 75 
cm/sec and a linearity better than 0.2%. Box pressure (Pbox), 
mouth pressure (P mouth) and flow were calibrated before each 
experiment. As part of the study the measurement of flow, box 
pressure and mouth pressure was automated.
The electrical signal from the body plethysmograph, either 
airflow and box pressure, or mouth pressure with zero airflow and 
box pressure, depending on the mode selected. These signals were 
sampled with 16 bit resolution and fed to a BBC model B computer 
(Acorn electronics).
2.3 EXPERIMENTAL METHODS IN VITRO
2.3.1 Measurement of Raw. TGV and sGaw
The subject sat in the closed body plethysmograph until the 
temperature of the air, and hence the pressure inside the box, had 
stabilised. The pressure was maintained equal to the external 
pressure by means of a pressure compensation switch. The subject 
then put on a nose clip, fitted the box mouthpiece and panted 
rhythmically through the pneumotachograph at a frequency between 1 
and 2 Hz. The act of panting ensured an open glottis, and the 
cheeks were supported by the hands to minimize the bucial component 
to the pressures and flows generated.
While the subject panted, the pressure compensation switch was 
turned off. The first mode selected was the airflow/box pressure 
and this was followed by the mouth pressure/box pressure mode 
during/
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during which the subject panted against a closed shutter which 
closed automatically at end expiration. These two manoevres gave 
one determination of airways resistance (Raw), thoracic gas volume 
(TGV) and specific conductance (sGaw). During each period of 
panting, the complete sequence was carried out twice, Raw and TGV 
were thus measured almost simultaneously. All plethysmographic 
measurements were carried out by myself. The mean of the eight 
readings was taken as sGaw.
2.3.2 Analysis of Data
(i) Manual Measurement
Eight graphs of airflow against P.box and P.mouth against P.box 
were recorded and analysed later. Thoracic gas volume is 
obtained from the gradient of the P.mouth/P.box graph (Figure 
2.2), which was estimated by drawing a line between the two 
turnover points A and B and measuring its slope, and then used 
in the following equation
TGV ml = 1/grad (B-47) - VKorr 
Where KjGV was a standardisation factor for TGV dependent on 
the range taken for box pressure, 1/grad is the reciprocal of 
P.mouth/P.box gradient, B is the barometric pressure in mm 
Hg. and V Korr was composed of the following values; apparatus 
dead space 140 ml., stomach volume with diaphram breathing 170 
ml. (Bedell et_ al_ 1956)
Raw was calculated from Airflow/P.box (Figure 2.3) and 
P.mouth/P.box gradients using the following formula - 
Raw = (KRaw (B-47) G ) - 0.25 
( TGV )
Where was a standardisation factor for Raw dependent on
range taken for flow and box pressure, B was barometeric 
pressure (mm Hg), G was the reciprocal of the gradient of the 
airflow/Pbox graph and 0.25 was a constant value taken to be 
the resistance of the mechanical equipment between mouthpiece 
and breathing bag.
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(ii) Automatic method (Figure 2.4)
(a) The Airflow/P.box graph (Figure 2.3)
The data acquisition programmes were written in machine 
code and data were sampled from both output channels at 
rate of 1.6 K/Hz. Once the Airflow/P.box mode had been 
selected the flow channel was monitored continuously until 
the flow exceeded 0.5 1/s for at least 160 milliseconds, as 
this indicated that the respiratory cycle was properly 
underway. As soon as the flow dropped to less than 0.4 
1/s data were sampled until the flow exceeded 0.5 1/s in 
the other direction. The sampling then ceased and 
recommenced when the flow was in range on the other half of 
the respiratory cycle. If the button was released before 
both sides of the cycle had been sampled, an error flag was 
set. An error flag was also set if too many samples had 
been taken while the flow was in range thus causing a 
memory overflow. This could be caused by the patient 
breathing either too quickly or with insufficient 
amplitude, or a combination of both.
The data were processed at a later stage, while the subject 
rested, before the next sampling period. The processing 
was performed by a compiled Basic program which identified 
the section of data on the inspiratory side of the cycle 
and evaluated the gradient with a standard least mean 
squares fit routine.
(b) The P.mouth/P.box Graph (Figure 2.2)
The relationship between the two variables in this case is 
much more linear than for the flow/box pressure measurement 
and it is adequate to measure the gradient at a region 
midway between the two extremes in mouth pressure. The 
mean value of mouth pressure is variable, however, and 
depends on the panting manoevre. Therefore, unlike the 
previous situation the region of interest cannot be 
specified/
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FIGURE 2.2
MOUTH 
PRESSURE
- l  Grad
BOX PRESSURE
Graph of mouth pressure (P.mouth) against box pressure (P.box). A. and B 
are the turnover points. As the relationship between the two points is 
close to linear, the line joining A and B is an adequate measure of the 
gradient.
FIGURE 2.3
 i  it .  +0.5
direction
flow
♦ pb
Graph of flow measured at the mouth against box pressure. Measurement of 
the gradient is made close to zero flow. In practice this is between
-0.5 1/sec (point B) and +0.5 1/sec (point A) on the inspiratory side of 
the cycle and the similar region between points C and D on the expiratory 
half of the cycle.
FIGURE 2.4
FIGURE 1
Flow
Flow or Mouth
—  .B o x  >  Pressure
Mouth
Pressure
Shutter ^
Pressure
Box Pressure
Control
Signal Processing 
(Gain±OC Offset
Mode Select
Hand-Held Unit Printer
TGV
Raw
X-Y Plotter
Oscilloscope
A/D
Converter
Plethysmograph
Electronics
Body
Plethysmograph
Computer
Disc
Drives
The computerised system for measuring Raw and TGV. The hand held unit 
controls the plethysmograph electronics and the computer data collection.
FIGURE 2.5
DIAGRAM OF FLOW-VOLDME TRACING
FLOW
E VOLUME
Graph of inspiratory and expiratory flow against volume
B - C Tidal breathing
C 4  E partial expiratory flow curve
E = RV
E > A inspiration to TLC
A TLC
A + E complete expiratory flow curve
D point on volume curve representing 30% of TLC
G = Flow rate at 30% of TLC on complete expiratory flow curve
F = Flow rate at 30% of TLC on partial expiratory flow curve \
H 1 second timer mark allowing FEV^ to be measured
specified until the respiratory cycle has finished. This 
meant that the whole cycle had to be stored in the memory, 
and thus to avoid memory overflow the sampling rate had to 
be slower. The actual sampling rate was 125 Hz and was 
such that two complete respiratory cycles could be stored 
in the memory space allocated.
During the analysis phase the data were analysed by a compiled 
Basic program which had identified the turnover points and hence 
the midpoint region in the respiratory cycle, and evaluated the 
gradient in this region by a standard least mean square fit 
process.
2.3.3 Measurement of Flow volume curves (Figure 2.&)
Flow-volume curves were recorded using the Flow-volume mode of 
the body plethysmograph (Fenyves and Gut, Basle, Switzerland). 
Partial and complete expiratory flow volume (PEFV and CEFV) curves 
were obtained using a heated pneumotachograph with integration of 
flow, and recorded on an X-Y recorder (Hewlett-Packard 7041A). The 
flow volume curves were obtained in the following manner. After a 
period of normal tidal breathing each patient expired maximally 
from end tidal expiratory volume to residual volume (RV) to obtain 
the PEFV curve. When RV was reached the patient inspired to total 
lung capacity (TLC) and expired maximally to RV to obtain the CEFV 
curve. A one second timer was incorporated into this part of the 
curve. From the CEFV curve the forced expiratory volume in 1 
second (FEV^ ), and forced vital capacity (FVC) were obtained. The 
volume corresponding to 35% (or 30%) of total lung capacity was 
obtained from the mean FVC of at least 5 baseline curves. Maximum 
expiratory flow rates at this lung volume were measured from the 
partial (Vgg(p)) and (Vgg(c)) flow volume curves for baseline and 
subsequent curves - that is, curves were matched at TLC in order to 
compare flow rates. In all studies 1 minute was allowed between 
each measurement of PEFR as inflation to TLC may produce temporary 
bronchodilat ion/
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bronchodilation (Nadel and Tierney, 1961). The mean of 5 values 
was used for baseline value and the mean of two measurements 
used after each subsequent drug inhalation.
2.3.4 Routine Pulmonary Function Tests
Routine pulmonary function tests were carried out pre- 
operatively on all surgical patients. Spirometry was measured on 
a water sealed spirometer (Godart), static lung volumes were 
determined by the helium dilution technique; single breath transfer 
factor for carbon monoxide (T1cq) was determined by the method of 
Ogalvie et al (1957). Predicted normal values were taken from 
Cotes (1975).
2.3.5 Prick Skin tests
Prick skin testing against seven common antigens (Bencard) was 
carried out to assess atopic status of each subject. The allergens 
used were (1) control solution, (2) house dust, (3) 
Dermatophagoides pteronvssinus.(4) cat, (5) dog, (6 ) feathers,- (7) 
mixed grass pollens and (8 ) Aspergillus fumigatus.
2 .3.6 .Inhalation tests
Inhalation tests were carried out using a modification of the
method described by Cockcroft et, al (1983). Aerosols were
generated with the same Wrights nebuliser by air at 50 psi (345
Kpa) at a flow rate of 81/min to give an output of 0.15 ml/min.
i. .
Patients wore a nose clip and aerosols were inhaled by tidal
breathing through a lose fitting facemask. Phosphate buffered
saline was inhaled first followed by either methacholine 2-64 mg/ml
histamine 2-64 mg/ml or leukotriene (LTD^ ) 0.08-50 mcg/ml for
normal subjects. For asthmatic patients methacholine 0.06 - 4
mg/ml, histamine 0.06 - 4mg/ml or LTD^ 0.0032-2 mcg/ml were given.
All solutions were nebulised for 2 minutes at 10 minute intervals
for methacholine and histamine and at 15 minute intervals for
leukotriene.
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The volume added to the nebuliser was 4 ml for methacholine and 
histamine and 2 ml for LTD^ studies. It has been shown with this 
system that 0.3 ml of solution is nebulised each 2 minutes. The 
dose of drug reaching the airways was not formally measured but is 
likely to have been around 10% (Davies 1975).
Before inhalation the mean of 8 measurements of sGaw were 
recorded. Five measures of FEV^ V^q(p) and V3 q(c) were also 
recorded with a full minute between each measurement. The first 
inhalation was always that of vehicle and phosphate buffered 
saline. Eight sGaw and three FEVj, Vgp(p) and V3 q(c) were 
measured. The pre and post saline values were averaged and used as 
the baseline from which percentage fall was calculated.
2 .3.7.Calculation of responsiveness
After each inhalation study a log concentration-response curve 
was constructed (Figure 2.6) and the responsiveness expressed in 
terms of the provocation concentration (PC) of the drug in use 
which would produce a 10% fall in FEVp (FC^ q FEV^) or a 20% fall 
in FEV^ (FC2 0 E^V^ ), a 35% fall in sGaw (PCgg sGaw), a 30% fall in 
V3 q(p) (PCgQ V3 0 (p)) or a 30% fall in V3 q(c) (PC^q V3 q(c))»
If the appropriate fall was not obtained the value assigned was 
greater than (>) the highest concentration of the drug inhaled 
(e.g. >64 mg/ml).
2.4 EXPERIMENTAL METHODS IN VITRO
2.4.1.Tissue collection and handling
Patients undergoing thoracotomy were premedicated with 
papaveritum and hyoscine. Anaesthesia was induced by either 
Althesin or thiopentone sodium and maintained with nitrous 
oxide and halothane. A variety of neuro-muscular and 
anaesthetic blockers were given. The trachea was intubated 
and the lungs ventilated artificially. Bronchial tissue was 
obtained immediately after removal at thoracotomy. Similar 
sized/
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FIGURE 2.6
Concentration-response curve to histamine with derivation of PC^sGAW
% FALL 
IN sGaw
30 -
10-
0*5 1 2 4 8 16 32 64
LOG CONCENTRATION HISTAMINE (mg/ml)
Graph of log concentration inhaled agonist response, as measured by 
percentage fall from baseline level (FEV^ or sGaw). The 
concentration of agonist producing a 35% fall (PC2 5 ) [or 20% fall 
PC2 0 ] is derived and used as an index of in vivo responsiveness.
sized samples of second to sixth order bronchi were dissected 
from macroscopically normal tissue. The tissue was thoroughly 
oxygenated after removal and then stored overnight at 4°C in 
well oxygenated Krebs-Hensleit physiological saline (KHS).
Physiological Saline
KHS was prepared freshly each day. It was of the 
following composition (m mol litres*"^ ")
Na Cl 118 
K Cl 4.7
Mg S0 4  1.2
KH2 P04  1.2
Ca Cl2 2.5
Na H C03 25 
Glucose 11.7
To ensure that Ca Cl2 dissolved, the solution was 
saturated with a 95% 02: 5% C02 mixture to lower the pH of the 
solution. If this step was not taken Ca2 (P0 4 ) 3  tended to 
precipitate.
2.4.2 Tension measurement
Rings of bronchi were dissected and divided to produce 
transverse strips. These were suspended in organ baths in 
KHS at 37°C and bubbled with a gaseous mixture containing 95%
02 and 5% C02. An initial stretching tension of 1.5 - 2.0G 
(15-20 mN) was applied to each tissue which was then left for 
60 minutes to equilibrate, during which time the bathing KHS 
was changed three times. Changes in tension were recorded 
using isometric force-displacement transducers (FT03C, Grass 
instruments, Quincy, Mass. U.S.A.) coupled to a Grass (model 
7) curvilinear ink-writing polygraph. Tissues were attached 
to the transucers via a silk thread (6 /0 )
2.4.3/
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FIGURE 2.7
Arrangement for in vitro measurements
Polygraph
Recorder
Force
Transducer
Organ bath
bronchial strip
Diagram of bronchial strip suspended in organ bath attached to 
isometric transducer. The tone generated by the bronchial strip 
was recorded on a continuous polygraph trace. Agonist was added to 
the bath and the resultant change in tension measured from the 
polygraph recording.
2.4.3 Measurement of Tissue response
To assess the response of each tissue to agonist 
stimulation, cumulative concentration - effect curves were 
constructed for each agonist according to the method of Van 
Rossen (1963). After equilibration the tissue was exposed 
twice to near maximally effective concentrations of agonist at 
30 min intervals to gauge the magnitude, normality and 
reproducability of the contractions produced. A cumulative 
concentration - effect curve was then constructed by adding 
increasing concentrations of agonist increasing in log units 
(methacholine) or half log units (histamine and LTD^) until a 
maximum response was reached. Each addition of agonist was 
made at the peak of effect produced by the preceding 
concentration (Figure 2.8). In all experiments the 
concentration of agonist producing a 50% (EC^ q) of maximum 
contraction was calculated from the graphically displayed data 
(Figure 2.9). Additionally, the maximum tension generated was 
determined and expressed in g tension/mg wet weight of tissue.
At least four bronchial strips from each patient were tested 
and mean values for EC^q and maximum tension generated per mg 
tissue determined.
In vivo responsiveness and the in vitro sensitivity of 
tissue obtained from the same patient were then compared.
2.5 ' ULTRASTRUCTURAL STUDIES
Bronchial tissue was obtained immediately after removal at 
thoracotomy. Tissue rings were dissected from macroscopically 
normal tissue using a scalpel blade. The rings were stretched on a 
small spring and incubated in Calcium free KHS solution bubbled with 
95% 0£/5% CO2 gas mixture for ten minutes. The tissue was then 
fixed in freshly diluted 4% Gluteraldehyde solution.
The tissue was later embedded in Araldite. Sections of embedded 
tissue/
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FIGURE 2.8
Polygraph tracing of tension generated against time
2
tension 
(grammes) 1
Tracing obtained from the force transducer attached to a bronchial strip. 
Increasing concentrations of agonist were added, the next concentration 
being added when the response to the previous concentration had 
plateaued.
Fr^m the tracing a concentration-response curve was drawn and EC^q 
values derived.
max
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FIGURE 2.9
Log concentration-response curve for in vitro responses
LOG-CONCENTRATION EFFECT CURVE ON IN VITRO TISSUE
%
MAXIMUM
RESPONSE
1 0 0-.
50
20-
HISTAMINE CONCENTRATION (umoles/litre)
Figure2.7
Log concentration-effect curve for agonist added to organ bath.
Effect is expressed as the percentage maximum for that bronchial strip. 
From this the concentration producing a 50% of maximum EC^q or 20% of 
maximum EC2Q was derived and used as an index of in vitro smooth muscle 
sensitivity.
tissue were cut on a LKB Ultratome 1. The sections were double stained 
with uranyl acetate and lead acetate and the ultra structure of the 
tissue examined under a Phillips EM 301 transmission electron microscope. 
Photographs of various magnifications (2,600 - 22,000) were taken for 
future analysis.
i
2.6 SMOOTH MUSCLE QUANTIFICATION
After completion of the in vitro concentration-effect curve, the 
bronchial strips were fixed in corrosive formal acid and mounted in 
paraffin wax. Four representative sections of each tissue were prepared 
and stained with Unnas Variant of Van Geesons stain (Lillie 1954). 
Smooth muscle was quantified using light microscopy with x 100 
magnification with an incorporated 42 point eyepiece grid. For each 
section of bronchial strip, eight random fields were examined and the 
number of points overlying smooth muscle estimated. The percentage of 
muscle was measured for each of the four sections and an average % of 
muscle present in the bronchial strip derived. The percentage of smooth 
muscle present, the absolute amount of muscle present in strip (wet 
weight x % muscle) and the maximum tension per unit mass of smooth 
muscle was then calculated and maximum tension was compared with the 
percentage of smooth muscle present for each individual bronchial strip.
The average values of these in vitro measurements for the four bronchial 
strips from each patient was compared with in vivo measurements.
2.7 DRUGS
Drug solutions used were methacholine dihydrochloride (Sigma, 
London) made up in solutions to a concentration of 0.06 - 64 mg/ml, 
histamine dihydrochloride (Sigma, London) made up of solutions of 0.06 - 
64 mg/ml, and leukotriene D^ 100 mg and 10 mg ampoules diluted to 0.0032, 
0.016, 0.08, 0.4, 2.0, 10.0, 50.0 mcg/ml. LTD^ ampoules were stored at 
-70°C and diluted to appropriate concentrations immediately before use in 
experiments. Other drugs used were atropine sulphate 5 mg/ml (Antigen 
limited/
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limited) sodium cromoglycate 10 mg/ml (Fisons Limited) and verapamil 
hydrochloride 2.5 mg/ml (Abbott).
2.8 STATISTICAL ANALYSES
In comparing in vivo and in vitro results, correlation coefficients 
were calculated from linear regression using the method of least squares 
analysis. PC results were analysed under a natural logarithm 
transformation.
Comparison of results after drug and placebo were analysed by 
analysis of variance and Students t test. Comparison of responsiveness 
between different groups of subjects and/or patients was made using 
Students unpaired t test.
The level of significance was set at p < 0.05.
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C H A P T E R  3
C O M P U T E R I S E D  S Y S T E M  F O R  T H E  M E A S U R E M E N T  
O F  S P E C I F I C  A I R W A Y S  C O N D U C T A N C E
COMPUTERISED SYSTEM FOR THE MEASUREMENT OF SPECIFIC AIRWAYS
CONDUCTANCE
3.1 INTRODUCTION
The object of this project was to investigate the role of airway 
smooth muscle in determining airway responsiveness. The method to be 
used was to compare in vivo responsiveness with in vitro sensitivity. A 
reliable measure of in vivo airway calibre was therefore required. When 
FEVj is used, it can be difficult to obtain significant changes on 
bronchoconstrictor challenge in non-asthmatic subjects. Specific 
conductance has the advantage of being a sensitive measure of airway 
calibre so that relatively small changes can be detected and an index of 
in vivo responsiveness obtained. sGaw has the additional advantage of 
reflecting changes in the larger airways, the site from which the tissue 
to be tested in vitro is obtained. sGaw is determined using a constant 
volume body plethysmograph by the method of Du Bois et_ al_ (1956) 
described in the methods chapter. The measurement of specific 
conductance requires the drawing of two graphs mouth pressure (P.m) 
against box pressure (P.b) and flow (^ ) against (P.m) on a X-Y plotter, 
and then estimating the slope of each graph. Estimation of the gradient 
of a non-linear graph introduces error and is a time consuming practice. 
As part of this project, the measurement of sGaw was automated. The 
results of PC^sGaw and of baseline sGaw values obtained by the automated 
analysis were compared with those obtained by the traditional manual 
method.
3.2 METHODS
3.2.1 Equipment
A constant volume plethysmograph (Fenyves & Gut) was used for 
all measurements. The output signals from the apparatus were 
either airflow and box pressure or mouth pressure (with zero 
airflow) and box pressure, depending on the mode selected. These 
signals were sampled via an external 1 2 bit analogue to digital 
converter and fed to a BBC model B microcomputer for processing and 
to an X-Y plotter for future manual analysis. The mode was 
selected/
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selected by the operator pressing one of two buttons, and signals 
relating to the status of these buttons were also sampled and fed 
to the computer.
3.2.2 Procedure
The subject was asked to pant rhythmically at 1-2 Hz. The 
first mode selected was airflow/box pressure and this was followed 
by the mouth pressure/box pressure mode. These two manoeuvres 
gave one determination of sGaw and during each period of panting 
the complete sequence was carried out twice. The data were then 
processed within 4-5 seconds, while the subject rested. If no 
errors were identified, the two values of sGaw were stored in 
memory. The whole procedure was repeated four times, or more if an 
error had occurred, giving eight values of sGaw which were stored 
on disc. An outline of the programming techniques used for the 
acquisition and analysis of the data is given in the methods 
chapter.
3.2.3 Clinical Evaluation
To evaluate the system over a range of values under a clinical 
setting, histamine bronchial provocation tests were performed on a 
group of human subjects. Seven subjects were tested on two 
occasions, at the same time of day, not more than 7 days apart 
(Table 3.1). All were non-smokers. Three were asthmatic patients 
on inhaled bronchodilator treatment. Four were considered normal 
with no history of atopy nor respiratory disease. Five of the 
seven had never previously been tested in a body plethysmograph.
Histamine inhalation tests were carried out using a 
modification of the method described by Hargreave et al (1981). 
Aerosols were generated with the same Wright nebuliser by air at 50 
psi at a flow rate of 8 1/min to give an output of 0.15 ml/min. 
Patients wore a nose-clip and aerosols were generated by tidal 
breathing through a loose-fitting face mask. Buffered normal 
saline was inhaled first followed by doubling concentrations of 
phosphate/
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phosphate buffered histamine, 2-64mg/ml for non-asthmatic patients 
and 0.06-4 mg/ml for asthmatics. Each inhalation was for 2 
minutes at 10 minute intervals. Before the first inhalation eight 
sGaw determinations were recorded. From 1.5 minutes after each 
inhalation, responses were assessed by sGaw measurements. 
Inhalations were continued until the sGaw had fallen by 35% or 
more.
Measurements from the same panting manoeuvre were both recorded 
with the X-Y plotter (Hewlett-Packard 7041A) and analysed by the 
computerised system and, for both systems, 8 manoeuvres were 
analysed and the mean and standard deviation were calculated. 
Manual results were measured in a blinded manner after the 
challenge was over by me and I was unaware of the results of 
computer analysis. The graphs were analysed by measuring the 
gradient of one limb on the inspiratory part of the V/Pb graph. 
Using automatic and manual methods the sGaw following each 
concentration of histamine was estimated and the histamine 
concentration producing a 35% fall in sGaw (PCg^sGaw ) was 
calculated by linear interpolation. The PCg^sGaw values obtained 
for each patient by these methods were used to assess 
reproducibility of both methods and for comparison between the 
automatic and the manual method.
3.2.4 Analyses
Baseline values measured by the two methods across the two days 
were compared by Student's paired t-test. The reproducibility of 
each of the two methods was assessed across the two study days by 
calculating correlation co-efficients from linear regression using 
the method of least square analysis. The level of statistical 
significance was set at p < 0.05.
3.3 RESULTS
Results were recorded for all seven subjects on two occasions.
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FIGURE 3.1
PC^sGaw values obtained on 2 days by manual and automatic method
MANUAL AUTOMATIC
50-
“ “ 17
10*0 -
1-0 -
0-2 -
DAY 1 DAY 2 DAY 1 DAY 2
Comparison of PC^sGaw for the seven subjects on two days by the 
and automated methods. Results are expressed on a log scale, 
results across the two days correlated significantly (r = 0.77 p 
and automatic measurements correlated highly significantly (r = 
0.01).
manual, 
Manual 
< 0.05), 
0.99 p <
3.3.1 Baseline sGaw
The two sets of values obtained for sGaw before drug 
administration on each of the two test days are presented for both 
the manual method and the automatic method (Table 3.2). The mean 
co-efficient of variation for the manual method (31.6%) was 
inferior to the automatic method (m = 19.2%)
3.4.2 PC^sGaw Results
The relationship between the three methods of analyses was 
assessed by comparing the PC^sGaw histamine for the seven subjects 
across the two days (Figure 3.1). There was no significant 
difference in the mean PCg^sGaw values obtained by the two methods 
of analysis. The geometric mean PC-^sGaw values ( _+ SEM) were
4.6 +. 3.9 mg/ml (one limb manual), and 6.2 +. 5.4 mg/ml
(automatic).
As a measure of reproducibility, the correlation between the 
PCg^sGaw results for each subject obtained on day 1 and day 2 was 
investigated for each of the two methods. The correlation co­
efficients were r = 0.76 (p < 0.05) for the manual method, and r = 
0 .9 9 (p < 0.0 1 ) for the automatic method.
3.5 DISCUSSION
The constant volume body plethysmograph was automated in a straight 
forward and low cost way. Each value of sGaw is produced within 4-5 
seconds of completion of the panting manoeuvre and there is an 
improvement in the reproducibility of airways responsiveness as assessed 
by PC^sGaw, where sGaw is measured from one limb of the flow-pressure 
loop.
The co-efficients of variation of baseline sGaw values are 
comparable with values obtained in other studies and reported by 
Tattersfield and Keeping (1979). When the baseline values obtained by 
the/
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3.3.1 Baseline sGaw
The two sets of values obtained for sGaw before drug 
administration on each of the two test days are presented for both 
the manual method and the automatic method (Table 3.2). The mean 
co-efficient of variation for the manual method (31.6%) was 
inferior to the automatic method (m = 19.2%)
3.4.2 PC^sGaw Results
The relationship between the three methods of analyses was 
assessed by comparing the PC^sGaw histamine for the seven subjects 
across the two days (Figure 3.1). There was no significant 
difference in the mean PCg^sGaw values obtained by the two methods 
of analysis. The geometric mean PC^sGaw values ( SEM) were
4.6 +_ 3.9 mg/ml (one limb manual), and 6.2 +. 5.4 mg/ml
(automatic).
As a measure of reproducibility, the correlation between the 
PCg^sGaw results for each subject obtained on day 1 and day 2 was 
investigated for each of the two methods. The correlation co­
efficients were r = 0.76 (p < 0.05) for the manual method, and r = 
0.99 (p < 0.01) for the automatic method.
3.4 DISCUSSION
The constant volume body plethysmograph was automated in a straight 
forward and low cost way. Each value of sGaw is produced within 4-5 
seconds of completion of the panting manoeuvre and there is an 
improvement in the reproducibility of airways responsiveness as assessed 
by PCg^sGaw, where sGaw is measured from one limb of the flow-pressure 
loop.
The co-efficients of variation of baseline sGaw values are 
comparable with values obtained in other studies and reported by 
Tattersfield and Keeping (1979). When the baseline values obtained by 
the/
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the manual, method are compared with the automatic method there is a 
significant difference, the manual analysis producing a higher result. 
This suggests that the second limb gradient (at the end of the 
inspiration) is lowering the average value. On inspection of the flow- 
box pressure plots it is apparent that the gradient of the second limb is 
lower. It is possible that this is caused by the body plethysmograph or 
its electronics. However, preliminary work using an oscillating pump 
calibrator suggest that the difference in gradients is not due to 
equipment or measurement technique. Another possibility is that the 
effect is associated with changes in the airways characteristics during 
the respiratory cycle.
We tested our system under conditions similar to those encountered 
in practice - i.e. assessing change in sGaw during a bronchial 
provocation challenge. When measurements of airways' responsiveness to 
histamine were assessed on two occasions, the results obtained by our 
computerised system have a higher correlation coefficient than results 
obtained by manual analysis and were produced at the time of measurement 
rather than recorded for later analysis.
The PCg^sGaw results obtained by the automated method show that 
there was a considerable difference between the two days for subject 2. 
This difference was also present in the manual PC^sGaw analysis and in 
the baseline values measured by both systems, suggesting that the 
discrepancy between the two measurements was a genuine difference in
PCg^sGawa
The rapid presentation of results has several advantages. The 
subject is present when the results are obtained so that measurements may 
be repeated if analysis is, for some reason, unsatisfactory. It also 
means that the investigator determines the end point of the experiment 
when the required change in sGaw has occurred, thereby administering the 
minimum amount of drug necessary to obtain a result.
The high reproducibility of the automatic measurements means that 
smaller changes in airway responsiveness may be detected. This is 
particularly important in bronchocons trie tor pharmacological studies, 
such as those used in this thesis.
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Other groups have reported' an automatic system to measure airways 
resistance using a body plethysmograph. Lord et al (1977) developed an 
automated system to measure sGaw using a Hewlett-Packard 2116B computer. 
The gradient on the V/Pb curve was calcuated by measuring the box 
pressure at zero flow and at 0.4 ls-  ^on the inspiratory part of the 
cycle, and deducing the gradient from these two points. The method used 
in this thesis measures the gradient in the same region of flow. 
However, rather than using only the two end points all the data points 
are used (typically about 35), and a 'best fit' line is found by 
regression analysis.
The improvement gained by using such an approach is not as great as 
one might at first think because there is correlation between the points 
due to the limited system bandwith. Nevertheless there will be some 
improvement and because the time taken to perform such a regression 
analysis was not significant it is worthwhile.
The same is true in the case of the Pm/Pb curve where Lord at al 
(1977) use the two turnover points to calculate the gradient and our 
system uses regression analysis to fit a ,rbest line" to the middle region 
of the curve.
Our measurement protocol differs significantly from the technique 
used by Lord et. al (1977). Their technique was that the subject panted 
for about 10 cycles with no shutter (V/Pb mode) and then the shutter was 
introduced for 10 cycles (Pm/Pb mode) and the average gradients were then 
used to produce a value of sGaw. The time separation between the two 
modes is undesirable and panting against the shutter for 1 0 cycles is 
extremely tiring. In this method the subject has only to pant for 2 
cycles before the mode is changed.
Chowienczyk et al (1981) describe a novel approach to measure the 
V/Pb loop, in that they approximated sine waves to one cycle of the 
respiratory loop and deduce the value from the phase and amplitude 
relationships between the two signals. The processing time of this 
technique is about 3-4 times greater than with the system described here 
and could be significant in an experiment. The measurement protocol is 
similar to the one used in this system except that four cycles are 
acquired before changing mode compared with two.
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Their method averages the airways resistance throughout the whole 
respiratory cycle whereas this technique uses the inspiratory side. 
Zarins and Clausen (1982) have suggested that selecting a particular 
region of the respiratory cycle may improve the sensitivity of the 
airways resistance measurement. This is an interesting possibility and 
the system described may be modified such that this possibility can be 
investigated.
An important difference between the described method and other 
reported systems is that the operator controls when measurements are made 
by using a control button to activate data collection by the computer. 
This allows the operator to assess whether the subject is panting 
properly and to allow adequate time for recovery in less robust subjects 
who may find the panting manoeuvre tiring. A facility is also provided 
for rejection of curves by pressing either of the control buttons on 
completion of each pair of measurements.
In summary, a computerised system has been developed which produces 
results more reproducible than the one limb manual measurement. As the 
automated method improved the precision of results, gave results at the 
time of experiment and was more convenient, it was used in this thesis to 
measure sGaw.
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C H A P T E R  4
COMPARISON OF IN VIVO AIRWAY RESPONSIVENESS AND 
IN VITRO SMOOTH MUSCLE SENSITIVITY TO METHACHOLINE IN MAN
COMPARISON OF IN VIVO AIRWAY RESPONSIVENES AND IN VITRO SMOOTH MUSCLE 
SENSITIVITY TO METHACEQEINE IN MAN
4.1 INTRODUCTION
Airway responsiveness to the cholinergic agonist methacholine
varies between normal subjects (Parker et al 1965) and is increased in
patients with asthma (Parker et al 1965, Hargreave et al 1981). The
reduction in airway calibre induced by this agonist involves the
contraction of airway smooth muscle (Hawkins and Schild 1951). Thus,
the difference in responsiveness to methacholine in normal and asthmatic
subjects may be related to variations between individual subjects in
their airway smooth muscle sensitivity to this agent. Alternatively,
the variability between subjects in responsiveness may be a consequence
of differences in the neural and/or humoral control of airway smooth
muscle. Previous studies have found that in vitro airway smooth muscle
sensitivity to a cholinergic agonist varies between subjects (Hawkins and
Schild 1951, Brink et al 1980, Goldie et al 1982), but these
investigators have not related the in vitro values to in vivo
measurements of responsiveness. Therefore, the importance of airway
smooth muscle sensitivity in determining in vivo responsiveness is
unknown.
The purpose of this study was to compare in vivo airway 
responsiveness to methacholine with in vitro sensitivity of preparations 
of isolated bronchi taken from the same patient to determine whether 
variation in responsiveness to methacholine may be explained by 
differences in the sensitivity of airway smooth muscle to the drug.
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4.2 METHODS
4.2.1.Patients
Ten patients scheduled to undergo lobectomy or pneumonectomy 
were studied (Table 4.1). Eight patients had operable bronchial 
carcinoma, one had a tuberculoma and one had a solitary metastasis 
from a renal clear cell carcinoma. All had been smokers but at 
the time of study two had stopped for a period of > 1 year. Four 
patients fulfilled the Medical Research Council's definition for 
chronic bronchitis (MRC 1965). One patient (No. 2) gave a history 
of wheezy dyspnoea and hay fever. Five were atopic as indicated by 
> 2 mm wheal response to prick skin testing, although only three 
patients had raised specific IgE levels. Four patients were on 
regular drug treatment prior to surgery.
4.2.2 Experimental procedure
Patients were seen on the day of admission to hospital, usually 
2 days before surgery. They answered a questionnaire modified 
from the M.R.C. Respiratory questionnaire (Appendix 1) and prick 
skin tests were carried out. The patients were then trained to use 
the body plethysmograph. Baseline values were obtained and then 
increasing concentrations of methacholine were inhaled (2 - 64 
mg/ml)until a > 20% fall in FEV-^  was recorded.
The wheezy subject did not take Phyllocontin tablets for 24 
hours and his salbutamol inhaler for 72 hours before testing.
In vitro measurements were made the day after surgical removal
of tissue. After equilibration, increasing concentrations of
— Qmethacholine ( 1 x 1 0 - 1 x 1 0 ) were added to the organ bath at
the peak of the previous response. A minimum of four tissues from 
each patient was used. From the results obtained a log 
concentration-response curve was drawn and the concentration of 
drug producing a 50% of maximum response (EC^ g) measured and the 
mean of four values obtained for the subject used as an index of in 
vitro sensitivity. The concentration producing a 20% of maximum 
response/
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FIGURE 4.1
Range of responsiveness to methacholine
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Airway responsiveness shown on a log scale of ten patients to inhaled 
mechacholine, one of whom (0) had symptoms of wheezy dyspnoea. Results 
are expressed as the provocation concentration (PC) causing a decrease in 
FEV^ of 20% (PC2 qFEV^ ), a 35% fall in sGaw (PCg^sGaw) and the maximal 
expiratory flow at 35% of vital capacity, measured from the complete 
Vgg(c) and partial Vgg(p) flow volume curves PC^Vg^Cc) and PCggVgg(p)
response (EC2 q) was also calculated. In addition the maximum 
tension generated and wet weight of each tissue were recorded.
In preliminary experiments, no significant difference was found 
between the sensitivity of bronchial strips taken from second and 
sixth order bronchi.
In vivo and in vitro results were compared using correlation 
coefficients calculated from linear regression using the method of 
least squares analysis. The level of significance was set at p < 
0.05.
4.3 RESULTS
4.3.1 In vivo
Airway responsiveness to methacholine varied between individual 
patients (Figure 4.1). There were significant correlations (P< 
0.05) between PCgQ FEVj and PC3 5 V 3 5 (c) ( r= 0.64), PCggsGaw and 
PC3 5V3 5 (p) (r = 0.65), and PC3 5 V3 5 (p) and PC3 5 V3 5 (c) (r = 0.77). 
Baseline FEV^ (expressed as a percentage of predicted) correlated 
with PC3 gV3 3 (p) (r= 0.71; p < 0.05) but was not significantly 
related to the other measurements of in vivo responsiveness 
[PCgQFEV-j^  (r= 0.59). PC35sGaw (r= 0.32); PC3 5 V3 5 (c) (r= 0.53)]. 
There was no significant correlation between baseline sGaw 
(absolute value) and measurements of in vitro sensitivity.
4.3.2 In vitro
The sensitivity to methacholine of the bronchial strips from 
individual patients was highly reproducible (r = 0.87). There was 
no difference in sensitivity between second order, 4 th order, and 
6 th order bronchi (Table 4.2). For all subsequent analysis, the 
results for all bronchial strips from an individual patient were 
combined. In contrast there were marked differences in the 
sensitivity to methacholine of bronchial strips prepared from 
different patients as indicated by the range of EC3q and EC^q 
values obtained, Table 4.2. The mean EC2Q value (j^ SEM) from all 
preparations/
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preparations was 4.1 ± 1.2 x 10 7M (range 2.9 x 10*"^ M to 9.3 x
10” 7M) and the mean EC^q value was 3.9 ± 1.0 x 10~"^ M (range 4.1 x 
—7 —610 M to 8.1 x 10 M). The mean maximum tension generated was 1.44 
+. 0.29 g(range 0.37 g to 3.59 g).
4.3.3 Comparison of in vivo and in vitro responsiveness to methacholine
There were no significant correlations between any of the 
measurements of in vivo responsiveness and jji vitro smooth muscle 
sensitivity to methacholine. The lack of relationship is 
illustrated for PC2qFEVj against EC^q (Figure 4.2), for PC^sGaw 
against EC^q (Figure 4.3) and for PC^V^tc) and P^^VgijCp) 
against EC^q (Figure 4.4 (a) and (b)). Furthermore, there were no 
significant relationships between in vivo measurements and maximum 
tension generated.
The patient who had a history of wheezy dyspnoea and the lowest 
PC2qFEV^ (No.2) did not exhibit increased in vitro sensitivity to 
methacholine (EC^q 4.0 x 10. M) nor was the maximum tension 
generated -increased (1.41 g) Figure 4.4.
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FIGURE 4.2
H ^ qFEVj against EC^q for methacholine
PC20 FEV, 
(m g /m l)
PC 20 PE V] 
(moles)
lOO-i
10- 0 -
1-0 -
EC50 (moles)
Comparison of in vivo airway responsiveness to methacholine expressed 
PC2qFEVj and in vitro smooth muscle sensitivity expressed as EC^q (r = 
0.35 p > 0.05)
FIGURE 4.3
PCg^sGaw against EC^q for methacholine
PC35 sGaw  
(m g/m !) 
lOO-i
10-0 -
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10-7
• •
10-6 10-5
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PC35 sGaw  
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rO-51
-5*1x10-2
-5*1x10-3
Comparison of in vivo airvay responsiveness to methacholine expressed 
PCg^sGaw and in vitro smooth muscle sensitivity, expressed as EC^q (r 
0.03, p > 0.05)
PC35V35(C)
(m g/m l)
pc35v35 (P)
( m g / m l )
EC50 (moles)
PC35V35 (C)
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lOO-i
10-0 -
1-0 -
P C 3 5 V 3 5  ( p )  
(moles)
l O O - i 0-51
10- 0 -
1-0 -
EC50 (moles)
Comparison of in vivo responsiveness and in vitro smooth muscl 
sensitivity to methacholine. PC2 5 V2 |j(c) against EC^q (r = -0.33, p 
0.05 I>C3 5^3 5 P^) against EC^q (r = -0.30, p> 0.05
4.4 DISCUSSION
This study has demonstrated that no significant relationship exists 
between measurements of in vivo airway responsiveness to methacholine and 
in vitro sensitivity of isolated bronchial smooth muscle obtained from 
the same patients. Previous studies have examined either in vivo human 
airway responsiveness (Parker et al 1976, Hargreave et al 1981), or in 
vitro human airway smooth muscle sensitivity to this pharmacological 
stimulus (Hawkins and Schild 1951, Goldie et al 1982) but both in vivo 
and in vitro evaluation has not been performed in the same individual.
There are several possible factors which might have influenced both 
the in vivo and in vitro measurements. Unlike in vitro studies, the dose 
of methacholine administered to airway smooth muscle in vivo cannot be 
determined accurately. It is dependant on the technique of aerosol 
generation, particle size and breathing pattern (Brain 1980, Ryan et al 
1981). In this study methacholine was administered via the same 
Wright's nebulizer and by the same method in each individual. Thus, 
although the dose reaching the lung was unknown it should have been 
similar in each patient. The site of deposition of the drug within the 
airways might also influence the response obtained. The patients we 
studied were current or ex-smokers and had a degree of small airway 
disease. A Wright nebulizer produces a diffuse pattern of deposition 
within the lung (Ryan et al 1981), but in individuals with small airway 
narrowing the aerosol may be deposited to a greater extent in the larger 
airways, and so apparently increase the response. We examined tissue 
samples from second to sixth order bronchi. In vitro results therefore 
reflected the sensitivity of larger airways. Comparison of EC^q and 
PCg^ sGaw, a measurement of large airway responsiveness (Pride 1971), 
might have been expected to show the closest relationship, had any 
existed. However, a relationship between in vivo airway responsiveness 
and in vitro sensitivity of more peripheral airway smooth muscle cannot 
be excluded from this study. In addition, the access of a 
bronchocons trie tor drug to airway smooth muscle, and the response to that 
drug, may be affected by airway permeability (Hogg 1981). However, 
although/
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although airway permeability has been found to be increased in smokers 
(Jones et al 1980), no relationship has been found between the level of 
airway permeability and airway responsiveness in these individuals 
(Kennedy et al 1983).
It is impossible to produce a full dose response curve to a 
bronchoconstrictor agent in man, so the position on the curve at which 
responses are measured is unclear. It may be that all the in vivo 
measurements fall on the lower non-linear region of the full log dose 
response curve. If so, then in vivo meansurements might not be expected 
to correlate with a response taken from the linear region of the in vitro 
curve (EC^ q). However, we found no relationship between in vivo indices 
of responsiveness and a measure of in vitro sensitivity taken from the 
lower part of the dose response curve (EC2q).
Baseline airway calibre and/or tone may be an important determinant 
of airway responsiveness (Benson 1975). The same reduction in airway 
radius will cause different changes in airflow resistance depending on 
baseline airway calibre, because resistance is inversely proportional to 
the fourth power of the radius when flow is laminar. We examined the 
relationship between the four measurements of in vivo airway 
responsiveness and baseline values of FEV^ and sGaw; only starting FEV^ 
significantly correlated with PCg^Vg^p). This result would suggest that 
the variation in responsiveness to methacholine found between our 
patients was not due only to differences in baseline airway calibre, 
although it is possible that small but important differences in baseline 
airway calibre or tone may not have been detected by the methods used. 
Furthermore, there may have been differences between subjects in the 
distribution of resistance within the airways which would also influence 
in vivo measurements of responsiveness.
Variations in upper airway calibre may also affect airway 
resistance. Higenbottam (1980) demonstrated that aerolised histamine 
produced a variable reduction in laryngeal calibre with an associated 
fall in FEVj. This he proposed was via a vagal reflex. If this 
hypothesis were correct methacholine would not be expected to produce a 
similar/
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similar effect because it does not act on vagal sensory endings (Vidruk 
et al 1977).
In normal subjects inhalation to total lung capacity can reduce the 
effect of induced bronchoconstriction (Fish et al 1981). This would 
affect FEVj and Vgg(c) but not sGaw or Vgg(p) measurements. As we have 
demonstrated that none of these measurements correlated with in vitro 
sensitivity it is unlikely that this bronchodilation is an important 
factor in the lack of relationship between in vivo and in vitro 
measurements. Finally, other important factors which might influence in 
vivo responsiveness include difference between individuals in the neural 
and/or humoral control of the airways (Widdicombe 1963, Richardson 1979).
The pre- and peri-operative drugs received by each patient were 
similar. To minimize the effect of these drugs on the response of smooth 
muscle to methacholine, all tissues were washed twice on removal, stored 
for 16 hours in Krebs-Henseleit solution and then washed again both 
before and after suspension in the organ bath. As precautions were 
taken to treat all tissues in the same way, and all were washed 
thoroughly, it seems unlikely that previously administered drugs would 
influence the results obtained. In particular hyoscine premedication 
should not have influenced the in vitro sensitivity of smooth muscle to 
methacholine. The effects of atropine, a drug pharmacologically similar 
to hyoscine can be removed from in vitro preparations within minutes by 
washing (Clark 1926). Furthermore, Brink et al (1980) have shown no 
difference in the sensitivities of fresh and stored human airway smooth 
muscle preparations.
In addition to finding no relationship between In vivo 
responsiveness to methacholine and in vitro sensitivity to this drug as 
indicated by the EC^q value, we found no correlation with the maximum 
tension generated by bronchial strips from each patient. The maximum 
tension generated may be related to the quantity of smooth muscle present 
in each bronchial strip. Ideally, the amount of smooth muscle in each 
strip should be measured although this is technically difficult. In an 
attempt to correct for variations in the amount of tissue and hence 
smooth/
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smooth muscle present, the maximum force generated was corrected for the 
wet weight of tissue in each strip. This was compared with the indices 
of in vivo responsiveness but no relationship was found.
In this chapter methacholine was used as agonist. This drug acts 
on muscarinic receptors which may be situated in different structures in 
the airway such as airway smooth muscle (Hawkins and Schild 1951), 
submucosal glands (Nadel 1981), pre-synaptic receptors on sympathetic 
nerves (Westfall 1980) and mast cells (Kaliner et al 1972). The 
bronchoconstrictor response to methacholine may therefore be due to 
several different mechanisms, and not due solely to a direct effect on 
airway smooth muscle. The absence of any relationship between in vivo 
and in vitro responses to methacholine does not preclude a relationship 
existing if any agonist which acts more specifically on airway smooth 
muscle were used. Future chapters will consider other smooth muscle 
agonists.
Patients selected for this study were due to undergo thoracic 
surgery. The majority had bronchial carcinoma and were current or ex­
smokers. With the exception of one individual, they did not demonstrate 
in vivo hyperresponsiveness, since most symptomatic asthmatics would be 
expected to have a PC2qFEVj below 8 mg/ml (Hargreave et al 1981). In 
these patients our findings suggest that smooth muscle sensitivity alone 
does not determine in vivo airway responsiveness to methacholine. It is 
probable that the measurement of airway responsivness is complex, and 
that it is influenced by multiple factors.
The cause(s) of airway hyperresponsiveness in asthma is unknown. 
It could be due to an abnormality in airway smooth muscle and/or to the 
neural or humoral control of the airways (Thomson 1983). In this study 
only one patient had some features of asthma. Although we were able to 
study him only over a short period and were unable to assess the airway 
response to a "trial of steroids", he had symptoms of wheezy dyspnoea, 
demonstrated a 14% increase in FEV^ after bronchodilator, had 
Curschmann's spirals demonstrated in his sputum and was the most 
responsive to methacholine. However, the airway smooth muscle strips 
from/
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this individual were not hypersensitive to methacholine. If this finding 
is confirmed in other patients with definite asthma it would indicate 
that airway hyperresponsiveness is not attributable to an increased 
sensitivity to methacholine at the receptor level (as indicated by the 
EC^q value). In support of this finding with methacholine, Dahlen and 
coworkers (1983) recently reported that the response of bronchial strips 
to histamine, prostaglandin F2 ** and leukotriene were similar in 
normal and asthmatic subjects. These findings may indicate in vivo 
hyperresponsiveness is not due to a primary abnormality of airway smooth 
muscle. However, a post receptor defect in airway smooth muscle, 
manifest by any increase in maximum tension generated by the bronchial 
strip, cannot be ruled out as a cause of airway hyperresponsiveness. It 
is conceivable that an increase in maximum tension generated by the 
bronchial strips of the patients in this study as compared to the others 
was not detected because of differences in the quantity of smooth muscle 
present in the bronchial strips.
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C H A P T E R  5
airway responsiveness to histamine in normal and asthmatic subjects
AIRWAY RESPONSIVENESS TO HISTAMINE IN NORMAL AND ASTHMATIC SUBJECTS
5.1 INTRODUCTION
The responses of normal and asthmatic subjects to histamine are 
well established (Cockcroft et al 1977, Laitinen 1974) and, using the 
protocol devised by Cockcroft et al (1977), there are defined normal and 
asthmatic ranges for PC2qFEVj. In this study a modified protocol was 
used which entailed the measurement of sGaw, V^q(p) and FEVj 
sequentially. Patients tested were due to undergo thoracotomy for 
bronchial carcinoma. Most were smokers and therefore had varying degrees 
of chronic bronchitis and chronic airflow obstruction which have been 
associated with altered airway responsiveness (Taylor et al 1985, 
Ramsdale et al 1984, Benson et al 1978). It was important to determine 
an expected range of results for both normal and asthmatic subjects to 
facilitate interpretation of in vivo results. This would put the 
responsiveness of the surgical patients in perspective when their airway 
responsiveness was measured by the same protocol.
5.2 METHOD
5.2.1.Subjects
Ten non-smoking normal subjects (7 male and 3 female) with no 
history of respiratory disease, who had been admitted to hospital 
for elective surgery were chosen, Table 5.1. None were smokers. 
Three had positive prick skin tests, but none had increased 
specific IgE levels.
Ten asthmatic patients (4 male: 6 female) chosen to be in the 
same age range as surgical patients were recruited from the chest 
clinic (Table 5.2). They were aged 44 - 75. One was a cigarette 
smoker and one a pipe smoker. Four had positive prick skin tests 
and three had raised specific IgE levels. All were taking regular 
B2 adrenoceptor agonists, seven were on regular inhaled 
beclomethasone dipropionate and one patient was taking sodium 
cromoglycate.
5.2.2.Measurement s
Airway/
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Airway resistance and thoracic gas volume were measured 
sequentially in a constant-volume body plethysmograph (Fenyves and 
Gut) using the methods of Du Bois et_ al. (1956). The results were 
expressed as specific conductance (sGaw). The mean of eight values 
recorded was taken as sGaw. Partial and complete expiratory flow- 
volume (PEFV and CEFV) curves were obtained with a heated 
pneumotachograph with integration of flow, and recorded on an X-Y 
recorder. Body plethysmographic measurements always preceded flow 
volume recordings.
Histamine inhalation tests were carried out using a 
modification of the method described by Cockcroft et_ al_ (1977). 
Buffered normal saline was inhaled first followed by doubling 
concentrations of phosphate buffered histamine (2 to 64 mg/ml) for 
non-asthmatic patients, and 0.06 to 4 mg/ml for the asthmatic 
patients. Each inhalation was for 2 minutes at 10 minute 
intervals. Before the first inhalation eight sGaw and five PEFV 
and CEFV curves were recorded. From 1.5 min after each inhalation 
responses were measured by sGaw and to PEFV and CEFV curves. 
Inhalations were continued until the FEV^ had fallen by 20% or 
more, or until maximum concentration had been administered.
Log concentration-response curves were plotted and results were 
expressed as the provocation concentration causing a 20% decrease 
in FEV^ (PC2 qFEVj) a 35% fall in sGaw (PC^sGaw), a 35% fall in 
^35^P^PC35^35^P^  anc* a ^5% fall in V^c) (PCgijV^c)). If the 
appropriate percentage fall had not occurred by the maximum 
concentration the provocation concentration is shown as (> 64 
mg/ml).
5.3 RESULTS
Airways responsiveness varied within and between the asthmatic 
patients and the normal subject groups (Figure 5.1). There was no 
overlap between the groups as assessed by PC2QFEV2 , slight overlap 
when assessed by PC^sGaw (p < 0.01) and slight overlap between the 
groups/
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FIGURE 5.1
Range of responsiveness in normal and asthmatic subjects
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Airway responsiveness shown on a log scale to histamine of 10 subjects 
due to undergo routine non-thoracic surgery and who had no respiratory 
symptoms (•) and ten asthmatic patients (0).
Results are expressed as the PC2qFEV^ (left) PC^sGaw (centre and the 
^30^30^ (right).
groups as assessed by PCg^Vg^Cp) (p < 0.001). Baseline FEV^ 
expressed as a percentage of predicted (mean +_ SD) was 
significantly higher in the normal subjects (119 13.6) than the
asthmatic patients 79.1 +. 22.1 (p < 0.01).
In the normal subjects, baseline airway calibre as assessed by 
FEVj expressed as a percentage of the predicted value, was not 
related to airway responsiveness, the correlation coefficients 
being PC2qFEV^ r= 0.21, PC-^sGaw r= -0.33 and PC^V^p) r= -0.16.
Similarly the correlation coefficients for the asthmatic 
patients between baseline airway calibre and airway responsiveness 
was PC2qFEVj, r= 0.01, PCg^sGaw r = C.01, or PC^V^p) r = -0.13.
5.4 DISCUSSION
In this study there was a 1,000 fold variation in airway 
responsiveness over a group of twenty human subjects, ten of whom 
had asthma. A common feature of asthma is an increase in the 
responsivness of the airways to a variety of different stimuli. 
This appears to be non-specific for a number of triggers since, in 
a group of asthmatic patients the airway responses to one stimulus 
usually correlate with those to another. Individuals highly 
sensitive to histamine are also generally more sensitive to 
methacholine (Juniper et al 1978) prostaglandin F2 04 (Thomson et al 
1981) and Leucotriene (Bisgaard et al 1985).
The protocol used in this project differs from that described 
by Cockcroft et al (1977) in several respects. They gave 
inhalations at 5 minute intervals (compared to 10 in this study). 
This was possible as only FEV^ was measured. The ten minute 
period was required to measure sGaw (x8) and V^ q(p) and FEV^ (x2- 
3). Less solution was used in the nebuliser (4 ml cf 5 ml) and a 
flow rate of 81/min cf 7 1/min by Cockcroft was used. His group 
nebulised using O2 as vehicle rather than air. It has been 
demonstrated that changes in the concentration of O2 may affect 
airway calibre (Nadel and Widdicombe 1962). Thus it was 
important/
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important to establish expected values for both normal 
subjects and asthmatic patients using the protocol used in this 
thesis.
A highly significant difference was demonstrated between the 
normal subjects and the asthmatic patients by all three methods of 
assessment of airway calibre. This confirms the work of numerous 
other studies (Herxheimer 1951, Townley et al 1965, Cockcroft et al 
1977) all of whom measured FEV^ in normal subjects and asthmatic 
patients. FEV^ reflects overall airway function, Raw and hence 
sGaw reflect large airway function (Pride 1971, Ingram and McFadden 
1977) and expiratory flow rates at 25 to 50% of TLC, small airway 
functions (Tattersall et al 1978).
Differences in response between large and small airways could 
be due either to differential effect of the site of action of the 
bronchoconstrictor in use or an effect of distribution in the 
airway of nebulised solutions. However, by all three methods of 
measuring airway responsiveness there were highly significant 
differences between the normal subjects and the asthmatic patients.
Baseline airway calibre has been proposed as a factor in 
determining human airway responsiveness (Chung et al 1982) 
althought this has been disputed (Cartier et al 1982). In this 
study, bronchial responsiveness was unrelated to baseline airway 
calibre in both the normal subjects and the asthmatic patients.
Thus a normal range and an asthmatic range has been determined 
for the three measures of airway responsivess used in this thesis.
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C H A P T E R  6
COMPARISON OF IN VIVO AIRWAY RESPONSIVENESS AND IN VITRO SMOOTH 
MUSCLE SENSITIVITY TO HISTAMINE AND THE EFFECT OF 
IN VIVO CHOLINERGIC BLOCKADE (Ml THIS RELATIONSHIP
COMPARISON OF IN VIVO AIRWAY RESPONSIVENESS AND IN VITRO SMOOTH MUSCLE 
SENSITIVITY TO HISTAMINE AND THE EFFECT OF IN VIVO CHOLINERGIC BLOCKADE ON THIS 
RELATIONSHIP
6.1 INTRODUCTION
The bronchoconstrictor response to a stimulus such as histamine 
involves contraction of the airway smooth muscle (Hawkins and Schild 
1951) which is under nervous, humoral and intrinsic muscular control 
(Widdicombe 1963, Richardson 1963, Davis et al 1982). Patients with 
asthma and chronic airflow obstruction (Oppenheimer et al 1968, 
Laitinen et al 1974) exhibit increased airway responsiveness compared 
with normal subjects. The cause of this increased responsiveness is 
unknown. Histamine produces bronchoconstriction by acting directly on 
airway smooth muscle H^ receptors (Nogrady et al 1978, Thomson and Kerr 
1979) and also reflexly via vagal pathways (Simonsson et al 1967). Thus 
airway hyperresponsiveness to histamine may be due to increased 
sensitivity of the smooth muscle itself, or may be related to an 
abnormality of the nervous and/or humoral control of the airways (Thomson 
1983). If the primary abnormality resides in the smooth muscle, then 
increased in vivo airway responsiveness to histamine would be expected to 
be associated with an enhanced in vitro smooth muscle sensitivity. 
Alternatively if in vivo airway responsiveness to histamine is modified 
by an interaction between vagal nerve input and smooth muscle sensitivity 
then a relationship between in vivo and in vitro responses may only be 
apparent after cholinergic blockade with atropine.
In this study in vivo responses to histamine, both with and without 
atropine pretreatment, were compared with in vitro responses of isolated 
strips on bronchi removed from the same patients in order to assess the 
contribution of smooth muscle sensitivity to in vivo airway response to 
inhaled histamine.
6.2 METHODS
6.2.1 Patients
Twenty-one patients due to undergo lobectomy or pneumonectomy 
were/
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were studied (Table 6.1). Twenty had operable bronchial carcinoma 
and one had an aspergilloma. One had a history of asthma since 
childhood and had reversible airflow obstruction. Sixteen were 
current smokers and all others except the asthmatic patient were 
ex-smokers. Eight fulfilled the MRC criteria for chronic bronchitis 
(MRC 1965). Seven including the asthmatic patient were atopic as 
indicated by a ^ 2 mm weal response to prick skin testing with one 
or more of seven common allergens and three of these, including the 
asthmatic patient had raised specific IgE levels. Nine patients 
were on regular drug treatment prior to surgery. The asthmatic 
patient did not require regular bronchodilator therapy.
6.2.2 In vivo measurements
Histamine inhalation tests were carried out using a 
modification of the method described by Cockcroft et al (1977). 
Buffered normal saline was inhaled first followed by doubling 
concentrations of phosphate buffered histamine (2 to 64 mg/ml) for 
non-asthmatic patients, and 0.06 to 4 mg/ml for the asthmatic 
patient. Each inhalation was for 2 min at 10 minute intervals. 
Before the first inhalation eight sGaw and five PEFV and CEFV 
curves were recorded. From 1.5 min after each inhalation 
responses were measured by sGaw and by PEFV and CEFV curves. 
Inhalations were continued until the FEV^ had fallen by 20% or 
more, or until maximum concentration had been administered. In 11 
of the patients (No. 11-21) histamine responsiveness was measured 
after pretreatment with atropine. Following baseline measurements, 
atropine sulphate (5 mg/ml) was inhaled from the same Wright 
nebuliser for 5 mins. Thirty min after inhalation eight sGaw and 
three PEFV and CEFV curves were recorded. The histamine 
inhalation test was then performed.
Log concentration-response curves were plotted and results were 
expressed as the provocation concentration causing a 20% decrease 
in FEVj (PC2 qFEVj) a 35% fall in sGaw (PC^^sGaw), a 35% fall in
v35(p)/
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Vss(p) ^ 3 5V3 5 (p)) and a 35% fall in V^Cc) CPC3 5^3 5 (0 )). If the 
appropriate percentage fall had not occurred by the maximum 
concentration the provocation concentration was shown as (> 64 
mg/ml). Routine pre-operative pulmonary function tests were 
performed.
6.2.3 In vitro measurements
Bronchial tissue was obtained immediately following removal at 
thoracotomy. Samples from second to sixth order bronchi were 
dissected from macroscopically normal tissue and then maintained 
overnight at 4°C in well oxygenated Krebs-Hensleit solution. The 
next day rings of bronchi were dissected and sectioned to produce 
strips of tissue which were suspended (under a resting tension of 
1.5 to 2.0 g) in 20 ml organ baths containing Krebs-Hensleit 
solution at 37°C bubbled with 5% CO2 in O2. At the conclusion of a 
60 min equilibration period the tissues were washed three times. 
Changes in isometric tension were measured using Grass force- 
displacement transducers (FT03C) and recorded on a Grass (model 7) 
polygraph.
The normality of the bronchial strips and reproducibility of
their contractile changes were assessed by adding histamine ( 1 x 
—5 -1
1 0 moles. 1 ) on two separate occasions separated by an interval
of 30 min. A cumulative concentration-effect curve was then 
constructed by adding increasing concentrations of histamine (final 
concentration 1 x 10”  ^ to 4 x 10”^ moles.1^  ), each addition
of the drug being made at the peak of effect produced by the 
preceding concentration. In each experiment the concentrations of 
histamine that produced 20% (EK^ q) and 50% (EC q^) of the maximal 
contraction were calculated. Additionally, the maximum tension 
generated by each strip was determined and expressed in grammes 
tension per mg wet weight of tissue (tissue weight was measured at 
the conclusion of each experiment), and the slope of the dose 
response curve (%change/log unit) was recorded.
Two/
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Two to six bronchial strips from each patient were tested and 
mean values for EC2 Q, EC^q and maximum tension generated were 
calculated.
6.2.4 Statistical analysis
Comparisons between group values of baseline FEV^ and sGaw were 
compared using Student's unpaired t test. Comparison of in vivo 
and in vitro results was by calculation of correlation coefficients 
from linear regression using the method of least squares analysis. 
PC results were analysed under a natural logarithm transformation. 
The level of statistical significance was set at p < 0.05.
6.3 RESULTS
6.3.1 In vivo
Airway responsivness to histamine varied more than 100 fold 
within the group of 21 thoractomy patients. Their mean 
responsiveness was more than the group of non-smoking controls and 
less than the asthmatic subjects described in Chapter 5 (Figures 
6.1, 6.2). Results for the asthmatic patient undergoing thoractomy 
were within the range determined for the control of asthmatic 
patients and he was the most responsive of the surgical group. In 
the group who received atropine there was a significant increase in 
FEVj 7.3 + 4.5%, sGaw 111.7 + 84%, V35(p) 55.4 + 28.3% and V35(c) 
31.6 +. 40.8% after atropine (Figure 6.3).
In the surgical group not pre treated with atropine, baseline 
FEV^ (% predicted) correlated with PC2Q FEV^ r = 0.66 (Figure 6.4) 
but not with PC33V33(p) r = 0.57 or PC^sGaw r = 0.08.
6.3.2 In vitro
The sensitivity to histamine of the bronchial strips from 
individual patients as assessed by EC^q was high/ reproducible (r = 
0.82). There were small differences in the sensitivity to 
histamine of bronchial strips prepared from different patients. 
The/
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FIGURE 6.1
Range of responsiveness to histamine in normal asthmatic and surgical 
patients.
> 6 4
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•  oa Surgical Asthmatic Patient 
x
Airway responsiveness to inhaled histamine in normal (n = 10) and 
asthmatic subjects (n = 10) described in Chapter 5. In columns 3 and 4, 
results for the surgical patients (n = 11) and surgical patients after 
atropine pretreatment are shown. Results are shown for PC2QFEV2 (• ) 
and PC^sGaw (X). The results of the asthmatic patient who underwent 
surgery are also shown (0 A )
FIGURE 6.2
Range of responsiveness to histamine as assessed by V^qCp) and V^qCc)
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Airway responsiveness to histamine in normal (n = 10), and asthmatic 
subjects (n .= 10) as described in Chapter 5. The two surgical patients 
groups without and after atropine pretreatment are also shown. Results 
are shown for PC^V-^Cp) and PC^V^Cc). Results for the asthmatic 
patient are shown as S O
FIGURE 6.3
Effect of atropine on baseline FEVj^  and sGaw measurements
3-5 -i
3 0 -
2-5-
20 -
4-0-
3-5-
3 0 -
2-5-
20 -
1-5-
1 0 -
BASELINE POST 
ATROPINE
FEVj sGaw
BASELINE VALUES. CHANGE AFTER ATROPINE
Baseline FEV^ and sGaw in the surgical patients who were given 
pretreatment with atropine. Figure shows the effect of atropine 
inhalation on baseline readings.
FIGURE 6.4
Graph, of baseline FEV^  against responsiveness (PC2qFEVP f°r surgical.;, 
patients
COMPARISON of BASELINE FEVl ( %  PREDICTED ) and PC2Q FEV1 HISTAMINE
BASELINE FEVl 
(at %  pradictKl)
120-1
100-
8 0 -
6 0 -
10-01-0 >64
PC20 FEVl HISTAMINE (mg / ml)
O ASTHMATIC 
PATIENT
Graph of baseline FEV^ (expressed as a % of predicted value) and PC2qFEV^ 
for histamine n = 11, r = 0.83, p < 0.05. The asthmatic patient is 
shown as an open circle.
The mean EC^q value ( SEM) from all preparations was 4.0 - 
0.7 x 10" 6 moles 1^  (range 1.0 x 10""^  moles 1*^ ) to 1.4 x 10"""*
moles 1  ^and the mean maximum tension generated was 13.8 - 1.6 g/mg 
wet weight (range 4.2 to 30.3 g/mg wet weight). The slope of the 
dose-response curve varied between 35.6 and 70.3% change/log units 
(Table 6.2).
6.3.3 Comparison of in vivo and in vitro responsiveness to histamine.
There was no significant correlation between any of the 
measurements of in vivo and in vitro responsiveness to histamine. 
For the patients who did not receive pretreatment with atropine, 
the lack of relationship is illustrated for PC2qFEV^ and PCg^sGaw 
against EC^q (Figure 6.5) and for ££3 5^ 5(0 ) and PCgtjV^p) against 
EC5 0 (Figure 6 .6 ). Using EC2 0 as a measure of in vitro sensitivity 
did not alter the lack of relationship, correlation co-efficients 
being PC2QFEV2 (r = 0.32) PC^sGaw (r = 0.01) and ^ 3 5^3 5 ^) (r = 
0.49). The slope of the dose response curve did not relate to any 
of the measures of in vivo, responsiveness, the correlation co­
efficient ranging from 0.18 to 0.44 for the four measurements. 
Maximum tension per gram wet weight did not relate to in vivo 
responsiveness (Figure 6.7).
For the patients who received pretreatment with atropine, the 
lack of relationship is illustrated for PC2 QFEV2 and PC^sGaw
4 •
against EC^q (Figure 6 .8 ) and for PC3 5 V3 5 (c) and PC3 5 V3 5 (p) 
against EC^q (Figure 6.9).
Using EC3o as the measure of in vitro sensitivity did not 
change the lack of relationship. Neither the slope of the in 
vitro dose-response curve nor the tension generated/mg wet weight 
of tissue were related to the in vivo measurements.
The asthmatic patient who underwent surgery did not exhibit
increased in vitro smooth muscle responsiveness to histamine. 
— f. -1 _7 .1 .
EC^q 2.3 x 10 moles 1 EC2 0 5.7 x 10 moles 1 maximum tension 
generated 18.4 g/mg wet weight and dose-response curve slope =
37.1 % change/log unit.
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FIGURE 6.5
IN VIVO VS IN VITRO RESULTS WITHOUT ATROPINE
PC20 FEV1 
(mg/ml)
PC35 sGaw 
(mg /ml)
>64
6 4 -
J 100
n * 11 
r - -0.26 
p > 0.05
n “ 11 
r * 0.02 
p > 0.05
•5
EC50 (moles) O  ASTHMATIC 
PATIENT
Graph of iji vivo responsiveness to histamine [without atropine 
pretreatment] expressed as PC^qFEV^ and PC^sGaw with in vitro smooth 
muscle sensitivity to histamine expressed as the concentration of 
histamine producing a contraction 50% of maximum 
(0) result for patient with asthma.
FIGURE 6.6
PC35 V35 < p )
(mg/ml) PC35 ^35 (C) 
(mg / ml)
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n = 10 
r = 0.15 
p>0.05
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r = -0.02 
p >0.05
EC50 (moles)
O  ASTHMATIC 
PATIENT
Graph of jji vivo responsiveness to histamine [without atropine 
pretreatment] expressed as PC3 5V3 5 (p) and and in vitro smooth
muscle sensitivity to histamine expressed as EC^q 
0 = Asthmatic patient.
FIGURE 6.7
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Graph of average maximum force per mg tissue (wet weight) and PC value 
for FEVjj sGaw and V^qCp) for six surgical subjects (5 for PC^q )* 
Results were not statistically analysed because numbers were small, but 
results are widely scattered with no apparent relationship.
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FIGURE 6.8
IN VIVO VS IN VITRO RESULTS (after Atropine)
PC20FEV1 PC35jGaw
(mg/ml) (mg/ml)
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Graph of in vivo responsiveness to histamine [after atropine] expressed 
as PC2 0 FEV2 and PCg^sGaw and in vitro smooth muscle sensitivity to 
histamine expressesd as EC^q 
0 = Asthmatic patient.
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FIGURE 6.9
PC35V 35(p) pc35v 35(C)
(mg/ml) (mg/ml)
64-1
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p>0.05
n-11 
r—  0.43 
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Graph of in vivo responsiveness to histamine [after atropine] expressed 
as PC3 5V3 5(p) and PC3 5^3 5 (0 ) and in vitro smooth muscle sensitivity to 
histamine expressed as EC^q 
0 = Asthmatic patient.
Correlation co-efficients comparing in vivo and in vitro
parameters are tabulated (Table 6.3).
6.4 DISCUSSION
The surgical patients used in this study were more responsive 
than non-smoking normal subjects of a similar age, but less responsive 
than a group of asthmatic patients described in Chapter 5. Cigarette 
smoking, chronic bronchitis and airflow obstruction may have all 
contributed to the increase in responsiveness in the surgical group. 
The majority were cigarette smokers, which has been associated with 
increased non-specific airway responsiveness in asymptomatic subjects 
without airflow obstruction, (Malo et al 1982) although this finding has 
not been confirmed by others (Cockcroft et_ al 1983). Eight patients 
also had chronic bronchitis which has been shown, both with (Oppenheimer 
et al 1968, Laitinen 1974, Ramsdale et_ al 1982, Bahous et al 1984) and 
without airflow obstruction, (Gerrard et_ al_ 1980) to be associated with 
increased airway responsiveness. In the surgical group there was a 
significant relationship between baseline lung function and PC2qFEV^ but 
this was not true of the normal subjects nor of the asthmatic patients 
described in Chapter 5. This suggests that baseline airway calibre 
may be a more important determinant of airway responsiveness in smokers 
than in patients with asthma.
It is unknown whether the presence of a bronchial neoplasm has any 
effect on airway responsiveness. However, a comparison with the levels 
of responsiveness found by Bahous and coworkers (1984) in patients 
similar to those used in this study but without neoplasms, showed a 
similar range of airway responsiveness to that reported here.
In this study there was no significant relationship between in 
vivo airway responsiveness to histamine and in vitro measurements of 
smooth muscle responsiveness. In vitro measurements were made on 
tissues which had been washed thoroughly, stored overnight in fresh 
oxygenated saline at low temperature, and washed thoroughly again before 
testing. This procedure should have removed all intra-operative 
medications/
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medications (Clark 1923) which might have otherwise affected the results 
obtained. In vitro bronchial strips have no functionally active neural 
input, so the presence of differing degrees of vagal tone in vivo might 
obviate any relationship between in vivo and in vitro results. Our 
results demonstrate a variation in the response to atropine suggesting 
variation in vagal tone between patients. Furthermore, inhaled 
histamine produces a response, both by direct action on smooth muscle, 
(Hawkins and Schild 1951, Nogrady and Bevan, 1978, Thomson and Kerr 
1980) and via a nervous reflex mediated via vagal pathways (White and 
Eiser 1983).
Thus, by pretreating patients with atropine, at a dose which has 
been shown to decrease the response to methacholine by two log units 
(Thomson et al 1983) any vagal influence which might have confounded a 
relationship between in vivo and in vitro measurement should have been 
minimized. Such atropine pretreatment, however, did not enhance the 
relationship between in vivo and in vitro measurements.
One previous study has compared in vivo and in vitro responses to 
histamine in human airways (Vincenc et al 1983). These authors used only 
FEVj^  to measure in vivo responsiveness, and because of the lower dose of 
inhaled histamine administered, they were unable to record significant 
changes in airway calibre in all patients. As a result PC2qFEV^ values 
were only obtained for five out of 14 patients, and PC^qFEV^ in four 
more. Pretreatment of patients with atropine was not employed. The 
conclusion of this limited study was that no relationship existed between 
the in vivo and in vitro measurements. Our study confirms and extends 
these findings, and also confirms the lack of relationship found using 
methacholine as an agonist (Roberts et al) 1984 (Chapter 4).
Thus we have demonstrated that, using histamine as an agonist, no 
relationship exists between in vivo and in vitro responsiveness of the 
airways, and that the modifying effect of vagal input to smooth muscle is 
not the explanation for this lack of relationship. It is likely that the 
measurements of in vivo airway responsiveness obtained in these patients 
are the results of a complex interaction between a variety of different 
technical, physiological and pathological factors.
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A common feature of asthma is an increase in the responsiveness of 
the airways to a variety of different stimuli. This appears to be non­
specific for a number of triggers since in a given asthmatic the airway 
responses to one stimulus usually correlates with that to another. 
Individuals highly sensitive to histamine are also generally more 
sensitive to methacholine (Juniper etal 1978), prostaglandin 
(Thomson et al 1981), cold air (O'Byrne et al 1982) and exercise 
(Anderson et al 1979). A mechanism which could explain this non-specific 
hyperresponsiveness is an abnormality in the sensitivity of airway smooth 
muscle (Thomson 1962). In vitro hyperresponsiveness of airway smooth 
muscle could be manifest by a lower EC^q value and/or by an increase in 
the maximum tension generated by each smooth muscle strip. However, in 
this study the surgical patient who had asthma, and showed the expected 
in vivo hyperresponsiveness to histamine, did not exhibit increased in 
vitro responsiveness as assessed by EC^q or maximum tension generated. 
The maximum tension generated but not the EC^q could be affected by the 
quantity of smooth muscle present in each strip. It is possible that by 
chance there was less smooth muscle present in the bronchial strip from 
the asthmatic patient, which would mask a real increase in maximum 
tension generated. To offset this problem the maximum tension 
generated by each piece of tissue was expressed per unit mass of tissue. 
This failed to alter the conclusion reached. Nevertheless, it would be 
necessary to accurately determine the size and number of smooth muscle 
cells present in each bronchial strip to exclude a defect in airway 
smooth muscle function as a cause of airway hyperresponsiveness.
Another difficulty when comparing in vivo and in vitro responses 
is that a complete concentration -response curve is performed in vitro, 
but is not possible in vivo as it would be dangerous to produce further 
bronchospasm after the patient has become symptomatic. To address this 
problem the EC£q which is on the early region of the in vitro 
concentration-response curve, was compared with in vivo results.
Another explanation for a lack of relationship between iji vivo and in 
vitro results is that bronchial smooth muscle may be more sensitive over 
a /
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a small range of concentration such as occur in vivo. If this were the 
case the slope of the in vitro concentration-response curve would change. 
Although there was variation in the slope of this curve, it did not 
relate to in vivo results.
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C H A P T E R  7
ULTRASTRtJCTOKE OF HUMAN BRONCHIAL SMOOTH MUSCLE
ULTRASTRDCTDRE OF HOMAN BRONCHIAL SMOOTH MDSCLE
7.1 INTRODUCTION
The aim of this thesis has been to investigate factors which may alter 
the responsiveness of human bronchial smooth muscle. The basic approach 
was to measure the airway responsiveness of patients due to undergo 
surgery and to compare this with in vitro sensitivity of bronchial strips 
of the same patients. As an adjunct to this study it was proposed to 
examine bronchial strips with a transmission electron microscope to 
investigate whether structural differences of the smooth muscle cells or 
surrounding stroma might be related to jm vivo responsiveness and thus 
explain the variation seen in patient responses to bronchcons trie tor 
agents.
There are few ultrastructural studies on human airway smooth muscle 
(Richardson and Ferguson 1979, Daniel et al 1980), and only the latter 
study attempted to quantitate features. Airway smooth muscle is under 
both neural and myogenic control, so airway responsiveness could be 
affected by differences in one or other of these systems. Possible 
neural mechanisms affecting responsiveness include an abnormality of 
vagal pathways (Coburn and Tomita 1973), of sympathetic receptor density 
(Coburn and Tomita 1973) or of non adrenergic-non cholinergic (NANC) 
nerves (Cobum and Tomita 1973). The importance of these mechanisms 
remains controversial.
Possible myogenic mechanisms affecting responsiveness include 
increased smooth muscle contractility of individual muscle cells or an 
increase in cell to cell electrical coupling. There is a spectrum of 
smooth muscle types from those with pure myogenic control modulated by 
neural signals to those with predominantly neurogenic control (Daniel et 
al 1986). Systems with largely myogenic control are characterised by 
spontaneous electrical oscillations that are independent of nerve supply. 
Action potentials spread through the muscle via low resistance bridges or 
gap junctions. In contrast, systems with largely neural control do not 
generate spontaneous electrical activity and most muscle cells are 
innervated.
In/
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In human airway innervation is sparse (Daniel et al 1986). 
Specimens of human airway taken at post-mortem from accident victims with 
apparently normal airway show spontaneous contractile activity and 
numerous gap junctions (Daniel et al 1980).
Increased airway responsiveness could, therefore, be explained by 
increased cell-to-cell coupling. Subjects with the most responsive 
airways would be expected to have the largest number of gap junctions 
analogous to the increased numbers of gap junctions in the rat myometrium 
at the time of parturition. (Garfield et al 1978).
The hypothesis that airway responsiveness may be related to 
ultrastructural changes in airway smooth muscle has not been previously 
tested in man.
The object of this study was to compare in vivo airway 
responsiveness to various aspects of smooth muscle ultrastructure 
including the frequency of nerve endings and numbers of gap junctions. 
Unfortunately, due to difficulties with fixation and preservation of the 
bronchial specimens this part of the study was delayed. Eventually, 
collaboration was arranged with Dr. G. Gabella, University College, 
London. With his help a protocol producing reliable fixation has been 
developed and good quality electron micrographs are now being obtained. 
Tissue from the eleven patients who were assessed iri vivo with LTD^ are 
fixed awaiting processing. Tissue from the asthmatic patient was 
unfortunately poorly preserved so that no quantitative work will be 
possible.
A selection of electron micrographs which show particular features 
of human airway are presented and these features demonstrated.
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7.2 METHODS
Initially, bronchial rings from airway obtained at thoracotomy 
were immediately placed into 2% gluteraldehyde within minutes of removal 
at surgery. This procedure produced poorly preserved, contracted smooth 
muscle so the fixation procedure was modified until good results were 
obtained using the following protocol:
Thin (1-2 mm) wide bronchial rings were dissected using a scalpel 
blade, transversely, from macroscopically normal airway. Isometric 
tension was maintained with a springed clip. The rings were then 
suspended in calcium free Krebs-Hensleit physiological saline at 20°C 
continuously bubbled with 95%02~ 5%C02» to induce smooth muscle 
relaxation. After ten minutes the bronchial rings still on the springed 
clips were transferred to freshly made up 4% glutaraldehyde at 22° and 
left for a minimum of 20mins. Sample were then transferred to Dr. 
Gabella who prepared sections and stained and examined these under a 
Philips transmission electron microscope (EM 400) by methods described in 
Chapter 2.
7.3 RESULTS
Observations here reported are at a preliminary stage. The following 
electron micrographs demonstrate many of the features of human bronchial 
ultrastructure.
7.3.1 Arrangement of Structures
The smooth muscle cells lay in the tunica propria of the 
bronchial mucosa, usually beside cartilage. The muscle tissue 
commonly lay 100 micrometres (um) or more below the epithelial 
surface (Figure 7.1).
Sections were orientated to produce, as far as possible, 
transverse sections of smooth muscle cells. Smooth muscle cells 
were arranged in bundles or sheets of compact texture (Figure 7.2). 
Individual muscle cells or loosely arranged groups were only rarely 
observed. The smooth muscle bundles were separated by spaces 
containing/
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containing an amorphous matrix with collagen bundles and also other 
cell types such as mast cells and fibroblasts. Figures 7.3 and 7.4 
show a low magnification view to demonstrate arrangement of the 
various structures seen in the bronchial muscle.
7.3.2 Muscle cell size
Smooth muscle cell profiles measured up to 4 micrometres in 
diameter. About 12% of their profiles, usually with the largest 
area, displayed a nucleus. The length of nuclei, measured on 
orthogonal sections of the same blocks, ranged from 16-22 
micrometres. The total length of the muscle cells was therefore 
estimated to be 200-250 micrometres.
Many muscle profiles tended to be round in shape, but had many 
projections and indentations. In some preparations 4 to 6 muscle 
cell profiles were flattened and nested together in a way that 
suggested the presence of small functional units within the muscle 
(Figure 7.3).
7.3.3 Cell surface
The cell surface was studded with small inpocketings 
(caveolae). These were usually arranged in rows along the length 
of the cell. Rows were separated by regions of the cell membrane 
bearing dense bands in which thin (actin) filaments were inserted. 
Small cisternae of smooth endoplasmic reticulum were often 
associated with the caveolae (Figure 7.4).
7.3.4 Intracellular filaments
The preservation of filaments in smooth muscle cells is 
notoriously difficult and greatly affected by the preparative 
procedure (see Figure 7.7). This was the case in the material 
studied in this project. In some preparations only thin (actin) 
filaments and a few intermediate filaments were found, while in 
others both thin and thick (myosin) filaments were well 
represented, together with intermediate filaments (Figure 7.5).
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7.3.5 Cytoplasmic organelles
Mitochondria were abundant in all muscle cells. They amounted 
to more than 5% of the muscle cell volume. Mitochondria were 
preferentially located immediately beneath the cell membrane or 
close to the nucleus (Figure 7.6). Rough endoplasmic reticulum 
was absent from almost all muscle cell profiles although 
occasionally a cistema of rough endoplasmic reticulum was found, 
usually near a pole of a nucleus (Figure 7.6). In this region of 
the cell a small Golgi apparatus was often present. Smooth 
endoplasmic reticulum is common and appears as small flat 
cisternae (Figure 7.6). They are usually found near the caveolae 
and close to mitochondria.
7.3.6 Mast cells
Mast cells were present in most of the bronchial samples 
examined. Some were found close to regions of smooth muscle 
(Figure 7.10). There were projections from the mast cell which 
were flattened over the cell body. If these were extended, they 
would reach the surface of the smooth muscle cells.
7.3.7 Nerves
The tunica propria was densely innervated. The nerves ranged 
from large trunks containing a hundred or more axons, some of 
which were myelinated, to small nerve bundles consisting of a few 
unmyelinated axons. Only large nerve trunks were sheathed by an 
endoneurium (Figure 7.6).
Within the bronchial musculature, only small nerve bundles 
were found. These contained exclusively unmyelinated axons and 
were not encapsulated. The axons were associated with processes 
of Schwann cells. The numbers of intramuscular nerve bundles was 
small (Figure 7.6, 7.7). Although the density of innervation 
varied from preparation to preparation, there was not more than 
one axon per twenty muscle cells. Some intramuscular axons were 
expanded/
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expanded into varicosities and these contained clusters of 
synaptic vehicles, mainly of the small agranular type (Figure 
7.6).
7.3.8 Gap Junctions
Gap junctions were seen in all preparations and were a 
constant feature of human bronchial musculature (Figures 7.2, 
7.4, 7.5, 7.6, 7.7). The junctions were small, rarely exceeding 
0.2 micrometres in length, and had the characteristic structure of 
two closely apposed membranes with an intra cellular gap of around 
2 nanometres. This arrangement gives the gap junction a 5 or 7 
layered appearance under the electron microscope.
There appeared to be variation in the numbers of gap junctions 
between preparations although this has not yet been quantified.
7.3.9 Intercellular materials
In the spaces between muscle cells there were collagen fibrils 
measuring about 50 nanometres in diameter. They were orientated 
in all directions but predominantly were parallel to the long axis 
of the cells. In virtually all preparations the muscle cells were 
surrounded by a thick coat of material similar in texture and 
electron density to a basal lamina (Figure 7.2, 7.4.). This coat 
measured from 60-500 nanometres. In some preparations this coat 
filled the space between adjacent muscle cells, with only some 
collagen fibrils tunnelling through it.
7.4 DISCUSSION
A reliable method has been developed for the fixation and staining 
of bronchial samples removed at thoracotomy. Tissue preservation is now 
such that quantification of various structures is possible, which will 
allow comparison of numbers of these structures with in vivo airway 
responsiveness. There are several interesting features apparent in 
this preliminary study.
The/
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The caveolae seen in smooth muscle cells were of similar size and 
shape to those described in smooth muscle cells from other sources 
(Gabella 1981).
Thick filaments containing myosin and thin filaments containing 
actin and tropomyosin are important in the contractile response of the 
smooth muscle cell (Shoenberg and Needham 1976). Intermediate 
filaments are thought to form part of the Cytoskeleton of the cell and 
are non-contractile (Cooke 1976). If the relative quantities of these 
components varied within smooth muscle cells it would cause differences 
in contractility of the smooth muscle. However, with the inconsistent 
results in demonstrating filaments by EM, quantification of the 
different filaments would be impractical.
The role of the endoplasmic reticulum in the regulation of smooth
muscle contraction is poorly understood. Rough and some of the smooth
ER may be involved in synthetic processes such as that of synthesis of
membrane, filaments, glycogen and collagen. Smooth endoplasmic
reticulum, by releasing and sequestering calcium, is important in the
control of muscle contraction in striated muscle (Ebashi and Endo,
2+1968). However, the site of Ca storage within smooth muscle has not 
been determined although there is some evidence implicating the smooth 
ER (Carsten 1969). If this observation is confirmed, then qualitative 
or quantitative variations in bronchial smooth muscle smooth ER might be 
important in determining smooth muscle responses to non-specific 
stimuli.
Mast cells were present in most preparations. They were often 
found close to groups of smooth muscle cells confirming the observations 
on airway smooth muscle by Daniel et_ al (1986). Their proximity to 
smooth muscle is in keeping with their role in acute bronchoconstriction 
produced by mediator release (Holgate & Kay 1985). It would be 
important if there were variations in the quantity and site(s) of mast 
cells in different preparations as this might indicate why only some 
atopic individuals develop asthma. Similarly variations in the quantity 
of cytoplasmic granules where histamine and 5-hydroxytryptamine are 
stored would also be of interest.
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Perhaps the most interesting feature of smooth muscle is the gap 
junction. Action potentials spread through the muscle via these 
intercellular connections (Perrechia 1974). Studies on rat uterus have 
shown that the number of gap junctions between smooth muscle cells of 
the myometrium increase markedly around parturition, when the uterus is 
"hyper-responsive11 to stimuli, and fall again within two days. (Garfield 
et al 1977).
Daniel et al (1980) found that samples of bronchi from airway of 
accident victims with apparently normal airway showed spontaneous 
contractile activity and numerous gap junctions. More recently the same 
group have found, using post mortem specimens, that there were greater 
numbers of gap junctions in tracheal smooth muscle compared to smooth 
muscle of smaller bronchi. However, they made no attempt to assess 
whether there were differences in smooth muscle samples obtained from 
different individuals. Hence, it is important to assess whether 
variation in gap junction frequency and morphology occurs between 
individuals, and if differences do exist, whether they relate to in vivo 
responsiveness.
The thick coat of material surrounding smooth muscle cells in 
virtually all our preparations has been previously described only once 
(Daniel et al 1986). Although it is similar in texture and electron 
density to a basal lamina, the coat around the human bronchial smooth 
muscle cells measures 60 - 500 nanometres, compared to the 20 to 30 
nanometres dimensions of basal lamina in visceral muscle cells from 
experimental animals (Gabella 1981). This special material, 
hereinafter referred to as basement membrane, had an amorphous 
appearance. Its inner aspect was directly adherent to the cell membrane 
while its outer aspect was associated with collagen fibrils. Bundles or 
a thin layer of microfibrils of about 10 nanometres diameter, lay close 
to the outer aspect of the basement membrane. This basement membrane 
could affect the contraction of the smooth muscle, its nutrient supply, 
and also the diffusion of bronchconstrictor agents to their site of 
action on the surface of the smooth muscle cell. Variations in the 
quantity/
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quantity and distribution of this basement membrane could be important 
in smooth muscle responses.
In summary, reliable electron micrographs of bronchial rings can 
now be obtained. Several interesting features have been demonstrated 
which could be important in the contraction of airway smooth muscle. It 
is hoped that future quantification of these features may yield 
important insights into the understanding of the control of human airway 
smooth muscle contraction.
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FIGURE 7.1
Electron micrograph of bronchial strip obtained at thoracotomy. 
Epithelial cell (A) with associated cilia (B)
Endoplasmic reticulum (er) and mitochondria (m) are seen within the 
epithelial cell cytoplasm. Bundles of nerves (n) run close to the 
epithelial surface. Some cilia are seen in transverse section CT 
showing the 9 rod structure of the cilia. Adjacent to the epithelial 
cell is a mucous secreting cell with a group of secretory vesicles being 
discharged into the lumen. [No muscle cells are visible in this 
micrograph], (Magnification = 3,700).
FIGURE 7.2
Low magnification electron micrograph view of smooth muscle cells taken 
from a human bronchus. Nuclei (N) are only seen in some cells because 
the cells are cut transversely and the nuclei are often missed because 
of the axial length of the cell.
Even at this magnification cell-to-cell contacts which probably 
represent gap junctions (GJ) can be recognised.
Magnification = x 8000
FIGURE 7.3
A low power electron micrograph of human bronchial smooth muscle cells 
which lie in small bundles. These may operate as functional units. 
Sarcoplasmic reticulum (SR) and mitochondria (M) are present. Several 
gap junctions (GJ) are also visible. Numerous inpocketings of the cell 
membrane (caveolae) are present.
The muscle bundles are surrounded by a homogenous material.
Magnification = x6000
FIGURE 7.4
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Bundles of human bronchial smooth muscle cells surrounded by matrix 
material and collagen fibres seen in longitudinal and transverse 
section. Intracellular organelles are present and a nerve bundle (n) 
runs between the muscle cells.
(Magnification = x 8000)
FIGURE 7.5
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Low power view of human bronchial smooth muscle cells running 
longitudinally. Numerous collagen fibres (C) are present surrounding 
muscle cells.
Mitochondria (M) are present.
(Magnification = x 13,500)
FIGURE 7.6
Numerous caveolae (C) are present at the Electron micrograph of human 
bronchi smooth muscle cell surface. Sarcoplasmic reticulum and 
occasional gap junctions are also seen.
Myofilaments are visible within the cell cytoplasm. Homogenous grey 
material is present in the spaces between the smooth muscle cells. 
Preservation of structures, particularly mitochondria is poor in this 
specimen.
Magnification = x 17,000)
FIGURE 7.7
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A larger magnification of a human bronchial preparation (17,000) shows 
details of intracellular structures. Myosin (dark dots) and actin 
(paler smaller dots) filaments are seen within the cell cytoplasm. 
Occasional microtubulles are seen. The 5 layer structure of the gap 
junction is also apparent at this magnification.
FIGURE 7.8
s
A x 22,000 view of a human bronchial smooth muscle cell showing the
nucleus (N) and cell membrane.
Smooth sarcoplasmic reticulum (SR) lies close to the cell membrane and
to the nucleus.
Mitochondria are also present.
A small nerve bundle (nb) containing only two axons, one of which is 
expanded into a varicosity (v) packed with synaptic vesicles
FIGURE 7.9
•
A low power (x 6000) view of human bronchial smooth muscle bundles. 
Mitochondria and caveolae are numerous although preservation of 
mitochondria in this specimen is poor.
There are several gap junctions and a few nerves running within the 
bundles of muscle cell.
FIGURE 7.10
Electron micrograph of human bronchial strip.
A mast cell lies adjacent to smooth muscle. Secretory granules are 
present in the cytoplasm. If the cytoplasmic extensions were extended, 
they would be contiguous with the smooth muscle surface.
Small bundles of smooth muscle show numerous gap junctions.
(Magnification = x 6,000)
C H A P T E R  8
IN VIVO AND IN VITRO EFFECT OF VERAPAMIL ON HOMAN
Airway responsiveness to leokotriene d4
IN VIVO AND IN VITRO EFFECT OF VERAPAMIL ON HUMAN AIRWAY RESPONSIVENESS TO
ledkotriene d4
8.1 INTRODUCTION
In previous chapters of this thesis I have examined the effect of 
methacholine and histamine on airway smooth muscle tone in vivo and in 
vitro. Neither of these agonists is likely to have a major role in 
producing bronchoconstriction in the clinical situation. Methacholine 
is a pharmacological agonist acting on the smooth muscle receptors 
normally stimulated via the vagus, and histamine, although present in 
mast cells and released in allergen and exercise challenge in the 
asthmatic does not seem to be important in asthma, as potent anti­
histamines are ineffective as anti-asthma drugs. Furthermore histamine 
induced bronchoconstriction is rapid in onset and short in duration, 
unlike an asthmatic attack.
SRS-A is present in mast cells and released on allergen challenge 
(Orange and Austin 1969). Recent work has shown that SRS-A consists of 
a group of related chemicals known as leukotrienes (Simonsson 1980). 
One of these, Leukotriene (LTD^ ) is a potent bronchoconstrictor in 
man and may be an important mediator in asthma (Dahlen et al 1980, 
Barnes et al 1984). The onset of LTD^ induced bronchial smooth muscle 
contraction is slow and the duration of contraction prolonged (Barnes et 
al 1984) akin to bronchoconstriction in asthma.
Specific binding sites (receptors) have been identified in the 
lungs of different species including man (Pong and De Haven 1983, Lewis 
et al 1984). Although in vitro contractile responses of airway smooth 
muscle from these species have been shown to be receptor mediated, the 
mechanism(s) underlying leukotriene induced bronchoconstriction in man 
in vivo is uncertain. Since contraction of airway smooth muscle is 
dependent on calcium ion influx (Triggle 1983, Rodger 1985) this study 
investigated the effects of the calcium-channel blocking drug verapamil 
on the airway response to LTD^ in a group of normal subjects. In 
parallel, the effects of verapamil on the in vitro LTD^ concentration- 
response curve for human bronchial tissue were also examined.
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8.2 METHODS
8.2,1 In vitro Study
Bronchial tissue was obtained from patients undergoing lung 
resection for bronchial carcinoma, immediately following removal 
at thoracotomy. Samples from second to sixth order bronchi were 
dissected from areas of macroscopically normal tissue and 
maintained at 4°C overnight in oxygenated Krebs-Hensleit 
physiological salt solution. On the day following removal the 
bronchi were dissected free of extraneous connective tissue and 
sectioned in order to produce transverse strips of tissue which 
were suspended (under a resting tension of 1.5 to 2.0 g) in a 5 ml 
organ bath containing Krebs-Hensleit solution at 37°C bubbled with 
5% CO2 in 0£. During a 60 minute equilibration period the tissues 
were washed three times. Changes in isometric tension were 
measured using force-displacement transducers and recorded on an 
ink-writing polygraph.
The reproducibility of the contractile changes of the
bronchial strips was assessed by adding methacholine (1 x 10”^
moles 1^ ) on two occasions allowing an interval of 30 minutes for
recovery between each drug addition. A cumulative concentration-
effect curve to LTD^ or methacholine was then constructed by
adding increasing concentrations of the drug, each addition of the
drug being made at the peak of the response produced by the
preceding concentration. Following washout of the agonist and
full recovery to control resting tension, either verapamil (1 x 
—f i  -1
10 moles 1 ) or vehicle was added to the bath. Thirty minutes 
later a second concentration-effect curve was constructed. The 
concentration of LTD^ and methacholine that produced a 50% (EC q^) 
maximal contraction were calculated from the graphically displayed 
data.
In each experiment four to six bronchial strips from each 
patient were examined. For each bronchial strip the responses to 
LTD^ and methacholine elicited in the presence of verapamil were 
calculated/
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calculated as a percentage of that produced in the absence of the 
calcium channel blocking drug.
8.2.2 In vivo Study
Six normal subjects were studied (Table 8.1). Five were male. 
Their ages ranged from 22 to 36 years. All were non-smokers and 
give no history of respiratory disease. None were taking any drug 
treatment. All subjects gave informed consent and the experimental 
protocol was approved by the Western Infirmary Ethical Committee.
Airways resistance (Raw) and Thoracic Gas Volume (TGV) were 
measured automatically (Chapter 3). The results were expressed as 
specific airways conductance (sGaw). The mean of 8 values measured 
was taken as sGaw. The maximum expiratory flow at 70% of expired 
vital capacity, obtained from a partial flow-volume (V-jq(p)) curve, 
and the forced expiratory volume in one second (FEV-^ ) were measured 
automatically. Body plethysmographic measurements always preceded 
flow volume recordings. Aerosols were generated with a Wrights 
nebuliser by air at 50 psi (345 kPa) at a flow rate of 8 1/min to 
an output of 0.15 ml/min.
Each subject received either verapamil (2.5 mg/ml) or normal 
saline in a randomised single blind manner on four separate days. 
After baseline measurements of sGaw (mean of 8 readings) and *30(P> 
(mean of 5 readings), the solutions were inhaled for 5 minutes. 
After 15 minutes lung function tests were repeated. Leukotriene 
and methacholine inhalation tests were carried out with a 
modification of the previously described method. Buffered saline 
was inhaled first followed by increasing concentrations of LTD^ 
(0.4-50 ug/ml) or methacholine (2 - 64 mg/ml). Each concentration 
was inhaled for 2 minutes. Inhalations were repeated every 15 
minutes for LTD^ and every 10 minutes for methacholine. Two LTD^ 
and two methacholine inhalation tests were performed on each 
subject. Results were expressed as the provocation concentration 
(PC) producing a 35% fall in sGaw (PC-^sGaw) and a 30% fall in
v30(p»./
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TABLE 8.1
SUBJECT CHARACTERISTICS
Subjects Age Sex
(yr)
1 32 M
2 35 M
3 25 M
4 22 M
5 30 F
6 22 M
Baseline FEV^
Ht Litres % Pred
(metres)
1.74 4.1 102
1.71 3.4 92
1.68 3.7 94
1.75 3.9 93
1.80 3.6 99
1.75 4.4 105
VsqCp))* Results were compared using analysis of variance and 
Student's t test.
8.3 RESULTS
8.3.1 In vitro Study
LTD^ (1 x 10“^  to 2 x 10“7) and methacholine (1 x 10“  ^to
O 1
1 x 10 ) moles 1” elicited concentration-dependent contractions
of the bronchial strip preparations (Figure 8.1). There was no 
significant difference in the sensitivities to LTD^ or methacholine 
of bronchial strips prepared from the same patient. EC^q values (+. 
SE of mean) calculated from all experiments were 2.6+. 0.8 x 10 
moles l-  ^(n = 7) for LTD^ and 1.7+0.3 x 10”  ^ moles (n=18)
for methacholine.
Contractions to LTD^ were slow to develop, taking 12 +4 minutes 
to achieve peak effect for each concentration of drug used (Figure 
8.2). The mean maximum concentration elicited by LTD^ at the 
highest concentration tested (it was not possible to test 
concentrations in excess of 2 x 10-7 moles l-  ^ because of the 
limited supply of eicosanoid) was 17 +3 m N. This was not 
significantly different from the maximum contraction produced by 
methacholine (18 +2 m N). LTD^-induced contractions were slowly 
reversed, requiring 60 to 80 minutes to return to baseline tension 
levels with repeated washing of the tissue with fresh physiological 
salt solution.
—6 —1Verapamil (1 xlO moles 1 ) had no effect on baseline tension
during the 30 minute equilibration period. Similarly, verapamil 
was without significant effect on the concentration-response curve 
to LTD^ (Figure 8.1 a). The same concentration of verapamil 
inhibited contractile responses to methacholine and depressed the 
maximum contraction by 29+ 5% (Figure 8.1 b)
8.3.2 In vivo Study
Inhalation of verapamil did not alter baseline sGaw or Vgg(p) 
(Table 8.2)/
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FIGURE 8.1
In vitro responses to LTD^ (a) and methacholine (b)
b.
100100
[ M C h ] m o i r1
Graph of response expressed as a percentage of maximum contraction both 
without (•) and with (■) verapamil 1 x 10 to in graph a: LTD^ and
graph b: methacholine of in vitro human bronchial preparations.
Each point represents the mean of 7 (graph a) or 18 (graph b) bronchial
strips. The standard error of the mean is shown as a vertical bar.
FIGURE 8.2
In vitro response to LTD^
1 gram 
tension
10'10 10'9 10"8 10*7 5x10"7
LTD4 (moles/litre)
i_____ i_____ i_____ i_____ i_____ i_____ i_____ i_____ i_____ i_____ i_____ i----- 1----- 1
0 10 20 30 40 50 60 70 80 90 100 110 120 130
Time (minutes)
Polygraph tracing of tension generated by smooth muscle strip when LTD^ 
in increasing concentrations is added to the organ bath.
FIGURE 8.3
Effect of verapamil on LTD^ induced bronchoconstriction
ltd4
CONTROL VERAPAMIL
> 5 0
10 --
1.0 -■
VERAPAMILCONTROL
Effect of pretreatment with verapamil (2.5 mg/ml) or control (buffered 
saline) inhalations on airway responsiveness to LTD^. Results are 
expressed as the PC^sGaw and the PC-jqV^qCp).
(Table 8.2). In 5 subjects verapamil significantly inhibited LTD^- 
induced bronchoconstriction (Figure 8.3). One subject failed to 
respond to LTD^ on either day. The geometric mean PC values 
underestimate the effect of verapamil on LTD^-induced 
bronchoconstriction since 3 subjects did not bronchoconstrict to 
the highest concentration of LTD^ administered. These subjects 
were allocated the highest concentration of LTD^ (50 ug/ml) as 
their PC value to allow statistical analysis. Verapamil did not 
inhibit methacholine-induced bronchoconstriction (Figure 8.4). 
None of the subjects developed cough after LTD^ .
8.4 DISCUSSION
These results demonstrate that verapamil significantly inhibits 
LTD^ but not methacholine-induced bronchoconstriction in man. In 
contrast verapamil had no inhibitory effect upon the response of human 
airway smooth muscle strips to LTD^ and a small though significant 
inhibitory effect on the response to methacholine.
LTD^ and methacholine elicited concentration-dependent contraction 
of isolated bronchial smooth muscle. In the case of methacholine these 
effects were clearly mediated directly via stimulation of muscarinic 
cholinoreceptors in the smooth muscle since the responses are 
competitively inhibited by atropine (Raeburn 1984). In the absence of a 
suitable selective antagonist at LTD^ receptors a similar experiment was 
not feasible with LTD^ . However, contractions elicited by LTD^ were 
unaffected by mepyramine, atropine or inhibition of the cyclo-oxygenase 
pathway with flurbiprofen (Raeburn 1984). Similar findings have been 
reported by another group (Jones et al 1982). This evidence makes the 
following mechanisms of LTD^ induced bronchoconstriction unlikely:
1. an indirect effect of LTD^ mediated via histamine released from mast
cells
2. neurotransmitter (acetylcholine) released from vagal nerve terminals
in the smooth muscle
3,1
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FIGURE 8.4
Effect of verapamil on methacholine induced bronchoconstriction
METHACHOLINE
CONTROL VERAPAMILCONTROL VERAPAMIL
mg/ml 10*0 ' '
1.0 -■
PC 35 sGaw
Effect of pretreatment with verapamil or control inhalations on airway 
responsiveness. Results are expressed as PC-^sGaw and PC^qV^qCp).
3. the release of cycle-oxygenase products, e.g: thromboxane A£ or the 
constrictor prostaglandins PGF2 and PGD, derived from arachidonic 
acid.
It is probable that the observed effects of LTD^ in vitro were 
directly mediated.
Contraction of airway smooth muscle depends on an increase in the
/y,
concentration of calcium ions (Ca ) free within the myoplasm of the
cell (Triggle 1982, Rodger 1984). These activator Ca^+ molecules may be
supplied either from the extracellular fluid surrounding the cell or
from storage sites such as the sarcoplasmic reticulum, within the cell
(Triggle 1982, Rodger 1984). Contractions of guinea pig airway smooth
muscle preparations induced by agonists are highly resistant to
inhibition with calcium channel blocking drugs such as verapamil and
nifedipine (Raeburn & Rodger 1984, Foster et al 1984). There are few
reports of calcium channel blocking drugs on contractions of human
airway smooth muscle rn vitro. It is clear that high 
— —1concentrations (10 moles 1 ) of nifedipine and gallopamil (D600) are
required in order to produce relatively small inhibition of contractions
(Jones et al 1982, Drazen et al 1983). The results of our study using
verapamil are in agreement with these existing reports. The absence of
an inhibitory effect of verapamil on LTD^-induced contractions is
consistent with the hypothesis that this agonist may, in human airway
smooth muscle, as occurs in guinea pig airways (Raeburn and Rodger
9+
1984), rely principally upon an intracellular source of activator Ca
to initiate contraction. In contrast, the significant inhibitory effect
of verapamil on methacholine-induced contractions in vitro may indicate
that in human airway smooth muscle a proportion of the contractile
2+response to this agonist is dependent upon influx of extracellular Ca 
via calcium channels that are sensitive to inhibition by verapamil.
In contrast to our in vitro findings, in vivo verapamil 
significantly inhibited LTD^-induced bronchoconstriction, but not 
methacholine-induced bronchoconstriction. The marked difference between 
the effects of verapamil on LTD^-induced bronchoconstriction in vivo and 
in/
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in vitro and the selectively of its effect on LTD^ in vivo, suggests 
that verapamil is not acting solely on airway smooth muscle cells. 
Thus, the airway response to LTD^ in man may be mediated both by a 
direct effect on airway smooth muscle as well as indirectly via a 
verapamil sensitive pathway.
There are several potential pathways by which LTD^ might 
indirectly cause bronchoconstriction. If LTD^ is capable of stimulating 
sensory nerve endings in the airway this could result in reflex vagal 
bronchoconstriction.
In dogs with hyper-reactive airways and in guinea pigs, LTD^
induced bronchoconstriction is prevented by pretreatment with atropine
(Hirschman et al 1983, Advenier et al 1983). However, Holroyde &
Jackson (1983) found that LTD^ had no effect on sensory irritant
receptors in cats and dogs, although in cats it potentiated the response
to serotonin by a vagal-dependent mechanism. Thus, the role of vagal
pathways in the response to LTD^ in animals is unclear, and in man
untested. Furthermore, although neuro transmit ter release depends on
2+influx of extracellular Ca , this process is insensitive to inhibition 
by calcium channel blocking drugs (Hausler 1972).
The slow onset on bronchoconstriction with LTD^ is consistent with 
the response being due to release of secondary mediators. In guinea 
pigs, intravenously administered leukotriene produces a reduction in 
dynamic compliance after pretreatment with cyclo-oxygenase inhibitor 
suggesting that some of the bronchoconstriction may be due to the 
generation of thromboxane A^ (Weichman et al 1982). (Weiss et al 1983) 
however found that pretreatment with oral aspirin failed to attentuate 
the response to LTD^ in man.
LTD^ may increase airway permeability as well as producing 
bronchoconstriction. Epithelial transport mechanisms require calcium 
(Mavin et al 1982) and these could be susceptible to inhibition by 
verapamil. If verapamil were reducing LTD^ induced changes in airway 
permeability and impairing access of LTD^ to receptors on smooth muscle, 
the effect of LTD^ would be reduced in vivo but not in vitro.
In/
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In summary these results suggest that in normal subjects LTD^- 
induced bronchoconstriction may occur due to a combination of direct and 
indirect mechanisms. The pathway mediating the indirect effect of LTD^ 
is at present unknown.
Page 100
C H A P T E R  9
EFFECT OF VERAPAMIL AMD SODIUM CRCMOGLYCATE ON LEUKOTRIENE D* 
INDUCED BRONCHOCCKSTRICTICN IN ASTHMATIC PATIENTS *
EFFECT OF VERAPAMIL AND DISODIUM CROMOGLYCATE ON LEUKOTRIENE D, INDUCED 
BRMiCHOCONSTRICTIfflJ IN ASTHMATIC PATIENTS *
9.1 INTRODUCTION
The leukotrienes (LT) including LTD^ may be important mediators in 
asthma (Orange and Austen 1969, Dahlen et al 1983). LTD^ is released
both in vitro and in vivo after allergen challenge, and is a potent
bronchoconstrictor (Dahlen et al 1980, Holroyde et al 1981). However, 
the mechanism of LTD^-induced bronchospasm in asthma has not been 
established. In guinea pigs (Advenier et al 1983) and normal subjects 
(Chapter 8) the calcium channel blocker verapamil partially inhibits the 
bronchoconstrictor response to LTD^ in vivo but not in vitro in human 
bronchi, and only at very high concentrations in guinea pig isolated 
trachea. These results suggest that in guinea pigs and normal subjects 
LTD^-induced bronchconstriction occurs due to both a direct effect on
airway smooth muscle which is insensitive to the inhibitory action of
verapamil, and to an indirect effect via a verapamil sensitive mechanism. 
Similarly, in guinea pigs, sodium cromoglycate partially inhibits the 
contractile response to LTD^ in vivo but not in vitro (Advenier et al 
1983). Thus, in this species sodium cromoglycate appears capable of 
inhibiting an indirectly mediated bronchoconstrictor response of LTD^ .
In this study we examined the effect of pretreatment with verapamil 
and sodium cromoglycate on LTD^-induced bronchcoconstriction to determine 
whether, in asthma, LTD^-induced airway narrowing involves verapamil 
and/or sodium cromoglycate sensitive mechanisms.
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9.2 METHODS
9.2.1 Patients
Seven asthmatic patients were studied (Table 9.1). Four were 
female. Their ages ranged from 22 to 49 years. All were atopic 
and were non smokers. All were taking inhaled adrenoceptor 
agonists by pressurised aerosol, three were taking inhaled 
steroids regularly and two were taking sodium cromoglycate. All 
B2 agonists were discontinued 12 hours before testing and sodium 
cromoglycate 24 hours before testing. Inhaled steroids were 
continued.
9.2.2 In Vivo Measurements
Airways resistance (Raw) and Thoracic Gas Volume (TGV) were 
measured in a constant-volume body plethysmograph (Fenyves and 
Gut) using a computerised data collection and analysis system 
(Chapter 3). Results were expressed as specific airways 
conductance (sGaw) (=1/Raw x TGV). The mean of 8 values measured 
was taken as sGaw. The maximum expiratory flow at 70% of expired 
vital capacity, obtained from a partial flow-volume ( 3^ q(p)) 
curve, and the forced expiratory volume in one second (FEVj) were 
measured automatically (Collingwood Measurement). The flow- 
volume curves were performed as previously described.
9.2.3 Dose-Resnonse Curves
The study was performed in two parts. In the first each 
patient received either verapamil (2.5 mg/ml) or normal saline in 
a randomised double blind manner on three separate days (two 
saline). After baseline measurements of sGaw (mean of 8 readings) 
and V^q(p) and FEV^ (mean of 5 readings), the solutions were 
inhaled for 5 minutes. After 10 minutes lung function tests were 
repeated and each subject then inhaled increasing concentrations 
of leukotriene (0.0032 - 10 ug/ml). Each concentration was 
inhaled for 2 minutes and inhalations were repeated every 15 
minutes/
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minutes. Results were expressed as the provocation concentration 
(PC) producing a 35% fall in sGaw (PC^sGaw), a 30% fall in V^q(p) 
(PC^qV^qCp)) and a 10% fall in FEV^ (PC^qFEV^). The average PC 
values for the two post saline LTD^ dose-response curves was used 
when comparison was made with the post verapamil results.
To confirm that the asthmatic patients had increased non­
specific bronchial reactivity, a methacholine challenge was also 
performed following the method of Cockcroft et_ al_ (1977).
In the second half of the study, patients received either 
sodium cromoglycate (10 mg/ml) or placebo in a randomised double 
blind manner. Measurements were taken before and 10 minutes after 
each inhlation. A dose-response curve to LTD^ was then performed 
as described above. On a separate day a dose-response curve to 
methacholine was performed in a single blind manner using the 
protocol described by Hargreave et al (1981). Results were 
compared using analysis of variance and Student's t test.
9.3 RESULTS
The PC^qFEV^ methacholine (mg/ml) ranged from 0.17 to 0.64 
confirming that these asthmatic patients had increased non-specific 
bronchial reactivity.
9.3.1.Verapamil
Inhalation of verapamil did not alter baseline FEV^ , sGaw, or 
V3 q(p) (Table (9.2). All patients developed significant 
bronchoconstriction to LTD^ as assessed by PC-j^FEVp PC^sGaw 
(Figure 9.1) and PC^ qV^ qCp). Pretreatment with verapamil did not 
modify this response (Figure 9.2). Geometric mean PC^qFEV^ was 
0.35 ug/ml after verapamil compared with 0.47 ug/ml control (NS). 
PC^sGaw was 0.69 ug/ml after control and 0.37 ug/ml after
i
verapamil (NS) Mean P^QV^Qtp) was 0.41 ug/ml after control and 
0.31 ug/ml after verapamil (NS).
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FIGURE 9.1
Coneentration-response curves for individual patients with and without 
verapamil pretreatment
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LOG CONCENTRATION LTD4 (Mg/ml)
Sample concentration-response curves showing percentage change in sGaw 
against log concentration of inhaled Leukotriene after placebo 1 (0), 
placebo 2 (•) and verapamil (A)
FIGURE 9.2
Effect of verapamil on airway responsiveness
5”
1.0H
LTD  (ug /m l)
0.1“
0.01
PC35 S<3aW PC30 ^30(p)PC FEV
Effect of pretreatment with verapamil (V) (2.5 mg/ml) or control (C) 
(phosphate buffered saline) on airway responsiveness to LTD^ . Results 
are expressed as the provocation concentration (PC) producing a decrease 
in FEV^ of 10% (PC^ qFEV^ ), a 35% decrease in sGaw (PC2 5 sGaw) and a 30%-, 
fall in V^qCp) (PC^qV^qCp)). Mean values of PC^qFEV^, PC^sGaw and 
PC3 qV3 o(p) are shown as horizontal bars. Verapamil did not 
significantly reduce the response to LTD^ .
9.3.2 Sodium Cromoglycate
Sodium cromoglycate (SCG) did not significantly alter baseline 
FEV^ sGaw or V^qCp ) (Table 9.3). All patients developed 
significant bronchoconstriction as assessed by PC^qFEV^ , PC^sGaw 
(Figure 9.3) and PC^qV^qCp) (SCG) did not alter responsiveness to 
LTD^ (Figure 9.4). Geometric mean PC^qFEVj was 0.22 ug/ml after 
control and 0.24 ug/ml after sodium cromoglycate (NS). PC^sGaw 
was 0.21 ug/ml after control and 0.19 ug/ml after sodium 
cromoglycate (NS). ^30^30(p) was after control and
0.19 ug/ml after sodium cromoglycate (NS).
Patients inhaling LTD^ did not develop any side effects such 
as cough.
9.4 DISCUSSION
These results demonstrate that neither the calcium channel blocker 
verapamil nor sodium cromoglycate modify LTD^-induced 
bronchoconstriction in patients with asthma. This contrasts with 
results (Chapter 7) in normal subjects where verapamil reduced the 
constrictor response to LTD^ .
Why should verapamil have a protective effect against LTD^ 
induced bronchconstriction in normal subjects but not in asthmatic 
patients? It has been suggested that there may be heterogeneity of LTD^ 
receptors, and that the ability of different drugs to block the response 
to LTD^ may vary between the different affinity LTD^ receptors (Lewis 
and Austen 1984). In support of this hypothesis, the calcium channel 
blocker diltiazem inhibits the contraction of guinea pigs lung 
parenchymal strips to high dose LTD^ whereas the SRS-A antagonist 
FPL55712 inhibits only the low dose part of LTD^ induced contraction 
(Hirschman et al 1983). Since the normal subjects in this project 
inhaled higher concentrations of LTD^ than the asthmatic patients this 
may have resulted in the calcium channel blocker sensitive low affinity 
LTD^ receptors being stimulated only in the former. However, verapamil 
does/
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FIGURE 9.3
Concentration-response curves for individual patients with and without 
pretreatment with SCG
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FIGURE 9.4
Effect of SCG on airway responsiveness
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Effect of pretreatment with sodium cromoglycate (10 mg/ml) or placebo on 
airway responsiveness to LTD^. Responsiveness is expressed as
PC^QFEVp PC2 5 sGaw, and PC^ qV^ qCp). Geometric mean values are shown as 
horizontal bars.
does not significantly inhibit the contractile response of in vitro 
preparations of human bronchi to different doses of LTD^ although a 
slight (not statistically significant) reduction of response to the 
highest concentration of LTD^ was observed (Chapter 8).
An alternative explanation of these findings is that LTD^ induced 
bronchoconstriction in asthmatic patients may be due to a direct effect 
on airway smooth muscle whereas in normal subjects airway narrowing 
occurs due to a combination of direct action on bronchial smooth muscle 
receptors and indirect verapamil sensitive mechanisms. The latter 
indirect mechanism would have to have a higher threshold to LTD^ to 
explain these findings. Possible indirect mechanisms by which LTD^ 
might cause bronchoconstriction include reflex vagal bronchoconstriction 
(Advenier et al 1983, Hirscham et al 1983) or release of secondary 
mediators (Weichman et al 1982).
A third possibility is that the action of verapamil depends on an 
intact respiratory epithelium. Recently Raeburn et al (1985) showed that 
verapamil inhibits LTD^ induced airway smooth muscle contraction in the 
rabbit only when the airway mucosa is intact. Even mild asthmatic 
patients have damaged mucosa (Laitinen et al 1985), so the absence of an 
inhibitory effect of verapamil on LTD^-induced bronchconstriction could 
be explained by a lack of intact mucosa in asthmatics.
If LTD^ is confirmed as an important mediator in asthma, one would 
predict from these findings that verapamil would not be an effective drug 
in asthma. Most studies of calcium channel blocking drugs in asthma 
support this suggestion. Neither verapamil nor nifedipine significantly 
alter resting bronchomotor tone and produce little or no protection 
against bronchoconstriction induced by allergen (Henderson et al 1983, 
Patel et al 1983). They are moderately effective in inhibiting exercise- 
induced asthma (Cerrina et al 1981, Patel 1981).
Sodium cromoglycate inhibits mast cell degranulation, but may also 
have other modes of action (Martelli and Usandivaras 1977). In guinea 
pigs in vivo sodium cromoglycate partially inhibits LTD^-induced 
bronchoconstriction (Advenier et al 1983). In patients with aspirin 
sensitive/
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sensitive asthma, the response to aspirin challenge can be blocked by 
sodium cromoglycate (Martelli and Usandivaras 1977). The pathogenesis 
of aspirin sensitive asthma is unknown but may involve increased 
production of lipoxygenase products such as LTD^ (Seczcklik et al 1975). 
Sodium cromoglycate may have acted as a leukotriene antagonist. Our 
results demonstrate that sodium cromoglycate is not a specific inhibitor 
of LTD^ in asthmatic patients. This finding confirms and extends the 
work of Holroyde et_ al (1981) who showed that in normal subjects sodium 
cromoglycate had no effect on LTD^ induced airway narrowing.
In summary, neither verapamil nor sodium cromoglycate inhibits 
LTD^-induced bronchospasm in asthmatic patients. This contrasts with 
the action of verapamil in normal subjects.
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C H A P T E R  10
THE RELATIONSHIP BETWEEN IN VIVO RESPONSIVENESS TO 
LEOKOTRIENE D4 AND IN VITRO SMOOTH MUSCLE 
SENSITIVITY, AND THE QUANTITY OF SMOOTH MUSCLE
THE RELATIONSHIP BETWEEN IN VIVO RESPONSIVENESS TO LEUKOTRIENE D,. AND IN VITRO 
SMOOTH MUSCLE SENSITIVITYT^NUTHE QUANTITY OF SMOOTH MUSCLE *
10.1 INTRODUCTION
Airway responses to inhaled methacholine and histamine do not 
relate to in vitro sensitivity of airway smooth muscle obtained at 
thoracotomy from the same patients. The mechanisms of hyper­
responsiveness of the airways remains unexplained, but could be due to 
enhanced airway smooth muscle sensitivity to certain mediators (Bouchey 
et al 1980, Thomson 1983). Other investigations designed to examine 
this hypothesis have not found a relationship between measurements of in 
vitro sensitivity of human smooth muscle to methacholine (Chapter 4, 
Taylor et al 1985, Armour et al 1984), or histamine (Vincenc et al 1983, 
Armour et al 1984 Chapter 6) and in vivo airway responses to these 
agents. However, neither of these agonists is an important mediator in 
clinical asthma. LTD^ may be important in the pathogenesis of asthma 
(Lewis & Austen 1984). LTD^ is a potent bronchconstrictor agent both in 
vivo (Weiss et al 1983, Barnes et al 1984) and in vitro (Chapter 8, 
Dahlen et al 1980) and it is released from sensitized tissue after 
allergen exposure. (Orange and Austin 1980, Dahlen et al 1981). The 
slow onset, prolonged contraction produced by LTs have led to the 
hypothesis that LTs may be important mediators in asthma. This study 
extends previous in vivo and in vitro comparisons to leukotriene D^ . In 
this study in vivo airway responses to inhaled LTD^ in eleven patients 
undergoing thoracotomy were measured and compared with recordings of in 
vitro sensitivity to LTD^ of preparations of isolated bronchi taken from 
the same patients and also with the ability of smooth muscle from these 
patients to generate tension in vitro.
In previous chapters the relative quantity of muscle present 
was inferred from the wet weight of bronchial strips. In this chapter 
the amount of smooth muscle in each bronchial strip was assessed by 
light microscopy and the relationship with in vivo responsiveness, 
maximum tension generated, and sensitivity in vitro measured.
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10.2 METHODS
10.2.1 In vivo Measurements
Eleven patients due to undergo lobectomy or pneumonectomy were 
studied. All patients gave informed consent. Prick skin testing 
was undertaken with one or more of seven common allergens.
Airways resistance (Raw) and thoracic gas volume (TGV) were 
measured in a constant-volume body plethysmograph (Fenyves and 
Gut) using a computerised data collection and analysis system 
(Chapter 3) based on the method of Du Bois et_ al (1956).
Leukotriene D^ inhalation tests were carried out as previously 
described (Chapter 8). Buffered saline was inhaled first 
followed by increasing concentrations of LTD^ (0.06 - 50 ug/ml).
10.2.2In vitro Measurements
Bronchial tissue was obtained from patients undergoing lung 
resection for bronchial carcinoma, immediately following removal 
at thoracotomy. Samples from second to sixth order bronchi were 
dissected from macroscopically normal tissue and maintained at 4°C 
overnight in oxygenated Krebs-Hensleit physiological salt 
solution. On the day after removal, the bronchi were dissected 
free of extraneous connective tissue and sectioned to produce 
transverse strips of tissue which were suspended (under a resting 
tension of 1.5 to 2.0 g) in a 5 ml organ bath containing Krebs- 
Hensleit solution at 37°C bubbled with 5% C0£ in O2. During a 60 
minute equilibration period the tissues were washed three times. 
Changes in isometric tension were measured using force- 
displacement transducers.
The reproducibility of the contractile changes of the 
bronchial strips was assessed by adding methacholine (1 x 10”^ 
moles 1""^ ) on two occasions with an interval of 30 minutes for 
recovery between each drug addition. A cumulative concentration- 
effect curve to LTD^ was then constructed by adding increasing 
concentrations of the drug, each addition of the drug being made 
at/
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at the peak of response produced by the preceding concentration. 
Log concentration effects were calculated for each tissue and 
results expressed as the concentration of LTD^ producing a 
contraction 50% of maximum for that tissue. The maximum 
contraction for each tissue was also recorded. At the completion 
of the experiment the wet weight of each tissue was recorded.
The amount of smooth muscle present in each strip was then 
assessed by light microscopy. The pecentage of smooth muscle 
present, the absolute amount of muscle present in strip (wet 
weight x% muscle) and the maximum tension per unit mass of smooth 
muscle was then calculated and maximum tension was compared with 
the percentage of smooth muscle present for each individual 
bronchial strip. The average values of these in vitro 
measurements for the four bronchial strips from each patient was 
compared with in vivo measurements.
10.3 RESULTS
10.3.1In vivo Results
Details of the patients who took part in the study are shown 
in Table 10.1. Their age ranged from 48 to 70 years. Seven 
patients were male and four were female. Three patients had FEV^ 
recordings (expressed as a percentage of the predicted value) 
below 80%. One patient was atopic. All patients were current or 
ex-smokers and 4 patients had symptoms of chronic bronchitis. 
None had a history of asthma. All patients had bronchial 
carcinoma. One patient was on regular inhaled acebuterol prior to 
surgery.
Airway responsiveness to LTD^ varied between individual 
patients (Table 10.2). PC q^FEV^ ranged from 0.15 to > 50 ug/ml, 
PC^sGaw ranged from 0.18 to >50 ug/ml, and I ^ qV^qCp) from 0.04 
to > 50 ug/ml. There were significant correlations (P < 0.05) 
between PC^qFEV^ and PC^qV'jqCp) (r = 0.68), and between PC^sGaw 
and PC^sGaw and I ^ qV-jqCp) (r = 0.72). There was no significant 
correlation/
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correlation between baseline FEV^ (percentage predicted and 
PC^qFEV^ (r = 0.45), PC^sGaw (r = 0.55) or PC^qV^Cp) (r = 0.45).
10.3.2In vitro Results
There were differences in the responsiveness to LTD^ of 
bronchial strips prepared from different patients (Table 10.2).
_ Q  _ Q
EC^q values ranged from 1.8 x 10 to 3 x 10- umoles/1 and the 
maximum tension (in mg) generated per gram of smooth muscle 
ranged from 93 to 824.
The tension generated by the bronchial strips (40 samples) 
ranged from 0.28 to 2.4 G. The percentage of smooth muscle 
present in the bronchial strips ranged from 1.1 to 16.4%. When 
the wet weight of tissue was corrected for the percentage of 
smooth muscle present, the absolute amount of smooth muscle 
present ranged from 0.54 to 13.8 mg. The absolute amount of 
smooth muscle present in bronchial strips correlated with the 
maximum tension generated (r = 0.63; P<0.01) but not the EC^q (r = 
-0.08; P>0.05). Figure 10.1.
10.3.3Comparison of In Vivo and In Vitro Responsiveness to LTD^
There was no significant correlation between any of the 
measurements of in vivo and in vitro responsiveness to LTD^ . The 
lack of relationship is illustrated for EC^q against PC^qFEV^ 
(Figure 10.2) (r = 0.1; P>0.05), PC^sGaw (Figure 10.3) (r = 0.26; 
P>0.05) and PC30V30(p) (Figure 10.4) (r =-0.12; P>0.05). There 
was no significant relationship between maximum tension generated 
per mg of smooth muscle and PC^qFEV^ (r = 0.44; P>0.05), PC33sGaw 
(r = -0.17; P>0.05) and PC3QV30(p) (r = 0.23; P>0.05). The 
average amount of smooth muscle present in the bronchial tissues 
did not correlate with any of the in vivo measurements of airway 
^respons iveness.
10.4/
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FIGOBE 10.1
In vitro ‘tension generation versus smooth muscle quantity
Quantity of •
Smooth Muscle (mg)
30-i
n=40
r=0.63
p<0.05
20-
10 -
5 0 0 1500100 1000 2000
Maximum LTD4 Induced Tension (mg)
Comparison of absolute amount of smooth muscle present (mg) in each 
bronchial strip (n = 40) assessed by light microscopy and the maximum 
tension generated by each bronchial strip (in grams).
FIGURE 10.2 i
In vivo responsiveness (PC^ qFEV^) against in vitro sensitivity
PCjqFEVt 
LTD4 (jjg/ml) 
>50nj # •
10-
1-0 -
0-1
10-9 10-8
ECsojjmols/l
10-7
Comparison of in vivo airway responsiveness to LTD^ expressed as 
PC^qFEV-^  with in vitro smooth muscle sensitivity to LTD^ expressed as 
the concentration that produced a 50% (EC^ q) maximum contraction r = 
0.1 p > 0.05.
FIGURE 10.3
In vivo responsiveness (PC-^ sGaw) against in vitro sensitivity.
PC35sGaw 
LTD4 (pg/mO 
>50-i •
> 10-
10*0 -
1-0 -
0-1
• •
• •
1 0 - 9 10-8
FC5o(pmols/l)
10-7
Comparison of in vivo airway responsiveness to LTD^ expressed as 
PCg^sGaw with in vitro smooth muscle sensitivity to LTD^ expressed as
EC5 0 r =0.26 p 0.05.
FIGURE 10.4
In vivo responsiveness (PC3QV3Q.(p).)against in. vitro .sensitivity
PC30 V30 (p) 
LTD4 (ug/ml)
50 n
10-0 -
1- 0 -
0 -1-
EC50 ^imols /litre
Comparison of in vivo airway responsiveness to LTD^ expressed 
PC3oV3o(p) with in vitro smooth muscle sensitivity to LTD^ expressed 
EC5q r = -0.12 p 0.05
10.4 DISCUSSION
These results demonstrate that measurements of in vivo human 
airway responsiveness to inhaled LTD^ are not related to in vitro 
sensitivity to LTD^ of isolated bronchial smooth muscle obtained from 
the same patients. Furthermore neither the quantity of bronchial smooth 
muscle present in the tissue, nor the maximum tension generated by each 
tissue was related to in vivo results. Previous studies have examined 
in vivo (Weiss et al 1983, Griffen et al 1983, Barnes et al 1981) and 
in vitro (Chapter 8, Dahlen et al 1980) responses of human airways to
LTD^ but in vivo and iji vitro responses have not been
measured in the same patients.
In human studies it has been reported that LTD^ has a 
predominantly peripheral site of action (Weiss et al 1983, Griffen et al 
1983), although others have found bronchconstriction induced by LTD^ to 
affect both small and large airways (Barnes et al 1984, Smith et al 
1985, Bisgaard et al 1985, Chapter 8). In this study LTD^ produced 
similar degrees of change in tests thought to reflect small airway
function (V3q( )) and large airway function (sGaw). In vitro results
reflected the sensitivity of larger airways. Thus a comparison of 
measurements of in vitro responsinveness with PC^sGaw should have shown 
the best correlation had any existed.
The patients tested in this study were current or ex-smokers and 
three had evidence of airflow obstruction. As a group, airway 
responsiveness to inhaled LTD^ was similar to a group of normal subjects 
(Chapter 8). Although the mechanism of LTD^ induced bronchoconstriction 
in man is unclear a previous study in normal subjects has suggested that 
LTD^ acts by a combination of direct effects on airway smooth muscle and 
by indirect pathways (Chapter 9). If these patients were responding to 
inhaled LTD^ in a similar way to normal subjects, the presence of both 
direct and indirect pathways would explain the lack of correlation 
between in vivo and in vitro results.
An abnormality of the sensitivity of airway smooth muscle, which 
could produce airway hyper-responsiveness in vivo, would be manifest 
in/
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in vitro by a lower EC^q value for a given agonist or by an increase in 
maximum agonist-induced tension. Although the quantity of smooth muscle 
in the bronchial strips might be expected to affect the maximum agonist 
induced tension, Armour and coworkers (1984) reported a weak 
correlation between maximum tension change in response to histamine, and 
the volume of smooth muscle in each bronchial strip. In this study we 
used the wet weight of bronchial strips together with the measured 
percentage of smooth muscle in each strip to calculate the absolute 
amount of smooth muscle present in each strip. The maximum LTD^ 
induced tension positively correlated with the absolute amount of smooth 
muscle. Thus hypertrophy and/or hyperplasia of airway smooth muscle 
reported in patients with asthma (Takizawa and Thurlbeck 1971, Dunhill 
et al 1969, Heard and Hossman 1973) and chronic bronchitis (Mullen et al 
1986, Takizawa and Thurlbeck 1971) may contribute to in vivo airway 
hyper-responsiveness to constrictor stimuli. However, it is unlikely 
that this mechanism is the only explanation for airway hyper­
responsiveness. There was no relationship between in vitro measurements 
of airway sensitivity or the quantity of smooth muscle in the bronchial 
strips and in vivo measurements of airway responsiveness.
The presence of inf lammatory cells and mediators may be important 
in the development and maintenance of non-specific airway hyper­
responsiveness (Holtzmann et al 1983). Mullen and coworkers (1986) 
demonstrated that airway inflammation was associated with airway 
responsiveness in patients undergoing thoracotomy for bronchial 
carcinoma. The processing of bronchial smooth muscle may remove 
inflammatory cells and mediators which could alter responsiveness in 
smooth muscle strips and obscure a relationship with in vivo 
measurements.
None of the patients used in this study had asthma. Results 
obtained in these non asthmatic patients may not be applicable to 
patients with asthma. A few previous studies have examined the in vitro 
responses to bronchoconstrictor stimuli of airway smooth muscle from 
patients with asthma. The in vitro response to leukotrienes was shown 
not/
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Inot to be increased in two asthmatics by Dahlen and coworkers (1983) and 
in one asthmatic by Schellenberg and Foster (1984). In vitro response 
to cholinergic agonists were similar in asthmatic and non-asthmatic 
tissue (Chapter 4). A normal in vitro responsiveness to histamine was 
found (Chapter 5) in a patient who had a history of asthma since 
childhood.
In summary these results show that in non-asthmatic patients 
undergoing thoracotomy, the in vivo airway responsiveness to LTD^ is not 
related to _in vitro airway smooth muscle responsiveness. These 
findings suggest that factors other than the responsiveness of airway 
smooth muscle alone must determine _in vivo airway responsiveness. 
Nevertheless there was a positive correlation between the amount of 
smooth muscle present in bronchial strips and maximal - LTD^ induced 
tension suggesting that hypertrophy and/or hyperplasia of airway smooth 
muscle may contribute to in vivo airway hyper-responsiveness.
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C H A P T E R  11
THE EFFECT OF PASSIVE SENSITISATION OF HONAN BRONCHIAL 
SMOOTH MUSCLE ON IN VITRO SENSITIVITY TO HISTAMINE
THE EFFECT OF PASSIVE SENSITISATION OF HUMAN BRONCHIAL SMOOTH MUSCLE ON IN
VITRO SENSITIVITY TO HISTAMINE
11.1 INTRODUCTION
Atopy is closely associated with asthma and in sensitised subjects 
antigen exposure may precipitate acute bronchospasm and increase non­
specific bronchial responsiveness. Bronchial hyper-responsiveness is 
an important feature of asthma. Indeed, some authorities suggest it is 
a prerequisite.
Increased non-specific responsiveness is related to the late 
asthmatic response (Cartier et al 1982). If the late response is 
prevented, the responsiveness of the airway does not change. There are 
two likely mechanisms for the alteration in airway responsiveness. 
Mediators released from mast cells may modify the sensitivity of airway 
smooth muscle or, by chemotactic activity, may attract inflammatory 
cells which alter the airway, either physically or by the release of 
secondary mediators. For instance, proteins released from eosinophils 
can damage epithelial surfaces (Gleich et al 1979) and may increase 
mediator access to receptors.
In this study, the effect of specific allergen challenge on 
passively sensitised preparation of human bronchi on their in vitro 
responsiveness to histamine has been investigated.
11.2 METHODS
11.2.1 Sensitising^  Serum
Sera from atopic asthmatic patients was screened for in vitro 
sensitising activity. A 33 year old male asthmatic patient with 
positive skin test and elevated specific IgE levels against 
Dermatophagoides pterronissinus gave serum which was found to be 
effective. 50 ml of serum was obtained from this subject and was 
divided into aliquots and maintained at -40°C until use.
11.2.2Sensitisation procedure
Samples of bronchi were obtained at thoracotomy from six 
patients undergoing thoracotomy for bronchial carcinoma. From 
each/
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each patient four bronchial rings were dissected from 
macroscopically normal tissue and washed x 3 in Krebs-Hensleit 
saline (bubbled with 95% 0 2 /5 % C0£). From each patient the 
bronchial rings were treated as follows -
Two rings (Nos 1 and 2) were incubated overnight at room 
temperature (20°C) in bubbled Krebs-Hensleit solution containing a 
10% solution of the above serum. Rings 3 and 4 were also incubated 
(at 20°C) overnight in oxygenated Krebs-Hensleit saline containing 
10% control serum (from a non-atopic, non-asthmatic subject (me)).
TABLE 11.1
PROTOCOL
Tissue 1 2 3 4
Sensitisation - - + +
Antigen added - + - +
Histamine
dose-response + + + +
Antigen added + + + +
11.2.3Tens ion measurement
The next day the tissue rings were divided to produce strips 
of tissue and hung in an organ bath in Krebs-Hensleit solution 
aerated by 95% 02/5%C02 (as previously described) attached to an 
isometric force transducer and chart recorder under a resting 
tension of 1.5 -2.0 grammes. Tissues were allowed to equilibrate 
for 1 hour. During this period the organ bath fluid was changed 
three times. After equilibration house dust mite (HDM) allergen 
extract (Pharmacia) was added to tissues 2 and 4 and control 
diluent/
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diluent solution to tissues 1 and 3. Tissues were rinsed in fresh 
saline 20, 40 and 60 mins after allergen challenge. Once tension 
had returned to the resting value, a histamine concentration- 
response curve was performed. Increasing concentrations of 
histamine, 10"^ - 10""^  moles/litre were added to the baths. Each 
concentration was not added until the response to the previous 
concentration had plateaued.
At the conclusion of the experiment HDM solution 0.1ml was 
added to all 4 organ baths and the presence or absence of response 
noted (Table 11.1).
11.3 RESULTS
All sensitised tissues contracted when exposed to HDM solution and 
no unsensitised tissue contracted (Figure 11.1) Contraction following 
antigen took 12 ± 4 mins to reach maximum and relaxation took 85+. 40 
minutes (m +_ SD). EC^q values ranged from 3.2 x 10-  ^to 5.3 x 10""^  
mM/litre (Table 11.2). The mean EC^q for unsensitised tissues was 
(2.09 +. 0.69) x 10"6 and for sensitised tissue (1.88 +. 0.48) x lO""^  
(NS). For tissue to which antigen was added before histamine 
concentration-effect curve the mean values were (1.92 +. 0.32) x 10”^
and 2.55 +. 0.47 x 10~^ for sensitised tissue (NS).
The maximum tension per gram wet weight tissue m _+ SEM were as 
follows. For unsensitised tissue not exposed to antigen 13.6 ± 5.2 and 
exposed to antigen 18.4 +_ 8.2 and for sensitised tissue 15.0 +. 2.9 
without HDM exposure and 15.8 ± 6.5 with HDM exposure. None of these 
differences was significant.
11.4 DISCUSSION
This study has demonstrated that serum from an atopic asthmatic 
will passively sensitise human bronchial smooth muscle such that 
exposure of the bronchial smooth muscle to a solution of the specific 
antigen produces a rapid onset and sustained smooth muscle contraction. 
Sensitisation of the bronchial muscle does not alter in vitro 
sensitivity/
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FIGURE 11.1
Tissue response to . allergen followed by concentration-response curve to' 
histamine.
TENSIO N G ENERATED vs TIM E -  HISTAM INE DO SE RESPONSE CURVE
Tension
1 gram
Tension
Unsensitised
Sensitised
4020 3010 130 150140 160
minutes
Antigen
(D.pteronyssinus)
M i l l
10'7 10"6 10*5 10*4 4xlQ"4 
Histam ine (m oles L '1)
(fin a lc o n ce n tra tio n  )
Typical polygraph tracings from unsensitised and sensitised tissue. All 
sensitised tissue contracted on exposure to antigen, either before 
(shown above) or after (not shown) histamine concentration-response 
curve.
sensitivity to methacholine nor the maximum in vitro response of the 
muscle. Antigen challenge of sensitised tissue produces a sustained 
contraction but does not alter the sensitivity of the smooth muscle to 
subsequent histamine exposure.
Other workers have passively sensitised bronchial smooth muscle 
(Sheard et al 1967, Adams and Lichstensten 1979) and have found that 
allergen exposure of passively sensitised bronchial tissue produces 
smooth muscle contraction and causes release of mediators such as 
histamine (Sheard et al 1967), SRS-A (Sheard et al 1967) and 
prostaglandins (Murray et al 1986). It has been suggested that this 
release of mediators may be a factor in the development of bronchial 
hyper-reactivity (Cockcroft et al 1977, Cartier et al 1982). There are 
two mechanisms which might cause this increase.
One or several of the mast cell factors could be acting on the 
airway smooth muscle to increase its sensitivity to agonists. As 
bronchial hyperresponsiveness is non-specific it would be likely that 
the alteration would not be on receptor density or sensitivity, but in 
the contractile mechanism of the smooth muscle cell. These results do 
not support this hypothesis.
However, the bronchial strips were exposed to mediators for 20 
minutes. They were then washed to bring tension back to baseline 
values. It is possible that mediator induced alteration in smooth 
muscle could take longer than 20 minutes to occur. Another method by 
which mediator release could affect smooth muscle responses, is by 
acting as chemotactic factors (Schemkel et al 1982 O'Driscoll et al 
1983) provoking an influx of inflammatory cells to the respiratory 
tissue. These inflammatory cells could then produce secondary mediators 
which increase smooth muscle sensitivity. The protocol used in this 
experiment does not test this hypothesis, but with the system used in 
this study it would be possible to investigate whether the addition of 
white blood cells, either as whole blood or as separated cells to 
antigen exposed passively sensitised smooth muscle, altered in vitro 
sensitivity.
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C H A P T E R  12
C O N C L U S I O N S  
IN VIVO VERSUS IN VITRO STUDIES
CCRCUJSICHS ___
IN VIVO VERSUS IN VITRO STUDIES
12.1 INTRODUCTION
This project has compared in vivo human airway responsiveness and 
the sensitivity of smooth muscle obtained from the same patients at 
thoracotomy. Under the experimental conditions used, no relationship was 
found. Possible confounding factors were minimised by the design of the 
trials.
12.2 TRIAL DESIGN 
12.2.lln vivo
In vivo results could be affected by factors other than smooth 
muscle sensitivity. Aerosol deposition varies with disease state 
of the lung. Patients with small airway disease deposit a greater 
proportion of nebulised aerosol in the large airways. (Ryan et al 
1981). This could lead to an apparent increased responsiveness. 
Three separate measures of airway responsiveness were used. FEVj 
which reflects overall airway function, sGaw, which reflects mainly 
large airway calibre (Pride 1971) and V-jq(p) which is measured at 
30% of TLC and hence is thought to reflect mainly small airway 
calibre. Thus if patients tested have small airways disease, sGaw 
would be the measure of in vivo responsiveness to use when 
comparing responsiveness with in vitro sensitivity. However, this 
will not take account of differences in the pattern of deposition 
between patients.
Airway permeability could also confound a possible 
relationship, affecting delivery of the agonist to its site of 
action. However although alterations of airway mucosal 
permeability have been demonstrated in smokers (Jones et al 1980), 
these changes do not relate to variations in airway responsiveness 
(Kennedy et al 1983).
In vitro a full concentration-response curve is performed and 
the estimate of muscle sensitivity made from the steep region of 
the/
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the resulting graph (EC^q ). It is not possible to perforin an 
equivalent complete concentration-response curve in vivo. It is 
therefore possible that in vivo measurements are being made on the 
early part of the curve, where results are less reproducible. 
This did not appear to be the case in the sGaw measurements 
performed in this study. Profound falls in sGaw had often 
occurred before a 20% fall in FEV^ was reached. In many cases the 
fall in sGaw appeared to plateau. Another approach taken to 
counteract this problem was to use the EC£q (i.e. a 20% of maximum 
response in vitro) for comparison with in vitro results. This 
did not improve the relationship between results.
12.2.2In vitro
Measurement of _in vitro responses of smooth muscle may be 
affected by many variables. These were minimised by the design of 
in vitro protocol.
Intra-operative medications, if present, could modify in vitro 
responses. All tissues were washed thoroughly and maintained 
overnight in physiological saline. This treatment has been shown 
to remove intra-operative medications (Clark 1926) but does not 
alter in vitro sensitivity (Thulesius et al 1978). Temperature may 
also alter responses (Black et al 1984) as may changes in pH 
(Twort and Cameron 1986). Both parameters were carefully 
controlled in the organ bath used.
12.2.3In vivo ^  ASL vitro comparison
The agonists used in the in vivo versus in vitro protocol all 
have several physiological actions besides an action on airway 
smooth muscle. Methacholine affects muscarinic receptors which are 
found on submucosal glands (Nadel 1981), mast cells (Kaliner et al 
1972) and presynaptic region of sympathetic nerves (Westfall 1980) 
as well as airway smooth muscle (Hawkins and Schild 1931). Any of 
these/
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these other actions which would effect in vivo but not in vitro 
results could confound a relationship if present. The second 
mediator used, histamine, has a direct effect on airway smooth 
muscle (Nogrady and Bevan 1978, Thomson and Kerr, 1980) but also 
may induce bronchconstriction via a vagal reflex (White and Eiser 
1983). However, the lack of relationship between in vivo and in 
vitro measures was not improved by pretreating a group of patients 
with atropine.
The third part of the in vivo versus in vitro study used LTD^ 
as a mediator. Recent work has suggested that the leukotrienes 
may be important mediators in asthma (Barnes et al 1984, Bisgaard 
1985) and animal work has shown that LTD^ increased in vitro airway 
smooth muscle sensitivity (Creese and Bach 1983).
The mode of action of LTD^ is unknown. Investigation of LTD^ 
responses in this project suggested that, in normal subjects, LTD^ 
induced bronchoconstriction was due to a combination of a direct 
effect on smooth muscle, and an indirect, verapamil sensitive 
mechanism. There was no relationship between in vivo responses 
and in vitro sensitivity. Quantification of smooth muscle present 
in bronchial strip demonstrated wide variations in the proportion 
of muscle present. The quantity of muscle related to maximum 
tension generated in vitro, but did not correlate with any of the 
measures of in vitro responsiveness.
12.3 ASTHMA. VERSUS CHORNIC AIRFLOW OBSTRUCTION
Bronchial hyper-responsiveness is closely associated with, and 
may be a pre-requisite of, asthma (Hargreave et al 1981).
Increased responsiveness also occurs in chronic airflow 
obstruction but may not be due to the same mechanisms as those 
found in asthma (Du Toit et al 1986).
Baseline airway calibre (Mullen et al 1986) and cigarette 
smoking (Du Toit 1986) have both been shown to be factors in 
determining responsiveness in patients with chronic airflow 
obatruction/
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obstruction but are obviously less important in asthma.
Most of the patients who took part in this study were current 
or ex smokers, and many had evidence of irreversible airflow 
obstruction. Thus it is not possible to be categorical in 
dismissing smooth muscle hypersensitivity in the pathogenesis of 
asthma. However, two patients included in these studies were 
asthmatic. This was confirmed by increased responsiveness of in 
vivo measurements. Neither demonstrated increased in vitro 
sensitivity.
12.4 OTHER REPORTS OF IN VITRO ASTHMATIC AIRWAYS
Of the few reports in the literature where bronchial smooth muscle from 
asthmatic patients has been assessed for in vitro sensitivity, only one 
showed an increase when compared with tissue from non-asthmatic subjects. 
Dahlen et al (1983) examined bronchial strips from two birch pollen 
allergic asthmatics and found no increase in smooth muscle sensitivity to 
histamine or leukotriene D^ .
Patterson et al (1982) studied post mortem tissue from 3 asthmatic 
patients who died during acute attacks and found no increase in 
sensitivity to carbachol or histamine.
Schnellenberg and Foster (1984) did demonstrate an increased sensitivity 
to histamine, but not methacholine or LTD^ in an asthmatic patient who 
was operated on for removal of a carcinoid tumour. The presence of a 
histamine secreting tumour makes this finding difficult to interpret. 
Thus, the limited data, available from this project, and other published 
cases does not support the hypothesis that hyper-responsiveness is a 
primary bronchial smooth muscle abnormality.
12.5 OTHER PUBLISHED IN VIVO AND IN VITRO COMPARISONS
Since this project was commenced several other groups have compared in 
vivo airway responsiveness with in vitro smooth muscle sensitivity. 
Vincenc et al (1983) used histamine as agonist. They measured FEV^ as an 
index/
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index of in vivo response but only obtained PC2qFEV^ values in 5 out of 
14 patients. No relationship was found between in vivo and in vitro 
parameters. Armour et al (1984) confirmed the lack of relationship 
using histamine as agonist. A similar lack of relationship has also 
been found using methacholine as agonist (Armour et al 1984, Taylor et al 
1985). A recent paper by De Jongste et al (1987) found increased 
histamine sensitivity in smooth muscle obtained from patients with CAO 
compared to a group with normal lung function. Patients were divided 
into the two groups on the basis of in vivo spirometry.
In vitro tissue was then assessed by exposure to methacholine, 
histamine, and LTC^. The tissue from CAO patients had an increased 
maximum response (per dry wt of tissue), compared to the non CAO 
patients. Their results are puzzling in that the maximum tension 
produced to LTC^ and methacholine was similar for both groups. The 
histamine maximum were less than that produced by LTC^ and methacholine 
suggesting a reduced response in the normal subjects. This may be due to 
a decreased number of histamine receptors in the generation of bronchi 
chosen (10th to 13th) but further investigation is required before true 
increased sensitivity is demonstrated. The same group have also reported 
that tissue from an asthmatic subject was more contractile than control 
specimens. The main difference was in maximum response rather than 
increased sensitivity. Cerrina et. al_ (1986) found no evidence of 
increased smooth muscle responses in vitro in asthmatic patients but did 
find reduced responses to a B2 agonist. The asthmatic patients in this 
study were poorly characterised. The result is puzzling as B blockers 
do not alter in vivo NSBR. However it is an interesting possibility 
that the abnormality in asthma is a failure to respond chemicals to 
bronchodilator rather than an increased sensitivity to bronchoconstrictor 
agents. More work is required to further investigate this possibility.
The bulk of evidence to date suggests that in vitro tissue from 
patients with increased NSBR is no different from that from non 
responsive subjects. The data is fragmentary because it is unusual for 
patients with asthma to require thoracotomy as almost all are non- 
smokers/
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smokers.
Thus apart from the work of De Jongste and coworkers, there is 
general agreement in the literature that airway smooth muscle is not the 
sole determinant of airway responsiveness.
12.6 FUTURE WORK
Although airway smooth muscle is not a major determinant of hyper­
responsiveness, it clearly is an important part of the airway response. 
Future research will look at changes to the in vitro environment which 
might increase in vitro sensitivity. Neither sensitisation per se nor 
subsequent specific allergen challenge altered sensitivity to histamine. 
However, the current view of airway response to allergen is of a 
secondary influx of inflammatory cells stimulated by chemotactic factors 
released by the primary response. Addition of plasma factors and 
leukocytes to the organ bath might allow an in vitro inflammatory 
response to occur in the bronchial tissue. It would be of great 
interest to see whether this modified the in vitro sensitivity of airway 
smooth muscle.
12.7 MECHANISM OF ACTION OF LTD^
Verapamil was used as a probe to assess whether extracellular 
calcium influx through voltage operated calcium channels was important 
in the production of LTD^ induced bronchoconstriction. Verapamil 
inhibited in vivo but not in vitro constriction in normal subjects, but 
did not affect LTD^ induced bronchconstriction in asthmatic patients. 
Thus a clear difference in the responses of normal and asthmatic subjects 
to verapamil was demonstrated. Clear differences between the normal and 
asthmatic response are of interest as they suggest fundamental 
differences between the two states. There are several possible 
explanations for this observed difference. Two groups of LTD^ receptors 
have been demonstrated in human airway (Lewis and Austen 1983). One a 
high affinity, and the other a low affinity receptor. If verapamil were 
inhibiting/
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inhibiting the action of the low affinity receptor its effect might only 
be seen in normal subjects, who were able to tolerate higher 
concentrations of LTD^ .
LTD^ may be acting directly on smooth muscle receptors in asthmatic 
patients, and by both a direct action and via indirect verapamil 
sensitive mechanisms, e.g. neural reflexes. A third, and intriguing 
possibility is that verapamil could be stimulating the release of an 
epithelial cell relaxant factor from intact mucosa.
Epithelial factors which modulate airway responses have been 
demonstrated in animal models of asthma (Flavahan et al 1985). The 
action of verapamil on isolated bronchial preparations is reduced by 
damage to epithelium (Raeburn et al 1986). As epithelium is damaged even 
in mild asthma (Laitinen et al 1986), this may explain the observations 
described above. Further work characterising the nature of epithelial 
derived factors is necessary.
12.8 ULTRASTRUCTURAL STUDIES
There are few studies of the ultrastructure of human airway (Daniel 
et al 1980, Daniel et al 1986) and none of these have examined 
differences between normal and hyper-responsive airways. Classification 
and quantification of ultrastructural features of airway is now 
practical. This will allow comparison of normal and hyper-reactive 
airway. It will also be possible to assess whether in vitro changes made 
to smooth muscle will alter its sensitivity and ultrastructure, e.g. 
increase the numbers of gap junctions present.
In conclusion, this project has demonstrated that differences in 
human airway responsiveness cannot be explained simply in terms of 
different smooth muscle sensitivity. In vitro smooth muscle research 
holds many exciting possibilities for the future in investigating 
factors which change smooth muscle sensitivity, and in time, in 
developing an in vitro model for human bronchial hyper-responsiveness.
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A P P E N D I X  1
R E S P I R A T O R Y  Q U E S T I O N N A I R E
questionnaire on respiratory symptoms
Hospital No  ..... .  Date of Interview
Name   Date of Birth
(surname)
S e x ..................  Phone No.
(First names)
s m w
Address ........................  Civil state
Standard Height
Weight....... .
Occupation ...., 
Race  ....... .
Name of Interviewer 
Diagnosis ••••••••..
COUGH
1a Do you usually cough first thing in the morning (on getting up*)?
(count a cough with first smoke or on first going out of. doors. Exclude clearing 
throat or a single cough).
Ye^No
1b If yes - Is this worse in the Winter? Yea/Ho
2a Do you usually cough during the day -or at night
(ignore an occasional cough). Yeq/No
2b If yes - are symptoms worse during winter? Ye^/No
If No to both questions go to 4 
If Yes:
3. Do you cough like this on most days (or nights*) for as much as 3 months each 
yearf Yes/No
PHLEGM(SPUTUM
4a Do you usually bring up any phlegm from your chest first thing in the morning 
(on getting up*)? Ye^ Ho
• • (Count phlegm with the first smoke or on first going out of doors.
Exclude phlegm from the nose. Count swallowed phlegm).
4b If yes - Is it worse in the Winter? Ye^No
5a Do you usually bring up any phlegm from your chest during the day or night?
Ye^No
5b If yes - Is it worse in the Winter? Yee/Ho
5a Do you bring up phlegm like th*s on most days (or nights*) for as much as 3
* For subjects who work by night
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TOBACCO SMOKING
33. Are you smoking now? Yeq/No
if 'Yes’ i) Cigarettes/Pipe/Cigars......................... ......
ii) How many (No.) or How much (oz. tobacco)........ ......
iii) If cigarettes - Low/High tax
- Filter tipped ......
iLv) Age of starting smoking?..............................
If *No': Have you smoked previously? ^ Yes/No
i) Cigarettes/Pipe/Cigars .......
ii) How many (No.) or How much (oz.) ..... .
iii) When stopped ..••••<
OCCUPATION
34. What is your job? ......... ............. .
How long have you been doing it? ..... .
Previous occupations (with duration):
Have you ever worked in a dusty atmosphere? Ye^/No
Have you ever given up a job for health reasons? Ye^No
FAMILY HISTORY
Chronic bronchitis
FATHER MOTHER
Sibl
1
inzs
2
Emphysema
Asthma
Lung Cancer
Other Chest Conditions
Alive?
Age?
If ’No* - cause of 
death?
MEDICATION
36. List all pills amd medicines taken over past month:
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36a. List current medication:
37. How is your home heated? Coal/ga^/electricity/other.
36. Do you drink alcohol? Yes/No
If 'yes* i) In what form?
ii) How much (per day)?
iii) How often?
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LArSUKATUKI TESTS
NAME: .... .
HOSPITAL NO,
FBC □
Sputum □
Skin Testing □
Hb
HOT
Wbc
Eosinophil count
Eosinophil count
Most recent culture result
□
n
Date
Allergen Wheal Diameter
Control
House Dust
Dermatophagoids
pteronyssinus
Cat
Dog
Feathers
Grass pollen
Aspergillus fumigatus
j
Ig£ □ Total
Specific
C arb oxyhaemoglob in 
(No smoking for 
12 hrs)
□
□
□
Routine PFTs □
□ Tick box when test carried out
□
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6a as 3 months each year? Yeq/No
If yes - go to 6b
6b What colour is your phlegm? Grey/White
GreeiyYellow
7a In the past 3 years have you had a period of (increased*) cough and phlegm 
lasting for 3 weeks or more?
Yes/No
If no - go to question 8 
if yes:
7b/c. Have you had more than one such period. If so how many? Y e s ....... .
* For subjects who usually have phlegm,
8a Have you ever coughed up blood? Ye^No
Details Fresl/ altered
Volume e.g. streak^teaspoo^egg cup 
Frequency
Duration..............................................
When .,.•••
BREATHLESSNESS
9a Are you troubled by shortness of breath when hurrying on level ground or walking 
up a slight hill? W N o
9b Do you get short of breath walking with other people of your own age on level
8POUna? W ho
If no - go to question 10a 
If yes:
9c Do you have to stop for brdath when walking at your own pace on level ground?
Ye^No
9d If yes - how far can you walk before having to stop? ......
9e Are you breathless on dressing? ......
WHEEZING
10a Does your chest ever sound wheezing or whistling? Ye^/h’o
If no - go to question 11a 
If yes:
10b Do you.get this most days -or nightd? Ye^No
10c Is wheezing worse at night? Yes/No
10d Does wheezing occur after exercise? Ye^/No
10e Are you allergic to aspirin? If yes - what are your symptoms?
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11a Have you ever had attacks of shortness of breath with wheezing?
If no - go to question 12 
If yes:
11b la/vas your breathing absolutely normal between attacks?
WEATHER
12. Does the weather affect your chest?
(Only record Yes if adverse weather definitely and regularly 
causes chest symptoms).
If no - go to question 14.
If yes:
13a Does the weather make you short of breath?
13b Specify type of weather e.g. fog, damp, cold, heat or other .......
hay f e v e r (allergic r h i n i t i s)
14. Do you suffer from hay fever?
" " " " summer sneezing?
If yes - age at onset
15. Do you have non-seasonal nasal symptoms?
Describe them:
If yes - age at onset?
16a Have you ever had eczema?
Age at onset 
Age at end 
16b Any other Allergies?
16c.Any pets at home?
CHEST ILLNESSES
17 During the past three years.have you had any chest illness which has 
from your usual activities for as much as a week?
If no - go to question 20 
If yes:
18 Did you bring up more phlegm than usual in any of these illnesses?
If no - go to question 20 
If yes:
19 How many illnesses like this have you had in the past 3 years?
HAVE YOU EVER HAD:
20 Any injury or operation affecting your chest?
21 Heart trouble/Angina?
If yes i) confirmed by Doctoi?
ii) Age at first diagnosis?
Ye^No
Ye^No
Ye^/No
Ye^/No
Yes/No
Ye^No
Ye^No
Yes/Ho
kept you 
Ye^No
Ye^No
Ye^No
Ye^No
Yes/No
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22. Bronchitis? Ye%/No
If'yes' i) Confirmed by Doctor? Ye^No
ii) Age at first diagnosis?..............................
23. Pneumonia? Yes/No
If 'Yes* i) Confirmed by Doctor? Yes/No
ii) When did you have it? ......
24. Pleurisy? Ye^No
If 'Yes' i) Confirmed by Doctor? Yes/No
ii) When did you have it?................................
25. Pulmonary tuberculosis? Ye^No
If 'Yes* i) Confirmed by Doctor? Ye^/No
ii) When did you have it?.......................... .....
26. Bronchial asthma? Ye^/No
If 'Yes' i) Confirmed by doctor? Yes/No
ii) When diagnosed? .....
iii) Date of last attack............................. ......
27. Emphysema? Yes/No
If 'Yes' i) Confirmed by doctor Yes/No
ii) When diagnosed .«.•••••
28. Bronchiectasis? Yes/No
If 'Yes' i) Confirmed by Dcotor? Ye^No
ii) When diagnosed .....
29. Other chest trouble? Ye^No
If 'Yes* i) What? ...............
ii) Diagnosed by doctor? Ye^No
iii) When Diagnosed? ......
30. Any arthritic? Yee/Ho
If 'Yes' i) Diagnosis? ...............
ii) When diagnosed? ......
31. Any lung problems before the age of 16 Yes/No
If 'Yes' i) What was diagnosis?.................... ................
ii)Confirmed by doctor? Yea/Ho
32. Any high blood/pressure/hypertension Ye^/No
If'Yes' i) When diagnosed? ......
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